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Abstract 
Herpes simplex virus type I (HSV-1) is a significant human pathogen that 
infects a large portion of the human population.  As an obligate intracellular 
parasite, HSV-1 requires certain cellular factors for its replication; on the other 
hand, the cell deploys a variety of defenses to limit the extent to which the virus 
can replicate.  This thesis is the summation of projects that examined the impact 
of three host cell factors – those being CK2, hTERT, and PML – on HSV-1 
replication. 
CK2 is a cellular kinase that, through its phosphorylation of a large 
number of targets, broadly functions to promote cellular growth and survival.  
HSV-1 encodes nine proteins that are either potential or bona fide substrates of 
CK2, the virus packages the kinase into progeny virions, and CK2 activity is 
stimulated during infection, suggesting that this kinase is important for viral 
replication.  Two viral substrates (i.e., ICP0 and ICP27) act to counter the 
interferon response while a number of cellular targets function against HSV-1.  I 
show as part of this thesis that, while the activity of CK2 is largely dispensable 
for viral replication, the use of CK2 pharmacological inhibitors sensitized HSV-1 
to the interferon (IFN) response, an innate cellular antiviral pathway.  This effect 
appears to function through the viral E3 ubiquitin ligase, ICP0, though it did not 
affect ICP0’s ability to induce the loss of two of its targets.  Additionally, the 
effect these inhibitors had on IFN sensitivity was specific to HSV-1, as there was 
no such result on adenovirus or vesicular stomatitis virus. 
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hTERT is a cellular reverse transcriptase that functions in a complex 
termed telomerase to regenerate the ends of human chromosomes in 
pluripotent cells but whose lack of expression in the major factor limiting the 
lifespan of terminally differentiated cells.  While the reintroduction of hTERT into 
primary cells has been reported to extend the proliferative capacity of 
differentiated fibroblasts, other reports have demonstrated non-telomerase 
activities for hTERT and changes in the transcription profile in hTERT-restored 
cells.  To date, however, cellular antiviral pathways have not been examined in 
these studies.  In this thesis, I demonstrate that the IFN response is largely 
unchanged in fibroblasts immortalized by hTERT and that, unlike transformation 
by oncogenes, the requirement for HSV-1 proteins involved in overcoming 
cellular antiviral effectors remained high. 
PML is the nucleating and central organizing factor of a nuclear 
suborganelle, ND10s, and coordinates the cellular efforts in response to a 
number of stress stimuli.  Available evidence suggests that PML serves in 
intrinsic and innate cellular antiviral defenses against HSV-1.  While the role of 
PML in a number of pathways is regulated through post-translational 
modifications, the effects of phosphorylation on its antiviral activity toward HSV-
1 has been largely unexplored.  As part of this thesis, a mapping of 
phosphorylation sites on PML was undertaken and sites of phosphorylation then 
examined for their effects on a number of PML’s activities.  I have identified a 
number of novel sites of phosphorylation and found that sites near a SUMO 
interaction motif influence the ability of PML to respond to HSV-1 infection.  
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Chapter 1: Introduction 
1  
1.1 HSV-1 
Human herpesvirus 1 or, as it is more commonly known, herpes simplex 
virus type 1 (HSV-1), is one of eight members of herpesviridae for which humans 
are the primary host [1].  Collectively, these viruses infect most human beings.  
Though quite different in the cells that they infect and the symptoms they 
produce, these viruses are all characterized by a shared virion structure; a large 
coding capacity of viral factors that possess many functions (e.g., protein 
kinases, viral DNA polymerase); the destruction of the host cell by progeny virus 
production, and an ability to persist in a certain cell types in a latent state for the 
life of the host with the ability to reactivate and resume an active infectious cycle 
[1].  Owing to its relatively benign symptoms and ability to persist latently, HSV-
1 is a widespread human pathogen, with upwards of 70-80% of the population, 
depending on socioeconomic class, being infected by the virus [2]. 
HSV-1 is most notable as being the etiological agent of the facial 
ulcerations commonly referred to as cold sores.  The virus is spread by direct 
contact when virus-containing bodily fluid is transferred to a naïve individual and 
enters though cracks or abrasions in the skin or mucosal surfaces.  Although 
most infections are asymptomatic, the initial infection can result in high fever, a 
painful gingivostomatitis, swollen lymph nodes, and mononucleosis-like 
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symptoms in adults [2].  These symptoms last for one to two weeks, during 
which time virus is continuously shed.  As this initial infection in the epithelia 
resolves, progeny virus infects the surrounding sensory neurons and traffics to 
the trigeminal ganglia.  While there, the viral genome is maintained as a 
quiescent episome, remaining for the most part transcriptionally silent and 
producing no progeny virus.  Stimulation such as emotional stress, exposure to 
intense sunlight, fever, or forms of immunosuppression in a latently infected 
individual can result in a loss of immune surveillance or neuronal stimulation.  As 
a consequence of these events, the virus exits latency, with a resumption of viral 
gene expression and concomitant production of progeny virus in a process 
known as reactivation.  The virus then traffics back to primary sites of infection 
on the face, where it once again establishes a lytic infection, most commonly the 
margin around the lips.  This recurrent infection can result in blisters that 
eventually heal over the course of several days. 
While these facial ulcerations are a relatively minor concern from a health 
perspective, serious complications arise when the virus infects areas outside of 
its preferred orofacial region.  When virus is introduced into the eye, repeated 
cycles of lytic infection in corneal epithelial cells can result in scarring of the 
cornea and blindness in the infected individual.  Although rare, HSV-1 is capable 
of spreading to the brain in children or immunocompromised individuals, 
resulting in a frequently fatal encephalitis.  Damage done during reactivation to 
the trigeminal ganglion or nerves extending from it may produce a painful and 
debilitating condition termed herpetic neuralgia.  Additionally, an increasing 
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number of genital herpes infections are caused by HSV-1 and may be the 
primary agent in certain populations [3]. 
1.1.1 HSV-1 Structure 
HSV-1 is a dsDNA virus with a 152 kbp genome [4] that is linear when 
packaged into the virion and circularized within cells.  In the assembled virion, 
the viral DNA is surrounded by an icosahedral protein cage called the 
nucleocapsid, formed by the tight association of four viral proteins [1].  
Surrounding this is an amorphous proteinaceous layer termed the tegument, 
which is comprised of 26 viral and a variety of captured cellular proteins [5] that 
appear to be important during the early stages of infection.  The tegument in 
turn is enclosed by the viral envelope, a lipid bilayer derived from the host, and 
contains a number of viral glycoproteins necessary for attachment to the host 
cell and cell-to-cell spread. 
1.1.2 HSV-1 Lifecycle 
Infection begins with attachment of the viral glycoproteins to their 
cognate host receptors on the cell surface, the exact identity of which depends 
on the particular cell type that is being infected.  Binding of the virion to host 
receptors results in rapid internalization of the viral particle through either 
endocytosis or fusion with the plasma membrane.  In either case, the virion is 
ultimately de-enveloped, the contents of the tegument are released into the 
cytoplasm, and the viral capsid is transported along microtubules to the 
nucleus.  Once at the nuclear pore complex, the capsid docks and injects the 
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viral genome into the nucleus [6], where the genome undergoes circularization 
and chromatinization.  In the case of a lytic infection, viral gene expression 
occurs in a strict temporal cascade consisting of immediate-early (IE), early (E), 
and late (L) phases, with the expression of each phase dependent upon the 
preceding class [7].  Initially, the tegument member, VP16, interacts with the 
host proteins Oct1 and host cell factor (HCF) to transactivate the IE genes.  IE 
gene products, generally speaking, serve to establish an environment that is 
conducive to the successful establishment of infection.  This includes preventing 
silencing of the viral genome, inactivating host antiviral defenses, and initiating 
mechanisms that favor the production of viral proteins over those of the cell, and 
ultimately stimulate the transcription of the early genes.  Early gene products are 
involved in viral genome replication, which allows for the transcription of the late 
genes.  Late gene products serve either functional roles in the assembly and 
egress of progeny virus or as components used in their creation.  Eventually, 
this nascent virus buds through the nuclear membrane into the endoplasmic 
reticulum, acquiring members of the inner tegument, and undergoes a de-
envelopment/re-envelopment mechanism whereby it exits the ER, shedding its 
nuclear membrane-derived envelope.  It then enters into the trans-Golgi 
network, acquires the final envelope and embedded glycoproteins as it picks up 
the outer tegument on its journey outward, and buds from the plasma 
membrane into the extracellular environment. 
Latent infection differs from that of the lytic infection in that it occurs only 
within neuronal cells and most viral gene expression is ultimately repressed, with 
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the exception of the latency-associated transcript (LAT).  Though it has been 
suggested that LAT may encode for proteins or miRNAs that suppress the 
expression of IE proteins necessary for reactivation or inhibit apoptosis of 
infected neurons, the exact mechanisms by which LAT functions during a latent 
infection are unknown.  The latent viral genome persists as an episome, and, 
while there may be sporadic expression of certain IE or E genes, no infectious 
virus is produced. 
1.1.3 ICP0 
Infected cell protein 0 (ICP0) is one of five HSV-1 IE proteins that, while 
not strictly required for productive infection, is necessary for efficient lytic 
infection.  ICP0 is important for viral replication when the viral particle-to-cell 
ratio is low, when cells are in a pre-activated antiviral state, and when the virus 
reactivates from latency.  Its best-described activity is that of an E3 ubiquitin 
ligase; this activity directs the proteasome-dependent degradation of a number 
of cellular proteins.  Known targets of ICP0-directed degradation include PML; 
the centromeric proteins CENP-A [8], -B [9], -C [10], -I [11], -H [11], and –N [11]; 
RNF8 [12]; RNF168 [12]; DNA-PKcs [13]; CD86 [14]; USP7 [15]; IkBa [16]; IFI16 
[17]; and E2FBP1 [18], as well as SUMO-1- and SUMO-2/3-conjugated proteins 
[19]. 
Through its E3 ligase activity, ICP0 transactivates viral gene expression 
and overcomes cellular antiviral defenses by preventing, in part, the silencing of 
the viral genome by cellular factors. 
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1.1.4 Impairment of the host’s antiviral response by ICP0 
Due to the functional importance of ICP0 in the HSV-1 life cycle, a 
number of potential mechanisms have been proposed as to how ICP0 works on 
a molecular level.  One established role for ICP0 during viral infection is its ability 
to inactivate a number of components relating to host-cell antiviral defense and 
stress response pathways, including factors of both intrinsic and innate 
defenses [20–23].  Intrinsic defense, in which many core components are also 
regulated as part of the innate response, consist of pre-existing host cell factors 
that attempt to silence viral gene expression by making the viral genome 
functionally inaccessible [20–23].  ICP0 has been shown to affect one 
component of intrinsic defense, ND10 constituent proteins, and one component 
of innate defense, namely the type I interferon response (which is described in 
more detail in section 1.2).  Both topics in relation to ICP0 activities will be 
examined in this thesis. 
ICP0’s ability to activate viral gene expression is closely associated with 
its ability to disrupt ND10.  ND10s, as will be discussed later in section 1.5, are 
punctate, nuclear suborganelles that contain a variety of nuclear effectors, 
including transcription factors, chromatin remodeling factors, DNA damage 
response members, which participate in proliferation, differentiation, and the 
antiviral response (reviewed in [24]).  HSV-1 genomes were initially described as 
being deposited at ND10s [25]; subsequently, ND10-associated proteins have 
been observed to disassemble and reform around incoming viral genomes [26].  
ICP0 inhibits the cumulative repressive effects of various ND10 associated 
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proteins by inducing the disruption of ND10 structures through the degradation 
or dissociation of PML, Sp100 [27,28], Daxx, and ATRX [29].  Notably, depletion 
of one or more ND10 constituents increases the plaque formation efficiency and 
gene expression of an ICP0 null mutant virus but not wild-type HSV-1 [30]. 
Besides disrupting or degrading preexisting cellular defenses, ICP0 is 
also involved in subverting innate antiviral pathways.  It is required for the 
successful establishment of a lytic infection in cells in which the IFN response 
has been activated prior to infection.  In cells pretreated with type I IFNs (such 
as IFN-β), ICP0-null mutants can be up to a thousand-fold less likely to initiate a 
lytic infection than wild-type virus (personal observation).  Expression of ICP0 in 
trans by either an adenoviral vector or an integrated copy of ICP0 in a cell line 
can largely ameliorate the inhibitory effects of type I IFNs on the replication of an 
ICP0-null virus [31,32].  Studies performed with mouse embryo fibroblasts 
derived from knockout mice indicated that PML was primarily responsible for 
mediating the effects of the IFN response and that the loss of PML could 
compensate for the lack of ICP0 in IFN-treated cells [33].  However, in PML-
depleted human fibroblast cells, IFN-β was still capable of inhibiting the 
replication of an ICP0-null mutant, although this effect was diminished [34].  This 
result indicates that other interferon stimulated genes (ISGs), in addition to PML, 
likely play a role in the repression of HSV-1 replication by IFN-β.  Furthermore, a 
study by Halford and coworkers showed that the acute replication of an ICP0 
mutant virus was equally repressed in PML-knockout and wild type mice, unlike 
what happens in mice missing the key IFN-signaling molecule, STAT1, 
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suggesting that the loss of PML (as an ISG) cannot complement the replication 
of an ICP0 mutant virus in vivo [35]. Although the report that used PML-
knockout mouse embryo fibroblasts and the studies that used PML-depleted 
human fibroblasts and mice in vivo come to opposing conclusions, PML’s role 
as a mediator of the IFN response may be dependent upon the species of the 
host, homology between PML orthologs, and/or the cell types used in these 
studies.  It is still unclear how ICP0 enables HSV-1 to replicate in the presence 
of an established IFN response. 
1.2 Interferon 
The interferon (IFN) system provides an initial antiviral response by the 
innate immune system in vertebrates [22].  IFNs are cytokines that are capable 
of impairing or inhibiting viral replication and mark a cell as infected to the 
immune system.  In humans, IFNs are divided into several classes – type I IFNs, 
as typified by the IFN-α family and IFN-β; type II IFN, consisting solely of IFN-γ; 
and the type III IFN family, comprised of the IFN-λ family [36].  While most cell 
types are capable of secreting type I and III IFNs, secretion of type II IFN is 
restricted to a subset of the immune system consisting of NK cells, TH1 cells, 
and cytotoxic T-lymphocytes [37] and only select cell types express the IFN-γ 
receptor [36].  Detection of viral entry or intracellular viral intermediates by Toll-
like receptors or other pattern recognition receptors trigger events that lead to 
the activation of interferon regulatory factor (IRF) 3 and nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB), which translocate to the 
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nucleus.  Once in the nucleus, IRF3 and NF-κB coordinate to transactivate the 
IFN-β promoter and induce the production of IFN-β to initiate an IFN response.  
IFN is secreted from the cell, binds to its cognate receptors on the secreting 
cell, as well as surrounding cells, and activates the Jak-STAT (Janus kinase-
signal transducers and activator of transcription) pathway by stabilizing the 
dimerization of the IFN-α/β receptor and initiating the cross phosphorylation of 
the Jaks on each opposing receptor.  Activated Jaks phosphorylate their 
associated STATs, with the particular STATs activated depending on the 
species of IFN that initiated the signal – notably, in the case of IFN-β, STAT1 and 
STAT2 are activated [37].  Phosphorylation of STAT1 and STAT2 to their 
dimerization and binding to the protein interferon regulatory factor-9 (IRF-9) to 
form the interferon-stimulated gene factor 3 (ISGF3) complex, which 
translocates to the nucleus [37].  Once in the nucleus, IRF-9 and STAT1 bind to 
an interferon stimulated response element (ISRE) that is present in the enhancer 
region of interferon-stimulated genes (ISGs) and STAT2 provides the 
transcriptional activation activity [38].  The products of these ISGs have diverse 
activities that inhibit viral replication and limit the spread to surrounding cells.  
Examples of prototypical ISGs include 2',5'-oligoadenylate synthetases, which 
trigger mRNA degradation by activating an endoribonuclease, RNaseL [39]; the 
myxovirus-resistance proteins (Mx1 and Mx2), which interfere with viral 
component trafficking [40]; protein kinase RNA-dependent (PKR), which shuts 
down mRNA translation by phosphorylating the initiation factor eIF2ɑ [41]; and 
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), which binds 
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to mRNAs with a 5’triphospate and lacking 2’-O-methylation on the cap, specific 
properties of viral mRNAs [42]. 
As noted above, HSV-1 is somewhat resistant to the effects of IFN, in 
large part because of the activities of ICP0.  However, what aspects of the IFN 
response function against HSV-1 and the mechanism used by ICP0 to 
overcome this response are poorly understood.  This thesis examines the role of 
one host cell factor, CK2, whose activity assists in the replication of HSV-1 in 
cells with a preactivated IFN-response. 
1.3 CK2 
1.3.1 Subunits and phosphorylation activity 
CK2, formerly called casein kinase II, is a highly conserved protein kinase 
that is expressed in all tissues [43].  It is a heterotetramer comprised of two 
regulatory CK2β subunits and two catalytic subunits of which, in humans, there 
are two isoforms – CK2α and CK2α’ [43].  CK2 generally phosphorylates serines 
and threonines located adjacent to a patch of acidic residues, with the 
consensus sequence of S/T-x-x-D/E [44].  CK2, however, is also capable of 
phosphorylating tyrosine in a limited number of instances, including itself in an 
autoregulatory fashion [45].  The CK2 phosphorylation consensus sequence is 
found in a large number of proteins, with CK2 having over 300 putative cellular 
substrates, including those involved in cell cycle control, transcription, and 
apoptosis [43].  As such, CK2 plays a role in these pathways where its activity 
can be broadly described as pro-cell survival and pro-cell growth.  In fact, 
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deletion of CK2α is embryonic lethal in mice and deletion of CK2-β causes a 
loss of viability in cells [46]. 
1.3.2 Cellular functions of CK2 
With its wide array of targets, CK2 has a role in regulating multiple cellular 
pathways, including transcription, apoptosis, and the cell cycle. 
CK2 functions at multiple stages of the cell cycle.  For instance during G1 
phosphorylation of cyclin H by CK2 is necessary for the full activity of the cyclin 
H/CDK7/Mat1 complex that targets CDK1, CDK2, and CDK4 and enables these 
kinases to phosphorylate pRb and disassociate it from E2F proteins [47].  CK2 
also influences the p53 tumor suppressor pathway during G1 and S phases.  In 
unstressed cells, phosphorylation of MDM2 by CK2 allows MDM2 to target p53 
for polyubiquitination and subsequent proteasomal destruction [48]. Conversely, 
exposure to ultraviolet irradiation induces the FACT complex to shift CK2 
phosphorylation to p53, increasing p53 transactivation activity with a 
subsequent block in the cell cycle [49].  CK2 activity is also required at the onset 
of mitosis as the use of a CK2 inhibitor slows the degradation of Wee1A and the 
subsequent entry into mitosis [50].  Additionally, CK2α colocalizes with the 
mitotic spindle and a dysregulation of CK2α activity leads to centrosomal 
amplification and missegregation [51]. 
CK2 activity is required for the transcriptional activity of all three RNA 
polymerases.  For both RNAPI [52] and RNAPIII [53,54], CK2 phosphorylates 
several components, most notably TBP, and is required for reassembly of the 
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RNAP complex at the promoter [52].  However, the RNAPIII-related targets of 
CK2 are cell cycle dependent and CK2 changes from stimulatory to inhibitory 
during both S phase and mitosis [55].  The c-terminal domain of RNAPII is a 
target of CK2, as well as several other general transcription factors, with cycles 
of phosphorylation of the RNAPII CTD by CK2 and dephosphorylation by the 
phosphatase FCF being required for RNAPII recycling and reinitiation at 
promoters [56]. 
In apoptotic pathways, CK2 can be broadly described as having pro-
survival activity.  Overexpression of CK2 can protect cells from etoposide- or 
diethylstilbestrol-induced apoptosis in cancer cell lines and treatment with 
pharmaceutical inhibitors of CK2 can induce apoptosis in certain tumor cell lines 
[57,58].  The kinase activity of CK2 is capable of preventing the activation of 
several pro-apoptotic factors, including Bid, caspase-2, and caspase-9, as the 
cleavage recognition site overlaps with that of a CK2 consensus sequence and 
phosphorylation prevents the cleavage of these effectors [59,60].  Additionally, 
CK2 is able to prevent apoptosis by inducing an upregulation of the inhibitor of 
apoptosis family member, survivin [61]. 
1.3.3 CK2 and cellular antiviral defense 
Phosphorylation of cellular factors by CK2 is implicated in the regulation 
of the interferon response and at least three cellular proteins that have roles in 
antiviral pathways: PML (which will be discussed in more detail in section 
1.5.5.3), retinoic acid-inducible gene 1 (RIG-I), and interferon-induced gene 16 
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(IFI16).  However, there does not appear to be a unified theme in the case of 
CK2’s activities in antiviral pathways.  CK2 physically associates with both JAK1 
and JAK2, with the latter serving as a substrate of CK2’s kinase activity [62].  
CK2 activity is necessary for the proliferation of certain leukemic cells and while 
the use of CK2 inhibitors decreased STAT1 activation in response to Oncostatin 
M, it is unclear what effects CK2 has on the activation of STAT1 in response to 
type I IFN-signaling though CK2 has a positive effect on monocyte 
chemoattractant protein 1 expression in response to IFN-γ signaling.  Opposite 
its effects in monocytes, CK2 negatively regulates RIG-I, a pattern recognition 
receptor that senses certain viral RNAs and functions is upstream of the IFN-
response to activate IFN-β production [63].  CK2 phosphorylation of RIG-I 
prevents RIG-I from undergoing a multimerization necessary for its activation 
[63,64].  In the case of IFI16, a sensor of viral DNA that activates IFN-signaling 
[65], CK2 has been reported to be necessary for its nuclear accumulation, 
though the relevance of this phosphorylation during infection is unknown [66]. 
1.3.4 CK2 during viral infection 
In addition to its plethora of cellular targets, proteins from a variety of 
viruses serve as substrates of CK2-mediated phosphorylation.  As in the case of 
their cellular counterparts, the effect of CK2 on the activity of these viral proteins 
is varied.  Viruses that express functionally relevant CK2 targets include human 
immunodeficiency virus type 1 [67–71], human cytomegalovirus [72–74], Epstein 
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Barr virus (EBV) [75–77], hepatitis C virus [78–81], human papillomaviruses [82–
84], adenoviruses [85,86], and vesicular stomatitis virus [87–89]. 
In the case of HSV-1, proteins from all three kinetic classes contain CK2 
consensus phosphorylation sites, and in several instances mutation of these 
sites compromises viral replication [90–93].  Perhaps owing to the potential 
importance of CK2 in HSV-1 replication, CK2 is the only cellular kinase, to date, 
that has been shown to be packaged in the tegument of the assembled virion 
[5]. 
The best described interactions between CK2 and HSV proteins include 
those between it and ICP0, ICP4, ICP27, VP22, and VP16.  Focusing on IE 
proteins, potential CK2 phosphorylation sites have been implicated in controlling 
ICP0’s E3 ubiquitin ligase activity as mutation of the sites impair the disruption 
of ND10s, the degradation of USP7, and increase the stability of ICP0 [94].  
ICP4, the major viral transactivator during infection, contains a polyserine tract, 
with several sites matching a CK2 consensus sequence.  While removal of the 
polyserine tract weakens the ability of the virus to replicate in the trigeminal 
ganglion, mutation of the CK2 consensus sequence alone only has a minor 
effect on replication in the eyes or in ganglia [95].  CK2 modulates the nuclear 
import of ICP27, a multifunctional mRNA/protein nuclear import/export shuttling 
factor and regulatory protein that promotes viral mRNA translation and inhibits 
cellular protein synthesis [96].  The use of the CK2 inhibitor DRB or mutation of 
the phosphoacceptor sites prevents nuclear export of ICP27 [97,98].  
Additionally, mutants altered in the putative CK2 phosphoacceptor sites fail to 
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form replication compartments indicative of viral genome amplification [93] with 
a 2-log decrease in viral replication [98].  Lastly, ICP27 alters the intracellular 
localization of CK2 and stimulates its activity in in vitro assays [97].  Of note is 
that two of these viral targets, ICP0 and ICP27, are involved in counteracting the 
repressive effects of the IFN response. 
While the above implicates CK2 playing a role in the life cycle of HSV-1, 
the impact of inhibiting or removal of CK2 activity on HSV-1 replication has 
remained largely unexplored and thus is one area of study in this thesis. 
 
1.4 hTERT 
In performing studies that examine cellular immune responses to viral 
infections, it is often necessary to work with primary cells, as the efficacy of 
intrinsic and innate immune pathways are frequently diminished in immortalized 
cells [99–102].  One disadvantage of using primary cells is their limited 
proliferative capacity in cell culture, which is due in part, to the progressive 
shortening of telomeres [103]. 
1.4.1 Telomeres 
Telomeres are repetitive nucleoprotein structures that serve to cap the 
ends of chromosomes, facilitating their replication, and prevent their ends from 
appearing as DNA breaks [104].  While the exact composition of telomeres vary 
among species, in humans telomeres are comprised of the guanine-rich 
sequence TTAGGG, which may extend up to 8-12 kb long, and are coated by 
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what is termed the shelterin complex, a six protein complex that masks the 
telomeric DNA from being detected as damaged DNA by ataxia telangiectasia 
mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) kinases as well 
as suppressing non-homologous end joining and homology-directed repair at 
telomeres [105].  At the end of the telomere is a 3’ single stranded overhang, 
which invades an upstream double stranded region and forms what is termed 
the t-loop.  Due to the inability of mammalian polymerases to synthesize in the 
absence of a primer, in somatic cells each round of chromosomal duplication 
results in the loss of nearly 100 bp of telomeric sequence on the lagging strand 
[106,107].  In stem cells and pluripotent cells, telomeres are maintained by a 
complex known as telomerase, whose essential core consists of the catalytic 
subunit telomerase reverse transcriptase (TERT) and the telomerase RNA 
template component (TERC) [108,109]. TERT is loaded onto the 3’ overhang of 
existing telomeric DNA and utilizes TERC as a template to add TTAGGG 
repeats; concordantly, DNA primase and DNA polymerase are recruited to the 
new telomeric repeats, subsequently synthesizing the complementary 5’ strand 
[104].  In the absence of active telomerase, erosion of telomeric sequences 
occurs with each successive round of replication.  Once telomeres are reduced 
from their normal 15 kb length to ~4 kb, DNA damage sensors trigger p53- and 
pRb-dependent mechanisms that result in cellular senescence, inducing a G1 
cell cycle arrest [110]. 
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1.4.2 Senescence and immortalization 
Replicative senescence is thought to be a mechanism of cellular lifespan 
regulation, preventing diseases such as cancer, and is intrinsic to the health of 
an organism [111–114].  However, for technical reasons it can be desirable to 
extend the proliferative capacity and prevent the senescence of a primary cell 
culture or strain.  One way to avoid or reverse replicative senescence is 
transformation with viral oncogenes, such as the simian virus 40 (SV40) large T 
antigen (TAg) or the human papillomavirus (HPV) E6 and E7 proteins [115–117].  
In both cases, these viral proteins reverse senescence through the inactivation 
of p53 and/or pRb.  While this allows cells to resume progression through the 
cell cycle and replicate, these cells still undergo telomeric erosion and ultimately 
undergo a phenomenon termed crisis [115], where massive cell death occurs 
due to gross genomic rearrangements and instability in the absence of 
telomeres.  While the estimated 1 in 107 cells (for human cells) that survive crisis 
exit immortalized [118,119], this transformation results in the dysregulation of 
several cellular pathways, including the antiviral type I interferon (IFN) response 
[99]. 
As part of their differentiation program, human cells cease expressing 
hTERT, while continuing to produce other essential telomerase subunits such as 
TERC [120].  It has been shown by a number of labs that the lifespan of 
fibroblasts is efficiently extended by the reintroduction of hTERT into these cells 
[121,122].  Exogenous expression of hTERT presumably allows terminally 
differentiated fibroblasts to resume the extension of their telomeres, delaying or 
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avoiding the production of signals that trigger replicative senescence and in turn 
prevents the chromosomal damage encountered by replication through crisis 
[123].  Unlike transformation with viral oncogenes, fibroblasts that exogenously 
express hTERT do not, for the most part, exhibit an oncogenic phenotype [124].  
Notably, the effect that life-extension by exogenous expression of hTERT on 
innate antiviral pathways, and in particular the IFN response, has not been 
examined. 
 
1.5 PML 
1.5.1 Introduction 
As mentioned above, host cells initially attempt to limit the activities of 
HSV-1 through intrinsic defense mechanisms.  One mediator of the intrinsic 
antiviral defense is the promyelocytic leukemia protein (PML). 
PML is a nuclear regulatory protein present in a majority of cell types.  It 
is constitutively expressed but as the PML promoter contains both type I and 
type II interferon response elements as well as binding sites for p53-family 
members, it is upregulated in response to IFN-stimulation or activated p53 
[125,126].  The PML gene contains nine exons, giving rise to seven major 
isoforms that all share a common N-terminal set of domains but differ greatly in 
their C-terminus [127].  PML is capable of extensive interactions with itself and 
other proteins, especially those that are SUMO-modified, allowing it to serve as 
the nucleating constituent of the nuclear suborganelle, nuclear domain 10 
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(ND10).  Current evidence suggests that PML is itself an E3 SUMO ligase 
[128,129], though its physiological targets are currently unknown.  Through its 
ability to interact with a wide variety of partners, PML plays a role in numerous 
cellular pathways, such as apoptosis, the DNA damage response, telomere 
maintenance, stem cell maintenance, transcription, translation, cellular 
proliferation, differentiation, and antiviral defense; in most cases, PML responds 
to stress conditions to slow or limit growth [130]. 
1.5.2 ND10 
ND10s (also called PML oncogenic domains and PML nuclear bodies) are 
matrix associated protein aggregates with which numerous proteins associate 
but to which no definite function has been ascribed.  It has been suggested that 
ND10s serve as modification platforms where effector proteins and their 
substrates are brought together to facilitate post-translational modification or as 
storage depots that regulate the availability of transcription factors or other 
effectors [131].  While the list is ever growing, over 160 cellular proteins have 
been described as localizing to ND10s [132]; however, as ND10s appear to 
serve a role in protection from aggregated and misfolded proteins [133,134], it is 
unclear whether the localization of some of these proteins is due to artifacts of 
overexpression.  Notable ND10 members include p53, MDM2, CBP/p300, myc, 
pRB, Daxx, Nbs1, HIPK2, Mre11, and CHK2 [135]. 
Not surprisingly, ND10s are dynamic structures, with their number and 
size varying depending on cell type, position in the cell cycle, and exposure to 
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stress conditions.  These bodies are generally spherical shells with an exterior 
formed of PML and another ND10 resident, Sp100, and the interior consisting of 
proteins temporarily localized to ND10s [136].  Typically there are 2-30 ND10s 
per cell, which range in size between 0.2-1 µM in diameter [20]; however, a 
variety of stimuli can alter these attributes due to changes in the composition or 
modification of resident proteins or through changes in chromatin structure that 
results in torsional effects on ND10s, where increased condensation strains 
ND10s and causes their fragmentation [137]. 
1.5.3 PML Structure 
PML is a member of the TRIM family of proteins, so named because they 
all share a triplet set of characteristic domains, those being a Really Interesting 
New Gene (RING) finger, one or two B-boxes, and a coiled-coil domain (Figure 
1.1) [127].  The RING finger is a Zn2+-coordinating cross-brace structure that is 
commonly found in the E3-ligase proteins of the ubiquitin and ubiquitin-like 
modification systems.  Indeed, a number of TRIM family proteins, including 
PML, have been shown to possess E3 activity in one or more of these pathways, 
with the RING finger forming a site with which the E2 conjugation enzyme binds 
[129,138,139].  B-boxes comprise another Zn2+-binding motif, one found only in 
TRIM proteins; while their purpose is, as of yet, poorly understood, it has been 
suggested that they serve as an intramolecular E4 site that binds a substrate 
protein and enhances the activity of the RING finger in a manner similar to that 
of BARD1 in the BRCA1:BARD1 complex [140].  The coiled-coil is an alpha-
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helical structure involved in both PML dimerization and interaction with partner 
proteins [127,141,142]. 
While most TRIM proteins contain the above-described domains, they 
differ in those that are found in the C-terminus.  Specific to PML is a nuclear 
localization signal and a SUMO-interaction motif (SIM) [143].  The SIM, present  
in five of the seven major isoforms of PML, is a hydrophobic patch of amino 
acids that allows for the non-covalent interaction with a partner protein that is 
SUMO conjugated.  Additionally, the various isoforms of PML may contain 
different functional domains in the variable C-terminus.  For instance, PML-I 
encodes a nuclear export signal and an exonuclease III domain [144], whereas a 
region of PML-V is capable of recruiting other ND10-associated protein 
independently of any other PML-isoforms or regions [145]. 
1.5.4 Antiviral activities of PML 
Likely due to its effect on the various partner proteins found at ND10s, 
PML has a role in regulating a wide variety of cellular processes as previously 
mentioned.  As these pathways overlap with intrinsic antiviral defenses, it is of 
little surprise that PML serves to restrict the replication of a number of viruses.  
Currently, PML and ND10s have been shown to impair the growth of vesicular 
stomatitis virus (VSV), rabies virus, Lassa virus, lymphocytic choriomeningitis 
virus, influenza A virus, poliovirus, encephalomyocarditisvirus, murine leukemia 
virus, human foamy virus (HFV), adenovirus, human papilloma virus (HPV), 
herpes simplex viruses type 1 and 2 (HSV-1 and -2), varicella zoster virus (VZV), 
 22 
human cytomegalovirus (HCMV), and Epstein-Barr virus (EBV) [20].  Elimination 
of PML in cells or animals can result in an increase in replication for many of 
these viruses, whereas its overexpression can in turn diminish replication.  As 
yet, it is unclear how PML functions to restrict the replication of many of these 
viruses, especially for RNA viruses whose lifecycles take place in the cytoplasm.  
However, in the case of poliovirus, it has been shown that infection induces a 
phosphorylation- and SUMOylation-dependent increased recruitment of p53 to 
ND10s, potentiating p53’s activation of apoptotic programs [146].  For 
encephalomyocarditisvirus, PML sequesters the viral polymerase, 3Dpol, in 
ND10s, decreasing its ability to function in replication [147]. 
The antiviral functions of PML have been better defined for viruses that 
replicate in the nucleus.  In general, the presence of PML appears to decrease 
or delay viral gene expression and promote the apoptosis of infected cells.  In 
many cases, ND10s will break down and individual components will form around 
viral DNA as it enters the nucleus.  For infection by HSV-1 ICP0-null mutants at 
low multiplicities of infection, this can result in encapsidation of the viral 
genome, silencing it by precluding its accessibility to transcription factors [148].  
Additionally, PML colocalizes with latent viral genomes, suggesting that PML 
plays a role in maintaining latency in neurons [149]. In the instance of human 
foamy virus, PML physically binds to the major viral transactivator, tas, impairing 
its ability to activate LTR-driven gene expression [150].  As well as preventing 
VZV gene expression, PML can also form large cages around assembled 
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capsids and prevent them from leaving the nucleus and forming infectious 
particles [151]. 
While PML functions as part of the intrinsic antiviral response against 
some viruses, in some cases basal levels of PML do not provide adequate 
protection.  For HFV, only increased levels of PML caused by overexpression or 
upregulation by IFNs result in a PML-dependent decrease in viral replication 
[152]. 
As the viruses have evolved in the presence of PML, many have 
developed mechanisms mediated by viral proteins, allowing them to inactivate 
the antiviral effect of PML and ND10s. Encephalomyocarditisvirus 3Cpro [153], 
HSV-1 [154] and HSV-2 ICP0 [155], EBV EBNA1 [77], and HPV-18 E6 [156] 
induce proteasome-dependent degradation of PML.  HCMV IE1 and EBV BZLF 
inactivate PML by causing a loss of SUMOylated PML [157–159], while KSHV 
LANA2 does so by inducing SUMOylation of PML, which results in its loss 
through a proteasomal-dependent mechanism [160].  In some cases, viruses 
overcome PML’s activity by causing its redistribution, such as Rabies virus P 
protein, LCMV Z protein, and Lassa Z protein, all of which causes a cytoplasm 
sequestration of PML [161], or adenovirus E4orf3, which reorganizes ND10s into 
long tracts [162], though in the latter case it is not known how this 
reorganization inactivates PML. 
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1.5.5 Post-Translational Modifications 
As PML is constitutively expressed yet responds to a variety of cellular 
stimuli and changing conditions, the activity of PML must be dynamically 
controlled.  As such, PML is extensively post-translationally modified by 
SUMOylation, acetylation, ubiquitination, and phosphorylation [163] (Figure 1.1).  
These modifications are essential for the activity of PML, and its ability to form 
ND10s and respond to cellular signals.  This introduction will focus on 
SUMOylation, ubiquitination, and phosphorylation. 
1.5.5.1 SUMO 
SUMO-1 was first discovered as a PML interacting protein and was soon 
found to be covalently bound to PML [164].  PML is SUMOylated on at least 
three lysine residues [165], with several large-scale mass spectrometry screen 
suggesting additional minor SUMOylation sites, especially upon arsenic trioxide 
treatment [166,167].  The physiological relevance of these minor sites is 
unknown, as the effect that mutation of these sites has on PML SUMOylation 
has not been examined.  PML is modified by SUMO-1, -2 and -3, though the 
precise role of each paralogue in controlling PML activity and mechanisms 
determining the usage of a particular paralogue at a specific site are poorly 
understood.  Beside itself, PML interacts with at least three other E3 SUMO 
ligases, PIAS1, PIAS2α, and RanBP2, that result in conjugation of SUMO to 
PML [141,168,169].  Additionally, the histone deacetylases HDAC7 [170] and 
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Sirt1 [171] stimulate PML SUMOylation in a manner that is independent of their 
deacetylase activity. 
SUMOylation of PML at its major sites, including K65, K160, and K490, is 
necessary for proper ND10 formation, with mutation of the SUMOylation 
acceptor sites resulting in ND10s that are much larger and fewer in number 
[143].  Exchange of PML between ND10s and the nucleoplasm is regulated by 
SUMO modification, with lysine to arginine mutations at K160 and K490 
resulting in a form of PML that is poorly retained at ND10s, while additionally 
mutating K65 nearly eliminates diffusion into the nucleoplasm [172].  In some 
cases, SUMOylation of PML is required for partner protein recruitment, such as 
the ND10 protein, Daxx [173]. 
Modification by SUMO also controls PML stability.  SUMOylation by 
PIAS1 on K160 results in increased interaction with CK2, leading to 
phosphorylation of PML and subsequent polyubiquitination [141].  Likewise, in 
response to arsenic trioxide treatment, PML is polySUMOylated by PIAS1 [141], 
resulting in increased interactions with either of two SUMO-targeted ubiquitin 
ligases (STUbL), RNF4 [174] and Arkadia [175], which ubiquitinate the 
polySUMO chains on PML and induces PML’s proteasomal-dependent 
degradation.  On the other hand, SUMOylation of PML at K490 can inhibit 
interaction with the peptidyl-prolyl cis-trans isomerase, Pin1, preventing a 
conformational change that results in degradation of PML [176]. 
PML SUMOylation changes in response to cellular conditions and 
stresses.  Perhaps the best studied is the effect of arsenic trioxide, where 
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arsenic directly binds to cysteines present in the RING finger, causing a 
conformational change that results in a phosphorylation-dependent 
polySUMOylation and subsequent degradation of PML as detailed above [177].  
Other factors that change PML SUMOylation include TNF-α [170], IFN [152], and 
DNA damage [178], all of which increase PML SUMOylation while stress such as 
heat-shock and heavy metal exposure leads to deSUMOylation [179]. 
1.5.5.2 Ubiquitination  
PML interacts with the cellular E3 ubiquitin ligases RNF4 [174], Arkadia 
[175], Siah1/2 [180], Cul3-KLHL20 [181] and UHRF1 [182], as well a number of 
viral E3s as detailed above.  In all known cases, ubiquitination of PML results in 
its proteasome-mediated destruction.  Inhibiting PML ubiquitination results in a 
strengthening of its effects on proliferation and as such can slow cell cycling, 
diminish tumor growth in xenografts [183], and decrease cellular migration [182]. 
1.5.5.3 Phosphorylation 
PML is extensively phosphorylated, being modified on a number of 
serines and threonines.  While one early report showed that PML was labeled by 
a phosphotyrosine-specific antibody [184], no phosphotyrosine have been found 
in subsequent mass spectrometric screens [176,185]. 
Activation of three of the four MAP kinase groups, that is ERK1/2 [186], 
p38 [183], and BMK1 [187], in response to mitogens or cellular stress results in 
PML phosphorylation.  Treatment of cells with arsenic trioxide stimulates 
ERK1/2 to phosphorylate PML at T28, S36, S38, S40, S527, S530, with 
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phosphorylation of one or more of these sites in turn stimulating SUMOylation of 
PML [186].  Phosphorylation of PML at S403, S505, S518, and S527 by ERK2 
influence the ability of Pin1 to bind to PML in response to extracellular growth 
factor (EGF) [188] or insulin-like growth factor-1 [189] signaling.  The subsequent 
interaction with Pin1 induces a conformational change in PML that results in its 
polyubiquitination by the E3 ubiquitin ligase Cul3-KLHL20 [181].  EGF also 
regulates PML through its stimulation of BMK1, which phosphorylates PML on 
S403 and T409 [187].  Phosphorylation of PML by BMK1 disrupts interactions 
between PML and MDM2, promoting p53 degradation [190].  Mutation of the 
S403 and T409 phosphoacceptor sites in PML or the use of BMK1 inhibitors 
increase p21 levels, and pharmacological inhibition of BMK1 shrinks tumor 
formation in mice in a PML-dependent manner [187].  Osmotic stress, irradiation 
by ultraviolet light [183], or arsenic trioxide treatment [141] induce a p38-
dependent activation of CK2, which then phosphorylates PML on S560, S561, 
S562, and S565 [183].  These sites are adjacent to both the SIM and to an 
amino acid sequence that promotes PML degradation.  On the one hand, 
phosphorylation at these sites increases the ability of the SIM to bind to 
SUMOylated proteins [191,192]; on the other hand, phosphorylation at S565 
leads to polyubiquitination and proteasomal degradation of PML [183]. The use 
of CK2 inhibitors can prevent tumor growth in mice in a PML-dependent manner 
[183].  In contrast, heat shock and heavy metal exposure induce p38 and 
ERK1/2 dependent deSUMOylation of PML, ND10 fission, and the loss of the 
ND10 members [179]. 
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DNA damage result in changes to PML phosphorylation as well.  Upon γ-
irradiation, CHK2 phosphorylates PML at S117 [193].  Blocking this 
phosphorylation prevents apoptosis while exogenous expression of an S117E 
PML-IV mutant induced apoptosis in U937 cells.  DNA double strand breaks 
induced by doxorubicin treatment result in phosphorylation of PML by ATR 
[194], causing PML to relocate to the nucleolus, bringing MDM2 with it and 
sequestering Mdm2 away from p53.  DSBs also induce phosphorylation of PML 
at S8 and S38 by HIPK2 [178].  Again, phosphorylation of PML on the N-
terminus results in increased amounts of PML, though in this instance 
SUMOylation leads to increased stability. 
In addition to being phosphorylated in response to EGF stimulation, S518 
is phosphorylated under hypoxic conditions, although in this case it is by CDK1 
and CDK2 [181].  Again, this promotes interaction with Pin1 and, in turn, 
ubiquitination of PML by the Cul3-KLHL20 E3 ubiquitin ligase and allows for full 
upregulation of HIF1α target genes. 
Phosphorylation plays a part in the control of PML’s activity in 
granulocyte differentiation.  In this process, the ability of PML to cooperate with 
C/EBPε to transactivate G-CSF-responsive genes is dependent on 
phosphorylation of PML at S505, S518, S527, and S530 [195]. 
Finally, while the sites involved are currently unknown, PML undergoes a 
mitosis-regulated phosphorylation that is involved in the deSUMOylation and 
dismantling of ND10s as cells enter mitosis [196].  Additionally, this 
phosphorylated form of PML is also seen in heat-shocked cells. 
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Altogether, the large number of post-translational modifications and the 
amount of cross-talk between different modifications demonstrate the 
importance of these modifications in the activity of PML.  However, most 
attention, particularly in the context of HSV-1 infection, has focused on the role 
that SUMOylation plays in PML’s antiviral activity while the function of 
phosphorylation has been relatively unexamined and as such is one focus of this 
thesis. 
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Figure 1.1.  Location of functional domains and sites of post-translational 
modification on PML. 
Location of the Really interesting New Gene (RING) finger, B-box 1, B-
box 2, coiled-coil, Nuclear Localization Signal (NLS), and Nuclear Exclusion 
Signal (NES) are shown in as dark blue boxes (with the heptad repeats that 
create the coiled-coil in light blue boxes), the endonuclease type III domain of 
PML-I as a purple box, and the ND10 formation domains of PML-II and PML-V 
as mauve boxes.  Sites of phosphorylation (P), SUMOylation (S), acetylation 
(Ac), and ubiquitination (Ub) are indicated by the spheres above and below with 
the modified residue listed. 
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Chapter 2: CK2 Inhibitors Increase the Sensitivity of HSV-1 to 
Interferon-β 
2  
2.1 Introduction 
For HSV-1, the successful establishment of infection and progression 
through the lytic phase of replication requires the coordinated effort of many 
viral and cellular factors to stimulate viral gene expression to ultimately produce 
infectious progeny virus [7].  A common theme in the regulation of these 
proteins is their post-translational modification by phosphorylation.  Although 
HSV-1 encodes at least two of its own protein-directed kinases – UL13 and US3 
– efficient replication appears to require several cellular kinases, most notably 
certain cyclin-dependent kinases [197] and stress activated protein kinases 
[198].  HSV-1’s requirement for cellular kinases makes the use of 
pharmacological inhibitors against these kinases a potential avenue for anti-
herpetic treatments. 
The host kinase, CK2, has been shown or is predicted to modify a 
number of HSV-1 proteins and has been hypothesized to affect many aspects of 
the viral lifecycle.  Previous studies examining the role of CK2 during HSV-1 
infection were unable to assess the effect of CK2 on replication due to 
limitations of the inhibitors available at the time.  For example, at the 
concentrations necessary to inhibit CK2 with a commonly used CK2 inhibitor, 
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5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), the drug also blocks the 
activity of CDK9 [97,199].  In this study, we have taken advantage of recently 
developed compounds that are more selective in their inhibitory properties.  Our 
results indicate that CK2 inhibitors have a minor impact on HSV-1 replication in 
cultured human fibroblasts; however, the use of CK2 inhibitors compromises the 
ability of the virus to replicate in cells pretreated with the type I interferon, IFN-β, 
in a manner that was only observed with HSV-1. 
 
2.2 Methods and Materials 
2.2.1 Cell and viruses  
Human embryonic lung (HEL) cells were obtained from the American 
Type Culture Collection (CCL-137) and grown in Minimum Essential Medium 
Eagle Alpha Modification (αMEM) supplemented with 10% fetal bovine serum 
(FBS), 2 mM L-glutamine, 10 U/mL penicillin, and 10 U/mL streptomycin.  Vero 
cells and L7 cells, which are Vero cells that contain the ICP0 gene [200], were 
grown in Dulbecco’s modified Eagle’s medium supplemented with 5% FBS, 2 
mM L-glutamine, 10 U/mL penicillin, and 10 U/mL streptomycin. KOS [201] is 
the wild type HSV-1 strain used in these studies.  7134 is an ICP0-null mutant in 
which the ICP0 open reading frame is replaced by the E. coli lacZ gene [202]. 
KOS and 7134 viral stocks were prepared in Vero cells and titered on either Vero 
(for KOS) or L7 cells (for 7134) as previously described [91,203].  Adenovirus 5 
(Ad5) was purchased from the American Type Culture Collection (VR-5) and 
 34 
propagated and titered on HEK-293 cells [204].  The vesicular stomatitis virus 
recombinant, VSV-eGFP [205], which encodes the enhanced green fluorescent 
protein gene inserted between the G and L genes, was a gift from Dr. Asit 
Pattnaik and was propagated and titered on Vero cells. 
2.2.2 Reagents 
The CK2 inhibitors 4,5,6,7-tetrabromo-1H-benzotriazole (TBB) and 2-
dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) were purchased 
from EMD Chemicals and 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-
benzo[d]imidazol-1-yl)acetic acid (TMCB) from Ascent Scientific.  All CK2 
inhibitors were constituted in DMSO (Fisher Scientific).  Recombinant human 
IFN-β was purchased from R&D Systems. 
2.2.3 Viral plaque reduction assays 
For HSV-1 plaque reduction assays, HEL cells were plated in 24-well 
plates.  Upon reaching 70% confluency, cells were either mock treated or 
treated with a given concentration of IFN-β.  After 16 h of IFN-treatment, cells 
were prewashed with either medium; medium plus IFN-β; medium plus DMSO 
(as vehicle control), TBB, or TMCB; or medium plus IFN-β and either vehicle or 
CK2 inhibitor.  Cells were then infected with 10-fold serial dilutions of HSV-1 in 
the aforementioned media.  At 1 h post infection (hpi), the cells were overlaid 
with cell culture medium containing 0.5% methylcellulose and the appropriate 
compounds.  At 3 days post infection (dpi), monolayers were fixed with 3.7% 
formaldehyde, probed with a horseradish peroxidase (HRP)-conjugated anti-
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HSV antibody (Dako), and the resulting plaques were visualized with Vector Red 
substrate (Vector Labs).  Plaque areas were determined by capturing images of 
immunohistochemically stained plates with a flatbed scanner (Canon), 
measuring the number of pixels that corresponded to an individual plaque in 
Adobe Photoshop.  Pixel values were converted to mm2 by dividing by the 
number of pixels per inch for the image.  Four to twenty plaques were measured 
per treatment from two experiments. 
For Ad5 plaque reduction assays, HEL cells were treated and infected as 
described for the HSV-1 plaque assays.  At 5 dpi, cells were washed once with 
PBS, fixed for 5 minutes with 5% formaldehyde in PBS, washed three times with 
PBS, permeabilized at 4°C for 15 minutes with 0.5% NP-40 in PBS, and washed 
an additional three times with PBS.  Ad5 infected cells were detected by probing 
the cells with a FITC-conjugated anti-adenovirus antibody (B65140F, Meridian 
Life Science) diluted in PBS and the resulting plaques and cells were visualized 
and counted by fluorescence microscopy (Nikon). 
For VSV-eGFP reduction assays, HEL cells were again treated and 
infected as described for HSV-1 plaque assays with the exceptions that the cells 
were treated with 10 U/mL of IFN-β, and the monolayers were overlaid with 2% 
methylcellulose.  At 1 dpi, the cells were washed three times with PBS and fixed 
with 3.7% formaldehyde in PBS for 5 minutes at room temperature.  Plaques 
were detected and counted by fluorescence microscopy (Nikon). 
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2.2.4 Viral yield assays 
HEL cells were plated at 1 × 105 cells per well in 12-well plates and one 
day later were either mock treated or treated with IFN-β.  16 hs later, cells were 
prewashed as described above and subsequently infected for 1 h in the 
presence of the appropriate compounds with either KOS or 7134 at a multiplicity 
of infection of 1.  After 1 h, the cells were overlaid with cell medium containing 
the previously described compounds.  At 24 hpi, cells were harvested, and viral 
titers were determined on Vero or L7 cells for KOS or 7134, respectively. 
2.2.5 Western blots 
HEL cells were plated, treated, and infected as described for HSV-1 yield 
assays.  12 and 24 hpi, cells were washed once with PBS and then scraped into 
boiling Laemmli loading buffer [206] containing 1 µg/mL leupeptin, 1 µg/mL 
aprotinin, 1 mM phenylmethanesulfonylfluoride, 10 mM sodium vanadate, 50 
mM sodium fluoride, and 20 mM N-ethylmaleimide.  10% of each sample was 
resolved on a 4-12% Bis-tris polyacrylamide gel, transferred to nitrocellulose, 
blocked at room temperature for 1 h with 2% nonfat dry milk in Tris-buffered 
saline with 0.1% Tween 20 (TBS-T), and probed overnight at 4°C with antibodies 
directed against either ICP4 (H1A021, EastCoast), UL42 (mAB3678, Millipore), 
PML (A301-167A, Bethyl Laboratories), or β-actin ((I-19)-R, Santa Cruz 
Biotechnology).  Membranes were then washed three times with TBS-T and 
probed at room temperature with either goat-anti-mouse IgG or goat-anti-rabbit 
IgG conjugated to HRP (Jackson Immunoresearch).  Membranes were again 
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washed with TBS-T and developed with chemiluminescent substrate (Femto 
ECL, Pierce Laboratories).  Some membranes were stripped by incubation in 
2% SDS, 100 mM β-mercaptoethanol, 62.5 mM Tris-HCl (pH 6.7) at 55°C for 30 
minutes.  These membranes were thoroughly washed with TBS-T, blocked at 
room temperature for 1 h with 2% milk/TBS-T, and probed overnight at 4°C with 
antibodies directed against either ICP0 (sc-53070, Santa Cruz Biotechnology) or 
VP5 (ab6508, Abcam).  The membranes were then washed, probed with a 
secondary HRP-conjugated antibody, and developed as before.  
Chemiluminescence was detected using an Image Station 4000R (Kodak) and 
Carestream Molecular Imaging software.  Images were assembled using 
Photoshop and Illustrator (Adobe Systems) and band intensities were measured 
by densitometry analyses using ImageJ. 
2.2.6 Immunofluorescence 
HEL cells were plated at 1 × 105 cells per well in collagen-coated glass 
bottom 24-well plates, treated, and infected as described above for the HSV-1 
yield assays.  At 12 hpi, the cells were fixed and permeabilized as described 
above in the Ad5 plaque reduction assays.  Samples were blocked with 1% 
BSA, 5% FCS, 1% goat serum in PBS for 1 h at room temperature.  Cells were 
then probed with antibodies against ICP0 (sc-53070), PML (A301-167A), and 
DNA-PKcs (sc-5282, Santa Cruz Biotechnology) for 1 h in blocking solution at 
37°C.  Monolayers were washed with PBS and probed with goat-anti-mouse 
immunoglobulin (IgG) 2b Dylight 488 (Jackson Immunology), goat-anti-rabbit 
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IgG Alexa 405 (Molecular Probes), and goat-anti-mouse IgG1a Dylight 594 
(Jackson Immunoresearch) to detect ICP0, PML, and DNA-PKcs, respectively.  
Proteins were viewed by confocal fluorescent microscopy (Olympus) and 
captured with a digital camera (Hamamatsu).  Images were assembled using 
Photoshop and Illustrator (Adobe Systems). 
 
2.3 Results 
2.3.1 CK2 inhibitors reduce the plating efficiency and plaquing of 
HSV-1 in IFN-β-treated cells 
We initially sought to determine the requirement for CK2 activity during 
HSV-1 replication.  To this end, we employed plaque reduction assays to test 
the effect that two specific CK2 inhibitors, TBB (IC50 = 0.15 µM) and TMCB (IC50 
= 0.50 µM) [207], which block the active site of CK2, have on the plating 
efficiency and spread of HSV-1 in HEL cells.  Additionally, because cellular 
factors responsible for the innate antiviral response (e.g., IFN) and the viral 
factors that counteract this response are either known to be or are potential CK2 
substrates, we also examined how these inhibitors affected the ability of HSV-1 
to plaque in the presence of a type 1 interferon, IFN-β.  HEL cells were untreated 
or pretreated with 1000 U/mL of IFN-β for 16 hs and then infected with serially 
diluted HSV- 1 in the presence of the compounds as listed in Table 2.1.  In these 
and subsequent assays, TBB was used at 50 µM as previously described [183], 
while a preliminary dose response curve suggested that the same concentration 
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was appropriate for TMCB (data not shown); DMSO was used at 0.5% v/v as a 
vehicle control.  As seen in Table 2.1, the use of each CK2 inhibitor alone 
resulted in only a modest reduction in plaque size (3.9- and 1.4-fold decrease 
for TBB and TMCB, respectively) and plating efficiency of HSV-1 (0 and 2-fold 
decrease for TBB and TMCB, respectively) compared to the untreated samples.  
As expected, IFN-β reduced plaque size and plating efficiency 26- and 25-fold, 
respectively.  When DMSO was added to IFN-β, it had a slight effect on plaque 
size (1.8-fold decrease versus IFN-β alone), and a negligible impact on plating 
efficiency.  However, the combination of IFN-β and either CK2 inhibitor further 
reduced viral plaque size and plating efficiency (3.5- and 2.8-fold for TBB, and 
2.6- and 2.1-fold for TMCB, respectively), compared to IFN-β-treated cells.  
These results were further confirmed when we used a third CK2 inhibitor, DMAT 
(data not shown).  We then tested whether these inhibitors would also enhance 
the IFN-sensitivity in cells treated with a suboptimal concentration (50 U/mL) of 
IFN-β.  This reduced amount of IFN, in either media alone or with DMSO, indeed 
proved to be less effective at reducing either plaque size (~5-fold) or plating 
efficiency (4-fold).  Again, we found that both inhibitors, in combination with IFN-
β, reduced the plating efficiency of HSV-1 (9- and 7-fold) and both decreased 
viral plaque size (42.1- and 10.3-fold for TBB and TMCB, respectively) beyond 
that of IFN alone.  These decreases in viral replication were not due to a loss of 
cell viability, as treatment with IFN, CK2 inhibitor, or a combination of IFN and 
inhibitor did not increase cell death as measured by trypan blue exclusion 
assays.  Specifically, by three days post treatment, there was a 15% loss in cell 
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viability with mock-treated HEL, where all other treatment groups had a similar 
(9-23%) loss in cell viability. 
2.3.2 CK2 inhibitors reduce viral replication in IFN-β-treated cells in 
an ICP0-dependent manner 
We then examined whether the decreases in the plating efficiencies and 
plaque sizes observed in Table 2.1 correlated with reductions in productive 
infection.  In addition, we included an ICP0-null mutant virus in these 
experiments because ICP0 has been shown to assist HSV-1 in counteracting 
the IFN response [31,208,209] and is a potential target of CK2 phosphorylation 
[91].  Cells were pretreated with IFN-β and infected with 1 PFU per cell of either 
HSV-1 or an ICP0-null mutant virus in the presence of the reagents.  As shown 
in Figure 2.1, IFN-β treatment alone reduced the replication of HSV-1 by 28-fold 
and the ICP0-null mutant by 212-fold, while treatment with DMSO or either CK2 
inhibitor resulted in a minor (~2 fold) reduction in replication.  However, when the 
inhibitors were used in conjunction with IFN-β, the replication of HSV-1 was 
decreased by a factor of 145-fold with TBB and 69-fold with TMCB whereas the 
ICP0-null mutant was reduced by a factor of 182-fold with TBB and 141-fold 
with TMCB.  These results demonstrate that CK2 inhibitors increase the antiviral 
effects of IFN-β on HSV-1 productive infection and suggest the enhancement by 
the CK2 inhibitors may be related to the anti-IFN-mediated activity of ICP0. 
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2.3.3 CK2 inhibitors in conjunction with IFN-β decrease the levels of 
early and late proteins 
To identify the point(s) in the viral life cycle impaired by the combination 
of CK2 inhibitor and IFN-β, we analyzed the accumulation of specific viral 
proteins by western blot analysis.  HEL cells were again pretreated with IFN-β 
and infected with HSV-1 at 1 PFU per cell in the presence of the reagents.  At 12 
and 24 hpi, western blots were used to assess the levels of the viral proteins 
ICP4, UL42, and VP5 as representative examples of IE, E, and L proteins, 
respectively.  The results in Figure 2.2 show that, as expected, the CK2 
inhibitors alone had little effect on the accumulation of the viral proteins 
examined.  IFN treatment delayed viral protein expression, with an overall 
reduction for all three kinetic classes tested.  While the combination of IFN-β 
and CK2 inhibitor did not decrease ICP4 levels more than for IFN-β alone, there 
was a decline in UL42 (>100-fold for TBB and TMCB) and VP5 (>9-fold for TBB 
and TMCB) levels at 24 hpi.  These results indicate that the use of the CK2 
inhibitors impairs the function of at least one IE protein to activate the synthesis 
of E and L proteins. 
2.3.4 CK2 inhibitors do not affect the stability of ICP0-directed 
targets of degradation 
Since the viral replication assays indicated that the CK2 inhibitors did not 
increase the IFN sensitivity of an ICP0-null mutant, we assayed the impact that 
the CK2 inhibitors had on the E3 ubiquitin ligase activity of ICP0.  ICP0, through 
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its E3 ubiquitin ligase activity, induces the proteasomal-dependent degradation 
of a number of cellular targets in order to assist HSV-1 in overcoming cellular 
antiviral responses.  As a result, we examined whether the CK2 inhibitors 
impaired ICP0’s ability to induce the loss of two cellular targets, PML and DNA-
PKcs.  HEL cells were pretreated with IFN-β and infected with HSV-1 in the 
presence of CK2 inhibitors as described above.  At 12 hpi, the cells were 
assayed for the presence of ICP0, PML, and DNA-PKcs by 
immunofluorescence; at 12 and 24 hpi, cell lysates were analyzed for PML and 
ICP0 levels by western blot.  As shown in Figure 2.3, while the use of either CK2 
inhibitor, IFN-β, or the combination of CK2 inhibitor and IFN-β decreased the 
number of ICP0-positive cells, a majority of cells that were positive for ICP0 
either showed a decrease or loss of DNA-PKcs and PML, irrespective of 
treatment.  When we examined PML levels by western blot (Figure 2.4), 
however, it appeared that treatment with TBB alone resulted in a slight 
stabilization of PML at 12 hpi, and at 24 hpi when TBB was used with IFN-β in 
HSV-1 infected cells.  While this might indicate that CK2 is involved in ICP0-
induced PML degradation, it is also likely that PML levels were higher due to a 
smaller proportion of cells expressing ICP0 (Figure 2.3) resulting in the 
decreased levels of ICP0 produced in cells treated with CK2-inhibitor (Figure 
2.4).  These results suggest that the CK2 inhibitors do not compromise the E3 
ubiquitin ligase activity of ICP0, or at least the ability of ICP0 to induce the 
degradation of two of its targets. 
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2.3.5 The enhanced effect of CK2 inhibitors on IFN is observed with 
HSV-1 but not VSV and Ad5  
Our results suggest two possibilities to explain how the use of CK2 
inhibitors increase the sensitivity of HSV-1 to an IFN-β-induced antiviral 
response: CK2 negatively regulates one or more cellular components of the IFN 
response that repress HSV-1 replication and thus the inhibitors increase the 
overall potency of IFN-β or CK2 alters the activities of one or more viral 
components that impairs the ability of IFN to restrict HSV-1 replication.  It is also 
conceivable that both possibilities are true.  To test these possibilities, we 
examined the effect that the CK2 inhibitors had on the plating efficiency of two 
other viruses, VSV and Ad5.  VSV and Ad5 were chosen for these studies as 
they represent viruses that are genetically distinct from HSV-1 and are either 
very sensitive to the effects of IFN (for VSV) or show high levels of IFN resistance 
(for Ad5) [210].  HEL cells were pretreated with IFN-β for 16 hs and infected with 
10-fold serial dilutions of either Ad5 or the VSV recombinant, VSV-eGFP, as 
described for HSV-1.  At 1 dpi, VSV-eGFP-infected monolayers were fixed and 
GFP-positive plaques counted; Ad5-infected monolayers were fixed at 5 dpi, 
stained with an antibody directed against adenovirus, and plaques visualized by 
immunofluorescence.  As shown in Table 2.2, VSV replication was highly 
impaired by pretreatment with IFN, whereas Ad5 was highly resistant, as 
expected.  Similar to HSV-1, both of the CK2-inhibitors had little to no effect on 
either VSV or Ad5 replication; however, unlike HSV-1, neither inhibitor increased 
the IFN-sensitivity of VSV or Ad5.  These data suggest that the activity of CK2 is 
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necessary for the ability of HSV-1 to diminish the effects of IFN on replication, 
that this mechanism is specific to HSV-1, and that, at least in HEL cells, CK2 
activity is not required for the plaquing of either VSV or Ad5 regardless of the 
IFN response. 
 
2.4 Discussion 
HSV-1 requires the activities of a number of both viral and cellular kinases 
for efficient viral replication.  Because several of the potential viral CK2 
substrates are involved in overcoming cellular intrinsic and innate antiviral 
defenses and a number of those defenses are themselves CK2 phosphorylation 
substrates [63,66,91,183,211], we investigated the effect that CK2 inhibitors 
have on HSV-1 replication in cells treated with the type I interferon, IFN-β.  
Surprisingly, while the inhibitors alone had little impact on replication, they 
functioned synergistically with IFN-β.  When we investigated the point in the viral 
life cycle affected, we found that the levels of the IE proteins ICP0 and ICP4 
were relatively unaltered while there was large decrease in both the E protein, 
UL42, and L protein, VP5.  This result suggests that the CK2 inhibitors impair 
the activity of an IE protein that functions to overcome the IFN response.  Of the 
HSV-1 IE proteins, both ICP0 and ICP27 have been identified as antagonists of 
the IFN response.  This study focused on whether inhibition of CK2 activity 
influenced ICP0’s ability to counteract the IFN response.  We were unable to 
examine the role of ICP27 in this study as the loss of ICP27 is deleterious [212] 
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and, as is discussed below, mutations that either block or mimic 
phosphorylation at the CK2 phosphoacceptor sites of ICP27 significantly impair 
HSV-1 replication [93].  Our results demonstrate that the CK2 inhibitors were 
unable to increase the IFN sensitivity of an ICP0-null mutant, indicating a 
requirement for CK2 in ICP0’s anti-IFN activity.  To determine if the combination 
of CK2 inhibitor and IFN-β impede a key function of ICP0, we examined the 
ability of ICP0 to direct the degradation of two of its targets, PML and DNA-
PKcs, in cells treated with the CK2 inhibitors.  In these assays, we did not 
observe the inhibitors inducing a stabilization of either target.  While ICP0 may 
be a CK2 substrate, it appears that phosphorylation of ICP0 by CK2 is not 
necessary for its E3 ubiquitin ligase activity in our assays.  It is possible that 
phosphorylation of ICP0 by CK2 may affect an activity of ICP0 not linked to its 
E3 ligase activity in order to promote efficient viral replication in the presence of 
IFN-β, or that ICP0 activates the expression of an E and/or L gene and that the 
protein product of this viral gene is phosphorylated by CK2 to inactivate 
components in the IFN response.  Indeed, previously work using transient 
transfection assays showed that ICP0 mutated in two regions containing 
potential CK2 phosphorylation sites exhibit defects in its transactivation activity 
[91]; however, initial tests of a virus encoding one of these mutants, Phos1, 
behaved like a wild type virus in plaque assays (data not shown). 
We also noted in this study that the CK2 inhibitors alone do not appear to 
greatly impede the replication of HSV-1, thus making CK2 activity likely 
dispensable for the growth of HSV-1.  This is unexpected given the number of 
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HSV-1 proteins that have been identified as potential CK2 substrates and that 
mutation of these CK2 phosphorylation sites is detrimental to viral replication 
[92,93,213–215].  As one example, mutation of CK2 phosphorylation sites in the 
IE protein, ICP27, impairs viral replication [93].  This mutation, however, may 
prevent a large conformational shift in the N-terminus of ICP27 that appears to 
be necessary for its functions [98] and do so in a CK2 phosphorylation-
independent manner.  It is also probable that residual CK2 kinase activity may 
remain after TBB or TMCB treatment or that the stimulation of CK2 activity by 
ICP27 [97] is able to overcome the effect of the CK2 inhibitors; however, these 
possibilities seem unlikely as a further reduction in plaque size or plating 
efficiency was not observed when higher levels of either inhibitor were used 
(data not shown). 
While the enhanced sensitivity of IFN induced by CK2 inhibitors requires 
at least one HSV-1 protein, it is also plausible that this effect could be mediated 
by one or more cellular factors.  To explore this possibility, we examined 
whether the CK2 inhibitors influenced the IFN-sensitivity of two other viruses, 
VSV and Ad5.  We found that the CK2 inhibitors used alone affected neither 
virus.  While IFN-β impaired the replication of VSV, neither inhibitor increased 
this impairment beyond that of IFN-β alone.  Ad5, on the other hand, was largely 
impervious to the effect of IFN-β and the use of the CK2 inhibitors failed to 
change this.  Although the CK2 inhibitors alone did not alter VSV replication, it 
was recently reported that use of the CK2 inhibitor, DMAT, or siRNA-mediated 
silencing of CK2 increased VSV replication [63].  Likewise, the CR2 region of the 
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Ad5 E1A protein contains a consensus CK2 phosphorylation motif [216].  In the 
case of VSV, the discrepancy may lie in the cell lines used, as those studies 
were carried out in the highly transformed HEK-293s while we used primary-like 
HEL-299s.  As for Ad5, while the CK2 site was implicated in binding to the 
retinoblastoma protein and resistance to Ad-induced cell death, the role of 
phosphorylation at this site in Ad5 replication is likely to be minimal as mutation 
of this site failed to affect E1A transactivation activity [216].  In either case, the 
fact that the CK2 inhibitors did not increase the IFN-β sensitivity of VSV or Ad5 
suggests that the CK2 inhibitors compromise an anti-IFN mechanism that is 
specific to HSV-1. 
While we did not note either CK2 inhibitor having a large impact on the 
replication of either VSV or Ad5, a number of other viruses have shown a 
dependence on CK2 activity for efficient replication.  For example, CK2 
phosphorylation is involved in multiple steps of the human immunodeficiency 
virus 1 (HIV-1) life cycle, including reverse transcription and gene expression 
[69,217], and treatment with a CK2 inhibitor has been reported to inhibit HIV-1 
replication [217].  Additionally, a CK2 inhibitor was recently shown to have 
antiviral activity towards varicella-zoster virus [218].  It remains to be seen, 
however, if the enhancement by CK2 inhibitors on the potency of IFN is 
restricted to HSV-1 or if this extends to other members of the herpesvirus family 
or more broadly to other viral families.  Nevertheless, CK2 inhibitors show 
promise as anti-HSV-1 therapeutic agents when used in combination with other 
 48 
antiviral treatments.  Notably, the CK2 inhibitor, TBB, has been shown to be 
efficacious in limiting retinal pathologies in mice [219]. 
 
2.5 Tables 
Table 2.1 Plaque size and plating efficiency of HSV-1 in CK2 inhibitor-, IFN-
β-, or IFN-β plus CK2 inhibitor-treated cells. 
Treatment Area (mm2)a Area 
(fold 
change)
b 
Area 
(fold 
decrease 
vs IFN-
β)c 
Plating 
efficiency 
(fold 
decrease)d 
None 5.470 (± 0.564) – – – 
DMSO 4.670 (± 0.644) ↓1.2 – 1 
TBB 1.410 (± 0.193) ↓3.9 – 1 
TMCB 3.830 (± 0.414) ↓1.4 – ↓2 
50 U/mL IFN-β 1.160 (± 0.126) ↓4.7 – ↓4 
50 U/mL IFN-β + DMSO 0.970 (± 0.106) ↓5.6 ↓1.2  ↓4 
50 U/mL IFN-β + TBB 0.130 (± 0.011) ↓42.1 ↓8.9* ↓9 
50 U/mL IFN-β + TMCB 0.530 (± 0.065) ↓10.3 ↓2.2* ↓7 
1000 U/mL IFN-β 0.210 (± 0.025) ↓26.0 – ↓25 
1000 U/mL IFN-β + DMSO 0.120 (± 0.011) ↓45.6 ↓1.8 ↓27 
1000 U/mL IFN-β + TBB 0.060 (± 0.005) ↓91.2 ↓3.5* ↓71 
1000 U/mL IFN-β + TMCB 0.080 (± 0.007) ↓68.4 ↓2.6* ↓52 
a Plaque areas were determined by capturing images of immunohistochemically 
stained plates with a flatbed scanner and measuring the number of pixels that 
corresponded to an individual plaque in Adobe Photoshop.  The pixel values 
were converted to mm2 by dividing that value by the number of pixels per inch 
for the image.  Four to twenty plaques were measured per treatment for two 
experiments, and the results for one experiment are shown above.  Data are 
shown as the means (± SEM). 
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b Fold change relative to untreated cells (“None”). 
c One-Way ANOVA (P < 0.05), Bonferroni’s multiple comparison post-test (*, P < 
0.05) compared to the IFN-treated group 
d Plating efficiency decrease was calculated by dividing the number of plaques 
in the untreated sample by the number of plaques for a given treatment.  The 
data shown are the means of two experiments. 
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Table 2.2.  Plating efficiency of VSV and Ad5 in CK2 inhibitor-, IFN-β-, or 
IFN-β plus CK2 inhibitor-treated cells. 
Virus Treatment 
Plating 
efficiency (fold 
decrease)a 
VSV None – 
 DMSO 1 
 TBB 1 
 TMCB 1 
 IFN-β ↓100 
 IFN-β + DMSO ↓74 
 IFN-β + TBB ↓66 
 IFN-β + TMCB ↓65 
Ad5 None – 
 DMSO 1 
 TBB 1 
 TMCB 1 
 IFN-β ↓2 
 IFN-β + DMSO ↓3 
 IFN-β + TBB ↓5 
 IFN-β + TMCB ↓4 
aPlating efficiency decrease was calculated by dividing the number of plaques in 
the untreated sample by the number of plaques for a given treatment.  The data 
shown are the means of two experiments 
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2.6 Figures 
 52 Figure 2.1.  The effect of IFN-β and CK2 inhibitors on viral replication. 
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HEL cells were pretreated with or without IFN-β for 16 hs and 
subsequently infected with wild-type HSV-1, strain KOS, (A and C) or an ICP0 
null mutant, 7134, (B and D) at 1 PFU per cell in the presence of IFN-β, DMSO 
(vehicle), TBB, or TMCB or a combination of IFN and DMSO, TBB, or TMCB.  At 
24 hpi, infected cells were harvested, and wild-type HSV-1 was titered on Vero 
cells and the ICP0 null mutant on L7 cells.  The data shown in A and B are the 
mean titers (± SEM) of two experiments performed in duplicate; C and D are the 
titers expressed as fold decrease relative to untreated cells. 
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Figure 2.2.  The combination of CK2 inhibitor and IFN-β decreases early 
and late protein levels. 
HEL cells were treated and infected as described in Figure 2.1.  At 12 and 
24 hpi, cells were washed with PBS before being resuspended into loading 
buffer.  Lysates were resolved by SDS-PAGE and analyzed by western blot for 
ICP4, UL42, VP5, or β-actin expression.  Band intensities were measured by 
densitometry analyses using ImageJ.  UL42 (ce): the UL42 24 hpi lanes contrast 
enhanced (ce) using Adobe Photoshop. 
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Figure 2.3.  CK2 inhibitors do not prevent the loss of PML and DNA-PKcs 
staining mediated by ICP0. 
HEL cells were treated and infected as described in Figure 2.1.  At 12 hpi, 
cells were fixed and stained with antibodies against DNA-PKcs, PML, and ICP0.  
PML is shown as blue, DNA-PKcs as red, and ICP0 as green in the merged 
image.  The yellow, orange, and red arrows indicate a cell that stains positive for 
ICP0 (red arrow) but has reduced or no apparent staining for PML (yellow arrow) 
and DNA-PKcs (orange arrow). 
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Figure 2.4.  CK2 inhibitors do not stabilize PML levels during infection. 
HEL cells were treated, as described in Figure 2.1, infected with wild-type 
HSV-1, and harvested at 12 and 24 hpi.  Cell lysates were analyzed for PML, 
ICP0, or β-actin expression by western blot analyses. 
TBB
TMCB
DMSO
HSV-1
0-5ʹ
+ + ++ + + ++
+ + ++
+
+
+
-
-
- ---
-
-
-
-
- -
-
+
+
+
-
--
-
-
-
- -
-
-
-
-
-
-
-
+
-
-
-
-
-
-
+
-
-
+
-
+
-
PML
actin
ICP0
12 hpi
PML
actin
ICP0
24 hpi
 58 
Chapter 3: hTERT extends the life of human fibroblasts without 
compromising type I interferon signaling. 
3  
3.1 Introduction 
In performing studies that examine cellular defenses to viral infections, it 
is often necessary to work with primary cells, as the efficacy of intrinsic and 
innate immune pathways are frequently diminished in immortalized cells [99–
102].  One disadvantage of using primary cells is their limited proliferative 
capacity in cell culture, which is due in part, to the progressive shortening of 
telomeres [103]. 
Telomeres are repetitive nucleoprotein structures that serve to cap the 
ends of chromosomes, facilitating their replication, and prevent their ends from 
appearing as DNA breaks [104].  Telomeres are maintained by a complex known 
as telomerase, whose essential core consists of the catalytic subunit telomerase 
reverse transcriptase (TERT) and the telomerase RNA template component 
(TERC) [108,109].  Along with a number of other factors, TERT is loaded onto 
the 3’ overhang of existing telomeric DNA and utilizes TERC as a template to 
add repeats of a guanine-rich sequence, 5’TTAGGG3’, in all vertebrates; 
concordantly, DNA primase and DNA polymerase are recruited to the new 
telomeric repeats, subsequently synthesizing the complementary 5’ strand [104].  
In the absence of active telomerase, erosion of the telomeres occurs with each 
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successive round of replication, resulting in the loss of telomeric (~100 bps) 
sequence [106,107].  Once telomeres are reduced from their normal 15 kb 
length to ~4 kb, DNA damage sensors trigger p53- and pRb-dependent 
mechanisms that result in cellular senescence, inducing a G1 cell cycle arrest 
[110]. 
Replicative senescence is thought to be a mechanism of cellular lifespan 
regulation, preventing diseases such as cancer, and is intrinsic to the health of 
an organism [111–114].  However, for technical reasons it can be desirable to 
extend the proliferative capacity and prevent the senescence of a primary cell 
culture or strain.  One way to avoid or reverse replicative senescence is 
transformation with viral oncogenes, such as the simian virus 40 (SV40) large T 
antigen (TAg) or the human papillomavirus (HPV) E6 and E7 proteins [115–117].  
In both cases, these viral proteins reverse senescence through the inactivation 
of p53 and/or pRb.  While this allows cells to resume progression through the 
cell cycle and replicate, these cells still undergo telomeric erosion and ultimately 
undergo a phenomenon termed crisis [115], where massive cell death occurs 
due to gross genomic rearrangements and instability in the absence of 
telomeres.  While the estimated 1 in 107 cells (for human cells) that survive crisis 
exit immortalized [118,119], this transformation results in the dysregulation of 
several cellular pathways, including the antiviral type I interferon (IFN) response 
[99]. 
The IFN response is an innate antiviral pathway that, upon detection of 
viral molecular patterns, results in the production and release of the cytokine 
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and type 1 IFN, IFN-β [37,220,221].  The IFN response serves as a major 
restriction point for many viruses as evidenced by the increased pathogenesis of 
these viruses in animal models in which either the type I IFN receptor, IFNAR, or 
a key signaling molecule, STAT1, are deleted [222–228].  One virus that interacts 
with the IFN response is HSV-1 [1].  Notably, HSV-1 encodes for viral proteins 
that inactivate or delay this IFN response [229,230].  Studies examining how 
HSV-1 counteracts the IFN response are often performed in primary cultures or 
cell strains, such as human embryonic lung (HEL) cells, because these cells 
possess a robust IFN response and phenotypes that are apparent in HEL cells 
are often greatly diminished in transformed lines [99,231].  A potential drawback 
with using HEL cells is their rapid progression into senescence. 
As part of their differentiation program, human cells cease expressing 
hTERT, while continuing to produce other essential telomerase subunits such as 
TERC [120].  It has been shown by a number of labs that the lifespan of 
fibroblasts is efficiently extended by the reintroduction of hTERT into these cells 
[121,122].  Exogenous expression of hTERT presumably allows terminally 
differentiated fibroblasts to resume the extension of their telomeres, delaying or 
avoiding the production of signals that trigger replicative senescence and in turn 
prevents the chromosomal damage encountered by replication through crisis 
[123].  Unlike transformation with viral oncogenes, fibroblasts that exogenously 
express hTERT do not, for the most part, exhibit an oncogenic phenotype [124].  
Notably, the effect that life-extension by exogenous expression of hTERT on 
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innate antiviral pathways, and in particular the IFN response, has not been 
examined. 
Here we report the creation of a life-extended HEL cell line via 
transduction of a human diploid primary-like cell strain, HEL-299, with a 
retrovirus encoding hTERT.  HEL-299s were chosen as a parental cell line since 
they are both capable of supporting high levels of HSV-1 and VSV replication 
and retain a strong innate immune restriction of viral replication (Chapter 2 and 
[232]).  Our results show that the derivative cell line, HEL-TERT, unlike the 
parental cells, replicated to at least 100 population doublings, exhibited 
telomerase activity, and failed to undergo either replicative senescence or crisis.  
Morphologically, HEL-TERT cells appeared indistinguishable from HEL-299 
cells.  HEL-TERTs responded to IFN-β by upregulating representative ISGs and 
supported the replication of HSV-1 and VSV to similar levels as HEL-299 cells.  
Additionally, the introduction of the SV40 large TAg counteracted the IFN-β-
directed restriction of HSV-1 and VSV replication.  In summary, our data indicate 
that hTERT extends the replicative potential of human fibroblasts while not 
perturbing the type 1 IFN response, making these cells a valuable tool in 
virological and virus-cell interaction studies. 
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3.2 Methods 
3.2.1 Cells and Viruses 
HEL-299 cells from the American Type Culture Collection (CCL-137), HEL 
telomerase life-extended (HEL-TERT), and HEL-TERT SV40 large TAg 
transformed (HEL-TERT-T) cells (the latter two of which were created as part of 
this work, as detailed below) were maintained in Minimum Essential Medium 
Eagle Alpha Modification (αMEM) containing 10% fetal bovine serum (FBS), 2 
mM L-glutamine, 10 U/mL penicillin, and 10 U/mL streptomycin.  In addition, 
HEL-TERT cells were kept under drug selection using hygromycin-B (Sigma) at 
50 µg/mL while HEL-TERT-T cells were maintained under selection with 
hygromycin-B at 50 µg/mL and phleomycin at 10 µg/mL.  HeLa, GP2-293, Vero, 
and L7 (Vero cells that contain the ICP0 gene [200]) cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 5% FBS, 2 mM L-
glutamine, 10 U/mL penicillin, and 10 U/mL streptomycin. 
HEL-299 (passage 4) cells were transduced with the retroviral vector, 
pMX-hTERT-hygro vector.  pMX-hTERT-hygro was created by subcloning the 
hTERT (catalytic subunit of human telomerase) and hygromycin resistance 
genes from the vector, pBABE-hygro-hTERT [233] (Addgene plasmid 1773), into 
the retroviral vector, pMX-GFP [234]. A control vector, pMX-dTERT-hygro, was 
created by excising a BamHII fragment, which removes the N-terminal 849 
residues of hTERT (Uniprot: O14746) [235] (including the TERC-interaction and 
most of the reverse-transcriptase domains), from pMX-hTERT-hygro.  Retroviral 
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stocks were generated using the Pantropic Retroviral Expression System 
(Clontech) as recommended by the manufacturer.  HEL-299 cells were 
transduced with filtered retroviral stocks and two days later placed under 
selection with hygromycin B at 100 µg/mL, which was lowered to 50 µg/mL 7 
days later for subsequent culturing.  HEL-TERT SV40 large TAg-expressing cells 
were created by transduction with the vector, pLVX-LgT-zeo.  pLVX-LgT-zeo 
was created by subcloning the CMV promoter, SV40 TAg ORF, SV40 early 
promoter, and zeomycin resistance genes from pBABE-zeo largeTcDNA [236] 
(Addgene plasmid 1779) into the lentiviral vector, pLVX-AcGFP-N1 (Clontech), 
replacing the region containing the CMV promoter, AcGFP ORF, 
phosphoglycerate kinase promoter, and puromycin resistance genes.  Lentiviral 
stocks were prepared essentially as described above for pMX-hTERT-hygro with 
the inclusion of the lentiviral packaging vector, psPAX2 (Addgene plasmid 
12260) during lentiviral stock preparation.  HEL-TERT cells were transduced with 
filtered lentiviral stocks and two days later placed under selection with 
phleomycin (Invivogen) at 20 µg/mL for 42 days, which was lowered to 10 µg/mL 
for long term culturing. 
KOS was the wild type strain of HSV-1 used in our viral experiments 
[201].  7134 is an ICP0-null mutant HSV-1 strain in which the E. coli lacZ gene 
has replaced the ICP0 open reading frame [202].  KOS and 7134 were grown on 
Vero cells and titered on Vero or L7 cells, respectively [91,203].  The vesicular 
stomatitis virus recombinant, VSV-eGFP, contains the enhanced green 
fluorescent protein gene between the G and L genes [205] and was a gift from 
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Dr. Asit Pattnaik.  VSV-eGFP stocks were grown and titered on Vero cells.  
Sendai virus (SeV, Cantrell strain) was purchased from Charles River 
Laboratories. 
3.2.2 β-galactosidase Staining 
To detect senescence, HEL-299, and moderate and high passage HEL-
TERT cells were plated at 1 x 105 cells per well in 12 well plates and grown to 
confluence.  The cells were fixed in 3.7% formaldehyde, washed twice with 1x 
phosphate buffered saline (PBS), and stained for β-galactosidase activity as 
previously described [237].  Cells were viewed with a Nikon Eclipse TE2000-U 
microscope and photographed with a digital camera (Canon). 
3.2.3 Life-Extension Characterization 
Low passage HEL-299 and HEL-TERT cells were plated in 60 mm dishes 
at 1-2 x 105 cells per dish.  Prior to reaching confluence, the cells were 
trypsinized, counted with a hemocytometer, and replated at the above-
mentioned amount.  This was repeated until cells reached senescence and died.  
Using cell counts and days in culture, the population doublings were determined 
for each cell line. 
3.2.4 Telomeric Repeat Amplification Protocol (TRAP) Assay 
TRAP assays were performed essentially as described [238]. 2 x 105 HEL-
299, HEL-TERT, and HeLa cells were collected, pelleted, and frozen at -80°C.  
The cell pellets were resuspended in 200 µL of CHAPS lysis buffer (0.5% 
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CHAPS, 10 mM Tris-HCl pH 7.5, 1 mM MgCl2, 1 mM EGTA, 3.5% 2-
mercaptoethanol, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 1 µg/mL 
aprotinin, and 1 µg/mL leupeptin) and incubated on ice for 30 minutes before 
cell pellets were collected by centrifugation.  Telomeric repeats were amplified 
in a solution of 10 ng of cell extract, 1x Taq buffer (NEB), 0.2 mM dNTPs, 0.04 
µg/µL of T4 Gene 32 Protein (NEB), and 2 U of the Taq polymerase (NEB) 
containing 0.5 ng/µL of the primers: TS (5’-AATCCGTCGAGCAGAGTT-3’) and 
ACX (5’-GCGCGG(CTTACC)3CTAACC-3’) by polymerase chain reaction (PCR) in 
an MJ Mini Personal Thermal Cycler (Bio-Rad).  Final PCR products were gel 
electrophoresed on 20% polyacrylamide gel, visualized with ethidium bromide 
staining, and photographed with a VisiDoc-It Imaging System (UVP). 
3.2.5 Quantitative Reverse Transcriptase Real Time PCR 
HEL-299, HEL-TERT, and HEL-TERT-T cells were plated at 1 x 105 cells 
per well.  Twenty-four hs post-plating, cells were mock treated or treated with 
human IFN-β at 1000 U/mL (AbD Serotec).  At 9 hs post treatment, cells were 
washed twice with PBS and harvested in Trizol (Invitrogen) to isolate total RNA.  
RNA was converted into cDNA using iScript cDNA synthesis kit (Bio-Rad) 
according to manufacturers recommendations.  For each sample, real time PCR 
was performed using FastStart SYBR green master (Rox) (Roche) in a 
StepOnePlus Real-Time PCR System (Applied Biosystems).  Transcripts were 
amplified using the following primer sets: hTBP (5’-
TGCACAGGAGCCAAGAGTGAA-3’ and 5’-CACATCACAGCTCCCCACCA-3’), 
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ISG15 (5’-GGTGGACAAATGCGACGAAC-3’ and 5’-
ATGCTGGTGGAGGCCCTTAG-3’), IFIT1 (5’-TAGCCAACATGTCCTCACAGAC-3’ 
and 5’-GTGCCTTGTAGCAAAGCCCTAT-3’), IFIT2 (5’-
ACGCATTTGAGGTCATCAGGGTG-3’ and 5’-
CCAGTCGAGGTTATTTGGATTTGGTT-3’) [239], and Mx1 (5’-
AGAAGGAGCTGGAAGAAG-3’ and 5’-CTGGAGCATGAAGAACTG-3’) [240].  All 
transcript levels were normalized to hTBP. 
3.2.6 Western Blot 
HEL-299, HEL-TERT, and HEL-TERT-T cells were plated at 1.5 x105 of 
cells per well in a 12-well plate.  24 hs later, cells were either mock treated or 
treated with IFN-β at 1000 U/mL for 16 hs before being washed with PBS and 
then lysed into Red Loading Buffer (62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% 
glycerol, 0.01% phenol red, 42 mM DTT) plus with protease inhibitors (1 µg/mL 
aprotinin, 1 µg/mL leupeptin, 1 mM phenylmethylsulfonyl fluoride).  Samples 
were resolved on a 4-12% Bis-Tris gradient polyacrylamide gel, transferred to 
nitrocellulose, blocked with 5% BSA in Tris-buffered saline with 0.1% Tween-20 
(TBS-T) for 1 h at room temperature.  Membranes were probed with an antibody 
against IFIT1 (PA3-848, Thermo Scientific) diluted in 5% BSA/TBS-T overnight 
at 4°C.  Membranes were washed three times with TBS-T, probed with HRP-
conjugated goat-anti-rabbit IgG diluted in 5% BSA/TBS-T for 1 h at room 
temperature, washed three times with TBS-T, developed with chemiluminescent 
substrate (Femto ECL, Pierce Laboratories), and detected using an Image 
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Station 4000R (Kodak) and Carestream Molecular Imaging software.  The 
membranes were then striped and probed with β-actin ((I-19)-R, Santa Cruz 
Biotechnology) as described section 2.2.5.  Images were assembled using 
Adobe Photoshop and Adobe Illustrator (Adobe Systems). 
3.2.7 Plaque Reduction Assays 
Plaque assays for KOS and 7134 on HEL-299, HEL-TERT, and HEL-
TERT-T cells (-/+ IFN-β) were carried out as described in section 2.2.3.  Images 
of viral plaques were captured by scanning the immunohistochemically stained 
plates with a flatbed scanner (Canon). 
3.2.8 HSV-1 Viral Yield Assays 
To examine HSV-1 productive infection, HEL-299, HEL-TERT, and HEL-
TERT-T cells were plated at 1 x 105 cells per well in 12 well plates.  One day 
post-plating, cells were mock-treated or treated with 1000 U/mL of human IFN-
β.  Sixteen hs post-treatment, cells were infected with either KOS or 7134 at 5 
plaque forming units (PFU)/cell, washed with PBS (-/+ IFN-β) after 1 h to remove 
unabsorbed virus, and placed back in growth medium (-/+ IFN-β).  At 24 hs 
post-infection, cells were harvested and frozen at -80°C.  Virally infected 
samples were thawed and sonicated, and standard plaque assays were 
performed on either Vero cells (for KOS) or L7 cells (for 7134) to determine viral 
titers 
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3.2.9 VSV Viral Yield Assays 
To measure VSV replication, HEL-299, HEL-TERT, and HEL-TERT-T cells 
were plated, mock-treated or treated with IFN, and infected as for the HSV-1 
yield assays except that cells were infected with VSV-eGFP at 0.1 PFU/cell.  At 
24 hs post-infection, cells were harvested and frozen at -80°C.  Virally infected 
samples were thawed and sonicated, and standard plaque assays were 
performed on Vero cells to determine viral titers. 
3.2.10 Antiviral cytokine-production assay 
To assess the ability of various cell lines to produce antiviral cytokines, 
HEL-299, HEL-TERT, or HEL-TERT-T cells were plated at 1 x 105 in 12-well 
plates.  The next day, the cells were either mock infected with serum-free αMEM 
or infected with SeV at 100 hemagglutination units (HAU) per 106 cells in serum-
free medium for 1 h, after which the virus was removed from the cells and fresh 
ɑMEM containing 10% FCS was added to the cells.  At 24 hpi, SeV-infected 
HEL cells were irradiated with ultraviolet light to inactive the virus.  To test for 
the production of antiviral cytokines secreted from these cells, duplicate Vero 
cell monolayers (2 x 105 cells per well in 12-well plates) were exposed to HEL 
supernanes.  In addition, one set of Vero cells were treated with either fresh 
ɑMEM or ɑMEM containing IFN-β at 1, 10, 100, or 1000 U/mL as positive 
controls.  Six hs later, untreated and treated Vero cells were infected with VSV-
eGFP at ~200 PFU/well.  At 1 hpi, the Vero cells were overlaid with αMEM 
containing 10% FCS and 1% methylcellulose.  Twenty-four hs post-VSV 
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infection, the methylcellulose was removed, Vero cells were washed with PBS 
and fixed with 3.7% formaldehyde, and fluorescent plaques were counted. 
 
3.3 Results 
3.3.1 HEL-TERT cells exhibit an expanded proliferative capacity 
HEL-299 cells are a primary strain that have been used to study viral 
replication and the type 1 IFN response [209,241].  This cell strain, nonetheless, 
can only be passaged in culture a limited number of times before undergoing 
senescence [242].  We wanted to determine whether ectopic expression of 
hTERT in HEL-299 cells would allow for a longer period of culturing.  HEL-299s 
were transduced with a retrovirus encoding both hTERT and hygromycin 
resistance.  The resulting antibiotic resistant mass population, hereafter called 
HEL-TERT, were then used in subsequent experiments.  To first examine 
whether hTERT conferred an extended ability to replicate, HEL-299 and HEL-
TERT cells were maintained in culture for an extended period of time, comparing 
the number of population doublings to days in culture.  As expected, HEL-299s 
proliferated just under 60 days in culture and underwent a total of 23.5 
population doublings (from two experiments); at which point the cells ceased to 
divide and underwent widespread cell death two weeks later (Figure 3.1).  It 
should be noted that in a couple of instances, HEL-299 cells were able to 
undergo approximately 35 population doublings (data not shown).  In contrast, 
the HEL-TERT cells were maintained in culture for 185 days and went through 
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114 population doublings (Figure 3.1), at which point the experiment was 
terminated. Transduction of HEL-299 cells with a retroviral vector that either 
expresses the green fluorescent protein or contains a deletion of hTERT failed to 
extend the life span of the HEL-299s (data not shown).  These results 
demonstrate that expression of hTERT significantly extends the life span of 
HEL-299 cells. 
3.3.2 HEL-TERT cells contain active telomerase 
To establish that transduced hTERT resulted in telomerase activity in 
HEL-TERT cells, we performed TRAP assays.  In this assay, telomerase activity 
is monitored by examining the laddering or amplification of 6 base-pair 
5’TTAGGG3’ telomeric repeats [243].  HeLa cells, which express hTERT [244], 
exhibited the characteristic 6 bp laddering, while the non-immortalized HEL-299 
failed to do so (Figure 3.2).  Unlike the parental cell line, the HEL-TERT cells 
showed a clear laddering effect, indicating that exogenous hTERT is active and 
capable of extending telomeres.  To ensure that the inability to detect 
telomerase activity in HEL-299 cellular extracts was not due to the presence of a 
PCR inhibitor [245], we amplified the cellular promyelocytic leukemia (PML) gene 
(data not shown).  Thus, HEL-TERT cells contain active telomerase, suggesting 
that the extended proliferative capacity of this cell line can be attributed to the 
maintenance of telomeres. 
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3.3.3 Prolonged culture of HEL-TERTs does not result in 
senescence  
As fibroblasts reach senescence, they exhibit characteristic changes in 
cellular morphology, such as an increase in area, due to dysregulation of 
cytoskeleton elements [103,246].  Additionally, senescent cells can be detected 
by their upregulation of a lysosomal β-galactosidase [247].  When we compared 
low (6 population doublings) and high (20 population doublings) passage HEL-
299 cells, we noted that many of the higher passage cells exhibited a clear 
enlargement of the cytoplasm, with a change from their typical narrow, drawn-
out morphology to one that was shortened and/or broader (Figure 3.3A).  When 
we compared the HEL-TERT cells to low passage HEL-299 cells, we were able 
to detect little if any morphological changes either shortly after transduction with 
hTERT or at 100 population doublings later (Figure 3.3A).  As part of these 
studies, we also examined another HEL-TERT derivative cell line that expresses 
SV40 large Tag (hereafter named HEL-TERT-T).  SV40 large Tag is known to 
alter the IFN-response [248]. From this experiment, HEL-TERT-T cells appeared 
to have an altered cellular morphology, with the cells decreasing in length and 
broadening in width.  When we examined all the cell types for senescence-
associated β-galactosidase activity, β-galactosidase activity was clearly 
detected in older HEL-299 cells, whereas we failed to detect β-galactosidase 
activity in either low passage HEL-299 or low or high passage HEL-TERT, or 
high passage HEL-TERT-T cells (Figure 3.3B).  These results indicate that not 
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only do HEL-TERT cells retain their ability to proliferate but also fail to exhibit 
signs of senescence. 
3.3.4 Treatment of HEL-TERT cells with human IFN-β induces 
strong ISG expression 
Because the IFN response has been reported to be altered in 
immortalized cells [100–102], we decided to examine the effect that exogenous 
hTERT expression had on ISG levels upon IFN-β-treatment.  HEL-299, HEL-
TERT, and HEL-TERT-T cells were stimulated with IFN-β for 9 hs and the 
transcript levels of four prototypic ISGs (IFIT1, IFIT2, ISG15, and Mx1) were 
monitored by qRT-PCR.  Both HEL-299 and HEL-TERT cells showed robust 
upregulation in the transcript levels of all four genes after the addition of IFN-β 
(Figure 3.4).  Three of the ISGs induced to similar levels between the two cell 
lines while ISG15 was induced to slightly higher levels in the HEL-TERTs.  On 
the other hand, the overall upregulation of these genes upon IFN-β treatment 
was greatly diminished in HEL-TERT-T cells.  When we examined IFIT1 protein 
levels, we found that, as expected [42], unstimulated HEL-299 and HEL-TERT 
cells contained little to no detectable IFIT1; however, IFIT1 was readily detected 
9 hs after IFN-β treatment (Figure 3.5).  Notably, IFN-treated HEL-299 and HEL-
TERT cells showed comparable levels of IFIT1 protein.  HEL-TERT-T cells, on 
the other hand, showed persistent production of IFIT1 and a greatly reduced 
difference between the unstimulated and IFN-treated states (as compared to 
that found in the other two cell lines), in agreement with a previous report [249].  
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Thus, the ectopic expression of hTERT in HEL-299 cells via retroviral 
transduction does not largely affect the ability of HEL cells to induce the 
expression of these four ISGs by IFN-β nor does it lead to a dysregulation of ISG 
protein production (i.e., IFIT1) as does the expression of TAg. 
3.3.5 HSV-1 and VSV replicate to comparable levels, +/- IFN-β, in 
HEL-299 and HEL-TERT cells 
As another measure to assess whether the IFN response is active and 
functional in HEL-TERT cells, we examined the replication of three viruses in the 
presence of IFN-β.  For these studies, we chose HSV-1 (strain KOS), which is 
largely resistant to type I IFNs, as well as both an ICP0-null mutant of HSV-1 
(7134) and VSV, as these latter two viruses are sensitive to type I IFNs 
[208,250,251].  Initially, we examined the ability of wildtype (WT) and ICP0-null 
HSV-1 to form plaques on untreated and IFN-β-treated HEL-299, HEL-TERT, 
and HEL-TERT-T cells.  Both viruses had visually comparable plaque sizes on 
both HEL-299 and HEL-TERT cell types (Figure 3.6), even on higher passage 
HEL-TERT cells (data not shown).  Plaques for both wild type and ICP0-null  
viruses appeared to be smaller on HEL-TERT-T cells, which is most likely due a 
decrease in the size of the cells that occurred upon transduction of TAg (Figure 
3.3A).  When the cells were pretreated with IFN-β, there was a large decrease in 
plaque size for both WT HSV-1 and the ICP0-null mutant on HEL-299 and HEL-
TERT cells, while plaque size on the HEL-TERT-T cells remained largely the 
same.  The ability of WT virus to form plaques was similar on the three cell lines 
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in untreated cells (Figure 3.7A), though the ICP0-null virus showed slight 
increases of 2-fold and 4.5-fold on HEL-TERT and HEL-TERT-T cells, 
respectively.  Upon the addition of IFN-β, the plaquing efficiencies of the WT 
and ICP0-null viruses were decreased ~10 fold and ~50-100-fold, respectively, 
on both HEL-299 and HEL-TERT cells (Figure 3.7C).  In contrast to the 
introduction of hTERT into HEL-299 cells, expression of large TAg greatly 
diminished the ability of IFN-β to restrict the plaquing of either WT or the ICP0-
null virus (3-fold for either) (Figure 7C), resulting in a nearly 80-fold increase in 
the plating efficiency of the ICP0-null virus on IFN-treated HEL-TERT-T cells as 
compared to IFN-treated HEL-299 cells (Figure 3.7B).  To further examine the 
effect of hTERT on HSV-1 replication, we also performed viral yield assays in the 
three cell types.  (Figure 3.7D).  WT HSV-1 replicated to comparable levels in all 
three cell lines, with IFN-pretreatment producing a slight reduction in yields from 
both HEL-299 and HEL-TERT but not from HEL-TERT-T cells.  Like WT HSV-1, 
the ICP0-null mutant replicated nearly as well among the three cell types in 
untreated cells; however, IFN-pretreatment resulted in a 100-fold decrease of 
viral yields in HEL-299 and HEL-TERT cells while producing little to no effect in 
HEL-TERT-T cells. 
To monitor reductions in VSV production, we again performed viral yield 
assays in the presence and absence of IFN-β.  Just as for HSV-1, VSV grew 
equally well among the three cell lines in untreated cells.  In IFN-β-treated cells, 
however, VSV growth in both HEL-299 and HEL-TERT cells was reduced by 
>106-fold while it was reduced by only 200-fold in pretreated HEL-TERT-T cells 
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(Figure 3.8).  Thus, HEL-TERT cells are similar to HEL-299s in their ability to 
support the replication of two genetically distinct viruses, and they retain an IFN 
response that is as functional as the parental cell line.  Overall, ectopically 
expressed hTERT does not appear to adversely affect viral replication or the 
type I IFN response in a human lung fibroblast cell strain. 
3.3.6 Effect of hTERT on antiviral cytokine production 
In addition to determining its effect on ISG upregulation and on the 
efficacy of an IFN-induced antiviral state, we decided to assess whether ectopic 
hTERT expression altered the ability of cells to produce IFN and other antiviral 
cytokines in response to infection.  We used infection by SeV, which is known to 
be a strong inducer of IFNs and other antiviral cytokines in human cells [252].  
For this assay, media from uninfected and infected HEL cells are placed onto 
naïve Vero cells, which respond to but cannot produce IFN, and restrictions on 
VSV plaquing are monitored [253,254].  Media from mock-infected HEL cells 
had no effect on the ability of VSV to plaque on Vero cells while IFN-β 
pretreatment, at the highest concentration tested (1000U/mL), was able to 
reduce the number of plaques formed by approximately 35-fold (Table 1).  When 
we tested the ability of media from SeV-infected HEL cells, we found that media 
from all three cell types were capable of lowering the number of plaques that 
formed by 5-7 fold.  These reductions were similar to the antiviral activity of 
100U/mL of IFN-β.  Although we are unable to distinguish between IFN-β or 
among the IFN-ɑ subtypes with this assay, the protective effect produced by 
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media from HEL-299 and HEL-TERT cells was identical and suggests that 
hTERT does not affect the activation of IFN-production in response to viral 
infection. 
 
3.4 Discussion 
Due to their unperturbed DNA damage, senescence, and antiviral 
pathways, primary cells are considered biologically relevant cells when studying 
how these cellular processes affect viral replication.  However, their limited 
ability to proliferate makes their use in examining these pathways technically 
challenging.  For example, the establishment of a cell line depleted for a 
particular cellular protein is generally difficult because of the rapid and inevitable 
onset of senescence.  Thus, in studying cell-virus interactions, there is a need 
for life-extended cell lines that retain many of the characteristics of a primary cell 
(e.g., antiviral responses) while allowing for the analysis of specific cellular genes 
or proteins (e.g., depletion, gene knockout).  It is possible to immortalize primary 
cells with viral and cellular oncoproteins, but immortalization can result in 
alterations of cellular processes and inhibit antiviral pathways, affecting the 
replication of wild-type and mutant viruses [255–258].  Another approach is to 
use the TERT gene, which has been reported to extend the life of human 
fibroblasts [121], and avoids many of the problems associated with cellular or 
viral oncogene immortalization or transformation [124].  Prior to this study, the 
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effect of hTERT expression on the IFN response had not, to the best of our 
knowledge, been examined. 
The traditional approach used to immortalize primary cells has been the 
introduction of cellular or viral oncogenes.  The most commonly used of these 
include E1A and E1B from adenovirus [259], E6 and E7 from human 
papillomavirus [116], and large TAg from SV40 [119,260].  In general, these 
proteins bypass senescence by the inactivation of one or both of the tumor 
suppressor proteins, p53 and pRb [261–263].  Unfortunately, in addition to 
perturbing the cell cycle, many of these viral proteins also serve to antagonize or 
inactivate antiviral pathways in order to promote viral replication.  E1A, E6, E7, 
and large TAg are capable of disrupting the activity of, among others, cellular 
histone deacetylases [264] and CBP/p300 [265–267] resulting in widespread 
transcriptional and epigenetic changes [268–272].  In the case of E1A, this 
interaction prevents the major type I IFN transcription factor, STAT1, from 
binding to CBP/p300 and upregulating ISGs [273].  Likewise, E6 is capable of 
preventing activation of the IFN response by blocking the transcriptional activity 
of IRF3 [274].  E1B proteins inhibit apoptosis and are capable of inactivating the 
cellular DNA damage response [275–277] .  Large TAg, on the other hand, has 
recently been reported to activate STAT1 and induce ISGs upregulation in the 
absence of IFN-exposure [249].  In agreement with this, we saw persistent 
production of IFIT1 protein in TAg-transduced cells.  However, the expression of 
large TAg, independent of SV40 infection, has also been shown to decrease the 
phosphorylation of the cellular translation factor eIF2α by an IFN effector, 
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double-stranded RNA protein kinase (PKR) [278].  This decrease in 
phosphorylation increases the translation capability of viral mRNAs.  Similarly, 
our results show that while large TAg may lead to high levels of ISG protein 
production, it functionally inactivates the IFN response.  Furthermore, 
immortalization by mechanisms not involving viral oncogenes may inactivate 
antiviral pathways, as observed with the loss of induction of ISGs in 
immortalized cells derived from Li-Fraumeni patients [99]. 
Our approach in this study was to extend the life of human fibroblasts 
with hTERT.  Cells transformed with hTERT arrest in response to serum 
starvation, maintain anchorage dependence, double at a rate similar to 
untransformed cells, and do not exhibit genomic instability [124].  While it has 
been reported that expression of hTERT can alter the expression of a limited 
number of genes, none of these have an apparent role in antiviral pathways 
[279].  We found that hTERT expression does not impair the upregulation of four 
representative ISGs (IFIT1, IFIT2, ISG15, and Mx1) does not lead to aberrant ISG 
protein production, nor does its expression affect the replication of two 
genetically distinct viruses, HSV-1 and VSV.  This is in agreement with previous 
work demonstrating that exogenous expression of hTERT in fibroblasts does not 
affect the replication of human cytomegalovirus [280,281] nor does it affect the 
upregulation of the IFN-induced senescence mediator, IFI16, upon IFN-
stimulation [282].  Furthermore, unlike SV40 large TAg, exogenous hTERT did 
not impair the ability of IFN to restrict the replication of VSV or an ICP0-null 
mutant of HSV-1, both viruses being quite sensitive to the effects of IFN-β, nor 
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did it hinder the ability of HEL cells to produce antiviral cytokines in response to 
viral infection.  While we did observe slight differences in the levels of induction 
for the four ISGs between HEL-299 and HEL-TERT cells, these differences failed 
to translate into an appreciable effect on the ability of IFN-β to suppress 
replication of VSV or the ICP0-null HSV-1 mutant.  hTERT overexpression has 
been reported to enhance the formation of apoptotic markers during HSV-1 
infection in HeLa cells, which express the human papillomavirus E6 and E7 
oncoproteins, and sensitizes them to apoptosis [283]. Our results, however, 
suggest that exogenous expression of hTERT in a primary cell strain has little 
impact on viral replication. 
In conclusion, HEL-TERTs are permissive for HSV-1 and VSV growth, 
have a robust antiviral response, and a significantly enhanced lifespan.  They 
recapitulate the phenotype of an HSV-1 ICP0-mutant, which is known to be 
complemented by the loss of proteins involved in the DNA damage response 
[284], antiviral pathways [35], or overexpression of certain cyclins [285], 
suggesting that these pathways are unperturbed.  Because the phenotypes of 
certain HSV-1 mutants are only apparent in primary cells, we believe the HEL-
TERT cell line to be an ideal choice due to their longevity and robust antiviral 
response.  Additionally, they will allow for the establishment of derivative cell 
lines that are depleted or overexpress targets of interest, facilitating a better 
understanding of cellular pathways (including the IFN response) and the viruses 
that alter these pathways. 
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3.5 Figures 
Figure 3.1.  HEL-TERT cells are life-extended compared to HEL-299 cells. 
HEL-TERT and HEL-299 cells were plated as duplicate cultures in 60 mm 
dishes at 1x105 and 2x105 cells per plate, respectively.  For each passaging, 
cells were counted and re-plated.  Population doublings were determined by 
using cell counts and days in culture. 
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Figure 3.2.  Telomerase activity is detectable in HEL-TERT and HeLa cells 
but not HEL-299 cells. 
HEL-299 (3 population doublings), HEL-TERT (3 population doublings), 
and HeLa cells were examined for telomerase activity using the TRAP assay.  
HeLa cells were used as a positive control for telomerase activity.  The numbers 
at the left side of the figure are DNA size markers (bp: base pair). 
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Figure 3.3.  HEL-299, HEL-TERT, and HEL-TERT-T cell morphology and 
senescence. 
(A) Transduction of HEL-299 cells with hTERT does not alter morphology.  
Light microscopy of live HEL-299 cells at 3 (left panel) and 22 population 
doublings (left middle panel), HEL-TERT cells after 6 (middle panel) and 100 
(right middle panel), and HEL-TERT-T (far right panel) after approximately 30 
population doublings.  (B) HEL-TERT cells fail to exhibit at least one sign of 
senescence.  HEL-299 cells at 6 (left panel) and 33 (left middle panel), HEL-
TERT cells after 42 (right middle panel), and HEL-TERT-T cells at approximately 
70 (right panel) population doublings were stained for β-galactosidase activity. 
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Figure 3.4.  HEL-TERT but not HEL-TERT-T cells show ISG induction at 
levels similar to HEL-299 cells after IFN stimulation. 
HEL-299s and HEL-TERT cells were treated or mock treated with 1000 
U/mL of human IFN-β.  At 9 hs post treatment, total RNA was isolated from cells 
and reversed transcribed into cDNA for qRT-PCR analysis to monitor ISG15, 
IFIT1, IFIT2, and Mx1 transcript levels.  Data represents the means of 6 samples; 
error bars represent the standard errors of the means.  *p < 0.05, one-way 
ANOVA, Bonferroni’s multiple comparison post-test, compared to HEL-299 
levels. 
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Figure 3.5.  IFIT1 protein production is induced to similar levels by IFN-β in 
HEL-299 and HEL-TERT cells. 
HEL-299, HEL-TERT, and HEL-TERT-T cells were mock treated or 
treated with 1000 U/mL of IFN-β and harvested 9 hs later.  Cell lysates were 
analyzed for IFIT1 or β-actin protein production by western blotting. 
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Figure 3.6.  HSV-1 shows similar plaque size and morphology on HEL-299 
and HEL-TERT cells. 
HEL-299, HEL-TERT, and HEL-TERT-T cells were mock or pretreated 
with IFN-β for 16 hs and then infected with WT HSV-1 or an ICP0-null mutant 
and plaques for both viruses were visualized by immunohistochemistry three 
days post-infection.  Bar = 1 mm. 
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Figure 3.7.  Replication of HSV-1 is diminished by IFN-β in HEL-299 HEL-
TERT but not HEL-TERT-T cells. 
(A) and (B) HEL-299, HEL-TERT, and HEL-TERT-T cells were mock (A) or 
pre-treated with IFN-β (1000 U/mL) (B) and were infected 16 hs post treatment 
with 10-fold serially diluted stocks of WT HSV-1 or an ICP0-null mutant.  
Plaques were visualized by immunohistochemistry 3 days post-infection.  An 
average of three experiments is shown.  Data is presented as the ratio of 
plaques formed on the indicated cell line to that on HEL-299 cells. 
(C) Data generated for A and B, but presented as a ratio of the number of 
plaques formed on mock-treated cells compared to that on IFN-treated cells. 
(D) HEL-299, HEL-TERT, and HEL-TERT-T cells were mock or pre-treated 
with IFN-β (1000 U/mL) and were infected (16 hs post treatment) with either WT 
HSV-1 or the ICP0-null mutant at an MOI of 5 PFU/cell.  Samples were 
harvested 24 hs post-infection.  Viral titers were determined by plaque assays.  
An average of three experiments is shown.  In all cases, error bars represent the 
standard errors of the means. 
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Figure 3.8.  Replication of VSV is diminished by IFN-β in HEL-299 and HEL-
TERT but not HEL-TERT-T cells 
HEL-299, HEL-TERT, and HEL-TERT-T cells were mock or pre-treated 
with IFN-β (1000 U/mL) and were infected (16 hs post treatment) with VSV-eGFP 
at an MOI of 0.1 PFU/cell.  Samples were harvested 24 hpi.  Viral titers were 
determined by plaque assays.  An average of three experiments is shown.  In all 
cases, error bars represent the standard errors of the means. 
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Figure 3.9. Ectopic hTERT expression does not affect the ability of HEL 
cells to produce antiviral cytokines. 
HEL-299, HEL-TERT, and HEL-TERT-T cells were mock- or SeV-infected 
at 100 HAU/106 cell. At 24 hpi, the media were transferred to naïve Vero cell 
monolayers.  6 hs later, the Vero cells were infected with 200 PFU of VSV-eGFP 
per well.  At 24 hpi with VSV-eGFP, the Vero cells were fixed and the number of 
fluorescent plaques counted.  Data shown represents the average of two 
experiments performed in duplicate (6 standard errors of the means). 
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Chapter 4: Role of phosphorylation in the antiviral activity of the 
promyelocytic leukemia protein in response to herpes simplex 
type I infection 
4  
4.1 Introduction 
PML has been shown to affect aspects of the HSV-1 life cycle 
[30,33,286–288].  Upon nuclear entry of viral DNA, preexisting ND10s 
disassemble and reform near the sites of the incoming viral genomes [26,289].  
At these sites, certain ND10 members assist in the loading of chromatin on viral 
DNA and form a shell that prevents the initiation of viral gene expression, 
presumably by occluding the ability of transcription factors from interacting with 
viral DNA and initiating transcription [148].  The recruitment of PML to viral 
genomes is contingent upon its SUMOylation, as forms that cannot be 
SUMOylated fail to appreciably respond to the nuclear entry of viral DNA and 
remain positionally stable [290].  Furthermore, these SUMOylation-deficient 
mutants fail to restrict the ability of HSV-1 mutants that are sensitive to intrinsic 
defense mechanisms.  HSV-1, however, overcomes these defenses through the 
activity of its E3 ubiquitin ligase, ICP0, which induces the ubiquitination and 
proteasomal destruction of PML [291,292].  Here again, PML SUMOylation 
influences the course of infection as ICP0 favors interaction with and 
degradation of certain SUMOylated forms of PML [292,293]. 
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While the mechanisms are unclear, phosphorylation at a number of sites 
on PML influence its SUMOylation [178,186].  Additionally, during mitosis and 
upon double strand DNA breaks, ND10s undergo a PML phosphorylation-
dependent disassembly and/or relocalization [196].  Furthermore, 
phosphorylation of a region near the SIM, which is required for recruitment to 
incoming viral genomes and restriction of viral plating [286], has been reported 
to influence the affinity of the SIM for SUMO [191,192].  However, the role of 
phosphorylation in the control of its antiviral activities, particularly toward HSV-
1, has received little attention. 
Herein we report that we have identified several regions of 
phosphorylation within PML that influence its stability in the presence of ICP0 
and that mutation of phosphoacceptor sites near the SIM impairs the ability of 
PML to be recruited to incoming viral genomes. 
 
4.2 Methods 
4.2.1 Cells 
Human embryonic lung (HEL-299) cells were obtained from the American 
Type Culture Collection (CCL-137) and were maintained in Minimum Essential 
Medium Eagle Alpha Modification (ɑMEM) containing 10% fetal bovine serum 
(FBS), 2 mM L-glutamine, 10 U/mL penicillin, and 10 U/mL streptomycin.  A549 
and A549-based cell lines were maintained in Dulbecco’s modified Eagle’s 
medium containing 5% FCS, 2 mM L-glutamine, 10 U/mL penicillin, and 10 
 93 
U/mL streptomycin.  HepaRG [294], HA-shNeg, HA-shPML [295], and all HA-
shPML-derivative cell lines were maintained in William’s E media containing 
10% FBS, 2 mM L-glutamine, 10 U/mL penicillin, 0.5 µM hydrocortisone, and 5 
µg/mL insulin.  Cells transduced with shRNA-encoding lentivirus were kept 
under antibiotic selection with puromycin at 1 µg/mL; HA-shPML+LNGY, HA-
shPML+LNGY-PML.I, and HA-shPML+LNGY-PML.I-derivative cell lines were 
additionally maintained under selection with G418 at 200 µg/mL. 
GP2-293, U2OS, HEp-2 cells and HEp-2 derivative cell lines were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 5% FBS, 
2 mM L-glutamine, 10 U/mL penicillin, and 10 U/mL streptomycin. 
A549 and HEp-2 cells depleted of PML or the luciferase-depleted control 
line were created by transducing cells with LKO-shPML or LKO-shLuci [30,287] 
lentiviral stocks using four sequential 1-hour incubations, replacing the previous 
round of incubation with fresh lentiviral supernate.  After the fourth round of 
transduction, the cells were incubated at 37°C overnight.  The next day, cells 
were washed three times with PBS and incubated in fresh medium.  Two days 
post-transduction, the cells were placed under selection using puromycin at 1 
µg/mL and thereafter maintained in puromycin. 
A549 and HepaRG-based cells expressing FLAG- and CFP-tagged PML 
were created by transducing cells as above with retrovirus in the presence of 10 
µg/mL polybrene as described above. 
HepaRG-based cells expressing eYFP-tagged PML were created as 
described for the creation of shRNA-expressing A549 cells.  Two days post 
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transduction, the cells were placed under antibiotic selection using G418 at 800 
µg/mL.  The resistant outgrowth was expanded before being enriched by 
fluorescence activated cell sorting as previously described [286]. 
4.2.2 Plasmids 
Vectors encoding the PML ORF were constructed as follows.  CFP was 
subcloned in the place of GFP by replacing the NotI-BamHI fragment of pMX-
eGFP (a gift from Toshio Kitamura) with that from pECFP-N1 (Clontech).  PML 
and eCFP were placed An EcoRI-MfeI fragment containing a myc-tagged PML 
isoform 4 from the vector pCImycPML-fl [293] was subcloned into the EcoRI site 
of pMX-eCFP to create pMX+mycPML4+eCFP.  A MluI-MfeI fragment of 
pMX+mycPML4+eCFP was replaced with that from pSG5PML-L, which 
encodes the C-terminus of PML isoform 3, to give rise to 
pMX+mycPML3+eCFP.  To place PML and eCFP in frame, the C-terminus of 
PML3 was amplified by PCR using Phusion polymerase (New England Biolabs) 
and the primers 5’-aaaacgcgttgtggtgatcagcagctc-3’ 
5’aaaaccgcggagcgcgggctggtgggga-3’, which removes the stop codon from 
PML3 and adds a SacII site.  This PCR product was then used to replace the 
MluI-SacII fragment of pMX+mycPML3+eCFP to create pMX+mycPML3_eCFP. 
The myc-tag was replaced with a FLAG-tag sequence by first subcloning 
the EcoRI-SphI fragment of pMX+mycPML3_eCFP into the same sites of pUC19 
to create pUC19-(Nterm)mycPML.  An oligomer encoding a 3xFLAG sequence 
(5’-atggactacaaagaccatgacggtgattataaagatcatgacatcgattacaaggatgacgatgacaa-
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c-3’) was TOPO-cloned into pCR4Blunt-TOPO (Invitrogen) according to the 
manufacturer’s instructions to create pCR4Blunt-TOPO+3xFLAG.  The BamHI-
NcoI fragment from pCR4Blunt-TOPO+3xFLAG was used to replace the BamHI-
NcoI fragment of pUC19+(Nterm)mycPML to create 
pUC19+(Nterm)3xFLAG_PML, the EcoRI-SphI fragment of which was then 
subcloned back into pMX+mycPML3_eCFP. 
To enable interferon-inducibility of the integrated transgene, a quadruple 
repeat of the ISRE from ISG15 flanked by XbaI restriction sites sites (5’-tcta-
gacccgccccatgcctcgggaaagggaaaccgaaacgggaaagggaaaccgaaac-
gggaaagggaaaccgaaacgggaaagggaaaccgaaactgaagccaatctagaaaa-3’) was 
inserted into the XbaI site of the 3’U3 element of pMX+3xFLAG_PML3_eCFP, 
giving rise to p3’415MX+3xFLAG_PML3_eCFP.   
To create a form of PML that is resistant to silencing by shRNA produced 
in HA-shPML cells, a BamHI-fragment of pMX+3xFLAG_PML3_eCFP was 
subcloned into the vector, pAlter-1, and silent mutations were introduced using 
the Altered Sites Mutagenesis system (Promega) using the primer 5’-
tgcatcacccaggggaaGgaCgcGgcGgtGAGTaaAaaGgccagcccagaggct-3’ (with 
upper case letters representing introduced mutations) as per the manufacturer’s 
instructions.  The BamHI fragment was then subcloned back into the parental 
vector to generate p3’415MX+3xFLAG_PML3R_eCFP.   
To create a vector that encoded PML isoform 1, the C-terminus of PML-I 
was amplified by PCR (using the primers 5’- aaagcatgcagtgccccatctgc-3’ and 
5’-aaaaaaccgcgggctctgctgggaggccctctc-3’) from a HEL-299 cDNA library and 
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subcloned between the SacII and SbfI sites of p3’415MX+PML3R_eCFP to 
create p3’415MX+3xFLAG_PML1R_eCFP. 
The PML phosphorylation knockout mutants were created using PCR 
mutagenesis with the following primers: 
S8A forward 5’-ggagcctgcacccgcccgaGctccgaggccccagc-3’ 
S8E forward 5’-ggagcctgcacccgcTcgaGAAccgaggccccagcag-3’ 
S8 reverse 5’-atggcgttgtcatcgtcatccttg-3’ 
T28;S36/38/40A 
forward 
5’-atgcctccccccgagGcGccctctgaaggccgccagcccGCTcccG-
CGccGGCccctacagagcgagc-3’ 
T28;S36/38/40E 
forward 
5’-atgcctccccccgagGAAccctctgaaggccgGcagcccGAAccc-
GAAcccGAAcctacagagcgagcc-3’ 
T28;S36/38/40 
reverse 
5’-ggtgggctcctggggccgggcggg-3’ 
S117A 5’-agtctgcagcggcgcTtAGcggtgtaccggcaga-3’ 
S117E forward 5’-tctgcagcggcgcctCGAggtgtaccggcagat-3’ 
S117E reverse 5’-ctctcgaaaaagacgttatccagggcggg-3’ 
S399/403;T409A 
forward 
5’-aaGgaCgcGgcGgtGGCTaaAaaGgccGCcccagaggctgcca-
gcGctcccagggacccta-3’ 
S399/403;T409E 
forward 
5’-aaGgaCgcGgcGgtGGAGaaAaaGgccGAAccTgaggctgcc-
agcGAAcccagggaccctatt-3’ 
S399/403;T409 
reverse 
5’-cccctgggtgatgcaagagctgag-3’ 
S480;T482;S493A 
forward 
5’-cagaagaggaagtgcGCGcagGcccagtgccccaggaaggtcatca-
agatggagGctgaggaggggaagg-3’ 
S480;T482;S493E 
forward 
5’-cagaagaggaagtgcGAGcagGAAcagtgcccTaggaaggtcatc-
aagatggagGAAgaggaggggaaggag-3’ 
S480;T482;S493 5’-ggctgtcgttgtattggagacatc-3’ 
S504/505A 
forward 
5’-ggcaaggttggctcgAGCcGccccggagcagccca-3’ 
S504/505A 
reverse 
5’-tccttcccctcctcagactccatc-3’ 
S504/505E 
forward 
5’-gcaaggttggctcggGAAGAGccggagcagcccagg-3’ 
S505/505E 
reverse 
5’-ctccttcccctcctcagactccat-3’ 
S518A forward 5’-cagcacctccaaggcagtcGcaccTccTcacctggatggaccg-3’ 
S518E forward 5’-cagcacctccaaggcCgtGGAaccaccccacctgga-3’ 
S518 reverse 5’-ggcctgggctgctccgg-3’ 
S527/530A 5’-ctggatggaccgcctGCccccaggGCccccgtcataggaag-3’ 
S527/530E 5’-ctggatggaccgcctGAAccTaggGAAcccgtcataggaagt-3’ 
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forward 
S527/530E 
reverse 
5’-gtggggtggtgagactgccttggag-3’ 
S560/561/562/56
5A forward 
5’-cgcgttgtggtgatcGCGGCcGcggaagacGcagatgccgaaaact-
3’ 
S560/561/562/56
5A reverse 
5’-ttcctctgcctccccggcgccact-3’ 
S560/561/562/56
5E forward 
5’-ggaggcagaggaacgTgttgtggtgatcGAAGAAGAggaagacGA-
Agatgccgaaaactcg-3’ 
S560/561/562/56
5E reverse 
5’-ccggcgccactggccacgtggttg-3’ 
S565A forward 5’-agcagctcggaagacGcagatgccgaaaact-3’ 
S565A reverse 5’-gatcaccacaacgcgttcctctgc-3’ 
S565E forward 5’-gttgtggtgatcagcTCTtcggaagacGAagatgccgaaaactc-3’ 
S565E reverse 5’-gcgttcctctgcctccccggcgcc-3’ 
V556/557/558A;I5
59S forward 
5’-aggcagaggaacgcgCtgCggCTaGcagcagctcggaaga-3’ 
Δ476-490 forward 5’-gaggcaaggttggctcgga-3’ 
Δ476-490 reverse 5’-ctgggctgtcgttgtattggaga-3’ 
K65R 5’-atgccaggcggaagcGCGCtgcccgaagctgctg-3’ 
K160R forward 5’-acaccagtggttcctACGTcaTgaAgcccggcccctagca-3’ 
K160R reverse 5’-gcctcgaagcacttggcgcag-3’ 
K490R 5’-cccaggaaggtcatcCGgatggagtctgagga-3’ 
K616R forward 5’-gttttctttgacctcCGgattgacaatgaaa-3’ 
K616R reverse 5’-cagaggtctgtcttctgcttggg-3’ 
In some cases, sequential rounds of PCR mutagenesis were required to 
introduce the desired mutations.  All constructs were verified by sequencing. 
Certain PML mutants were subcloned into pLNGY (a gift from Roger 
Everett) [286].  To enable rapid subcloning of the PML mutations from the 
p3’415MX+3xFLAG_PML1R_eCFP background, a PsiI-PsiI fragment (spanning 
the F1 origin of replication) from pLNGY was removed by restriction digest and 
the vector was re-ligated to eliminate an AvrII restriction site.  An AvrII-StuI 
region of the PML phosphorylation knockout mutants from 
p3’415MX+3xFLAG_PML1R_eCFP were subcloned into pLNGY(F1-). 
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4.2.3 Viruses 
KOS [201] and Syn17+ [296] are wild type HSV-1 strains used in these 
studies.  7134 is an ICP0-null mutant in which the ICP0 open reading frame of 
KOS is replaced by the E. coli lacZ gene [202].  dl1403/CMVlacZ is a Syn17+ 
ICP0-null virus containing a 2 kb deletion in both copies of the ICP0 gene [281]. 
Both dl1403/CMVlacZ and another Syn17+ mutant, in1863 (which is otherwise 
similar to wild type Syn17+), encode lacZ under the control of the HCMV IE 
promoter inserted into the tK locus [287,297].  KOS, Syn17+, and in1863 viral 
stocks were prepared in Vero cells, and 7134 and dl1403/CMVlacZ were grown 
in U2OS cells; all viruses were titered as previously described [91,203,287]. 
Retroviruses were generated the Pantropic Retroviral Expression System 
(Clontech) as recommended by the manufacturer.  Lentiviral stocks were 
generated essentially as for retroviral stocks except for the inclusion of the 
packaging vector, psPAX2 (Addgene plasmid 12260), and the use of HEK-293T 
cells for packaging [298]. 
4.2.4 Reagents 
The CK2 inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole 
(DMAT) was purchased from EMD Chemicals and 2-(4,5,6,7-tetrabromo-2-
(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid (TMCB) from Ascent 
Scientific. The CK2 inhibitors were constituted in DMSO (Fisher Scientific). 
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4.2.5 PML immunoprecipitation 
HEL-299 cells were transduced with pseudotyped 
pMX+3xFLAG_PML3_eCFP such that the cells were 70% positive for 
PML3_eCFP.  For uninfected samples, cells were plated in 10 100-mm dishes 
and grown to confluency.  Twenty-two µg of anti-FLAG (M2) were added to 165 
µL Dynabeads protein G (Invitrogen), which were washed and prepared 
according to the manufacturer’s instructions, and allowed to incubate together 
at 4°C overnight.  The cells from each plate were washed with 1 mL PBS 
containing protease inhibitors (1 µg/mL aprotinin, 1 µg/mL leupeptin, 10 mM 
phenylmethanesulfonylfluoride, 1 mM Na3VO4, 1x Complete protease cocktail 
inhibitor (Roche)), and scraped into PBS, centrifuged to pellet cells, and 
resuspended in 200 µL lysis buffer (4% SDS, 10 mM dithiothreitol, 300 mM 
NaCl, 100 mM HEPES (pH 7.5)) [299] containing inhibitors. The samples were 
solubilized by incubation at 100°C for 5 minutes, vortexing, and sonication at 
100 W for 1 minute using a cup sonicator.  The samples were then combined 
and diluted with 13 mL of diluent buffer (1.7% Thesit, 150 mM NaCl, 50 mM 
Hepes (pH 7.5)) containing the protease inhibitors.  The anti-FLAG-conjugated 
Dynabeads were added to the lysate and incubated at 4°C overnight.  The next 
day, the beads were precipitated using a magnet and washed with 2 mL of the 
diluent buffer (containing inhibitors) 4 times.  After the final wash, the beads 
were resuspended in 50 µL of Laemmli buffer [206], boiled for 5 minutes, and 
resolved on 4-20% Tris-glycine SDS-PAGE gels.  The gels were stained with 
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Coomassie blue, thoroughly destained, and the desired bands were excised and 
washed with a 50% acetonitrile/water solution. 
PML from infected cells was prepared essentially as above except that 
cells were pretreated with 10 µM MG132 for 1 h, infected with KOS at an 
estimated 5 PFU/cell in the presence of MG132, and cells were collected at 5 
hpi. 
Peptides were analyzed for phosphorylation by tandem mass 
spectrometry at the Harvard University Microchemistry and Proteomics Analysis 
Facility. 
4.2.6 Western blots 
To examine the ability of ICP0 to induce degradation of PML or its mutant 
forms, HEp-2 cells were plated at 1×105 cells per well of a 24-well plate.  The 
cells were transfected 24 hs later with either 100 ng of 
p3’415MX+3xFLAG_PML1R_eCFP or one of the PML phosphorylation mutants 
along with 1 µg of pcDNA3.1, pcDNA3.1+n212, or pcDNA+ICP0 using 
Lipofectamine 2000 (Invitrogen) as per the manufacturer’s recommendation.  At 
24 hs post transfection, the cells were washed once with PBS and lysed into 50 
µL of boiling Laemmli buffer containing 1 µg/mL aprotinin, 1 µg/mL leupeptin, 1 
mM PMSF, 10 mM sodium vanadate, 50 mM sodium fluoride, and 20 mM N-
ethylmaleimide.  One-fifth of each sample was resolved on 4-12% Bis-tris 
polyacrylamide gels, transferred to nitrocellulose, blocked at room temperature 
for 1 h with 2% nonfat dry milk in Tris-buffered saline with 0.1% Tween 20 (TBS-
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T).  The blots were probed either overnight at 4°C or for 2 hs at room 
temperature with primary antibodies.  Primary antibodies used included those 
directed against FLAG (M2, Sigma Aldrich) or β-actin ((I-19)-R, Santa Cruz 
Biotechnology).  Antibodies were diluted in 2% non-fat dry milk/TBS-T.  
Membranes were then washed three times with TBS-T and probed at room 
temperature with goat-anti-mouse IgG, or goat-anti-rabbit IgG conjugated to 
HRP (Jackson Immunoresearch).  Membranes were again washed with TBS-T 
and developed with chemiluminescent substrate (Femto ECL, Pierce 
Laboratories).  Chemiluminescence was detected using an Image Station 4000R 
(Kodak) and Carestream Molecular Imaging software.  Images were assembled 
using Adobe Photoshop and Illustrator (Adobe Systems) and band intensities 
were measured by densitometry analyses using ImageJ. 
To examine SUMOylation levels of PML, 1×105 HEp-2-shPML cells were 
plated per well in 24-well plates.  The next day, the cells were transfected with 
100 ng of p3’415MX+3xFLAG_PML1R_eCFP or one of the PML phosphorylation 
mutants along with 900 ng of pGEM-3 using Lipofectamine 2000 according to 
the manufacturer’s instructions.  At 24 hs post transfection, the cells were lysed 
as above.  One fifth of each sample was resolved, transferred, and probed as 
above except that proteins were resolved using 6% Tris-glycine polyacrylamide 
gels.  Images were assembled using Adobe Photoshop and Illustrator (Adobe 
Systems) and band intensities were measured by densitometry analyses using 
ImageJ. 
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4.2.7 Immunofluorescence 
To examine the ability of exogenous PML to recruit Sp100 and Daxx to 
ND10s, A549-shPML or HA-shPML cells were transduced with retroviral vectors 
encoding 3xFLAG_PML1R_eCFP or one of the phosphorylation site mutants 
generally as described for the creation of depleted cells.  These cells, as well as 
A549 and HA-shNeg cells, were plated on collagen coated coverslips and the 
next day were washed once with PBS, fixed for 5 minutes with 5% 
formaldehyde in PBS at room temperature, washed three times with PBS, 
permeabilized at 4°C for 15 minutes with 0.5% NP-40 in PBS, and washed an 
additional three times with PBS.  Coverslips were the probed for 30 minutes at 
37°C with antibodies against Sp100 (mAb1380, Millipore) and Daxx (S-20, Santa 
Cruz Biotechnology) diluted in 1% FCS, 1% BSA, 0.05% Tween-20 in PBS; 
A549 and HA-shNeg cells were probed with antibodies against PML (A301-
167A, Bethyl Laboratories) and Sp100.  Cells were washed three times with PBS 
and stained for 30 minutes at 37°C with donkey-anti-mouse IgG Dylight 594 and 
cow-anti-goat IgG Dylight 488 diluted in the same buffer; A549 and HA-shNeg 
cells were stained with donkey-anti-rabbit IgG Dylight 594 and donkey-anti-
mouse IgG Dylight 488.  Coverslips were washed three times with PBS, air 
dried, and mounted onto glass slides using ProLong antifade (Invitrogen).  
Proteins were viewed by confocal fluorescent microscopy (Nikon) and captured 
with a digital camera (Photometrics).  Images were assembled using Adobe 
Photoshop and Illustrator (Adobe Systems).  ND10 reformation in HA-shPML 
was examined in a similar manner, except that the antibodies used against 
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Sp100 and Daxx (sc-16328, Santa Cruz Biotechnology and mAB 5.14 [300], 
respectively). 
To examine colocalization between PML-I and ICP0, A549-shPML and 
HA-shPML cells were transduced as above.  Two days post transduction, the 
cells, as well as A549 and HA-shNeg cells, were infected with KOS at an 
estimated 2.5 PFU/cell.  To determine a time point at which to examine 
colocalization, an initial set of cells was fixed at 1, 2, 3, 4, 5, and 6 hpi as 
described above and all subsequent studies were examined at 2 hpi.  The 
transduced and infected cells were probed first with antibodies against ICP0 
(H11060, Santa Cruz Biotechnology) and ICP4 (EastCoastBio) diluted in 5% 
rabbit serum in PBS and then probed with goat-anti-mouse IgG1 Dylight 594 
and goat-anti-mouse IgG2b Dylight 488 as listed above for Sp100 and Daxx 
staining; A549 and HA-shNeg cells were stained first for endogenous PML 
(A301-167A) and ICP0 (H11060) and then with donkey-anti-rabbit IgG Dylight 
594 and goat-anti-mouse IgG2b Dylight 488. 
To examine the recruitment of PML-I or the PML-I mutants to incoming 
viral genomes, HA-shPML cells were transduced described above.  Three days 
post transduction, the medium was removed, and cells were infected with 
dl1403/CMVlacZ at an estimated MOI of 0.1.  At 1 hpi, the cells were overlaid 
with growth medium containing 0.5% methylcellulose.  At 24 hpi, the medium 
was removed, the cells were washed with PBS, and the cells fixed and 
permeabilized by incubation at -20°C in cold 20% acetone diluted in methanol 
for 15 minutes.  Samples were then washed and stained with an antibody 
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against ICP4 as described above.  HA-shNeg cells were also infected as 
described and were additionally stained with antibody against PML as described 
for the ICP0 colocalization studies.  For PML recruitment studies in CK2-
inhibitor treated cells, the medium on the cells was replaced 1 h prior to 
infection with fresh medium containing 0.4% DMSO, 20 µM DMAT, or 100 µM 
TMCB, with the subsequent infection and incubation taking place in the 
presence of these chemicals.  
4.2.8 HSV-1 β-galactosidase foci assay 
Cells were seeded at 1.5×105 cells/well in 24-well plates.  Twenty-four hs 
later, viral suspensions were created by preparing 3-fold serial dilutions of 
in1863 or dl1403/CMVlacZ such that target wells would receive between an 
estimated 0.5 to 140 or 45 to 3600 PFU for in1863 or dl1403/CMVlacZ, 
respectively.  Most of the medium was removed, cells were infected with 100 µL 
of viral inoculum, incubated at 37°C with shaking every 15 minutes, overlaid with 
growth medium containing 0.5% methylcellulose at 1 hpi, and incubated at 
37°C.  At 24-30 hpi, the wells were washed twice with PBS, fixed with 3.7% 
formaldehyde/PBS for 15 minutes at room temperature, washed three times 
with PBS, and stained using X-gal containing solution (1 mg/mL 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside, 5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6, 2 
mM MgCl2, 0.01% NP40, diluted in PBS).  Groupings of ≥4-6 blue cells (which 
was found to be roughly equivalent to foci that were visible by the naked eye) 
were counted as plaques. 
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4.3 Results 
4.3.1 Identification of phosphorylated residues of PML in uninfected 
and HSV-1 infected cells 
While PML is known to be phosphorylated on a number of sites when this 
project began, a full mapping of phosphorylated sites on PML had not been 
performed.  Additionally, PML phosphorylation during infection had not been 
examined.  To address these questions, we created an HEL-299 cell line that 
exogenously expresses a FLAG- and CFP-tagged form of PML-III.  PML was 
immunoprecipitated from cells mock-infected or infected with HSV-1 for 6 hs 
and subjected to mass spectrometry analysis.  As detailed in Table 4.1, we 
identified 19 phosphorylated serines and threonines in uninfected cells and 11 in 
infected cells, though we noted that there were significant gaps in the coverage 
of our scans.  All of the sites located within regions shared among the different 
isoforms were either previously identified or have been reported in subsequent 
studies, though we did find several novel sites within a C-terminal region 
specific to PML-III.  Of the sites identified, we found that S504 was 
phosphorylated only in uninfected cells while S565 was only detected as 
phosphorylated in infected cells.  Thus, we have identified a number of novel 
sites of phosphorylation on PML and found that isoform specific sites of 
phosphorylation exist and that there appears to be changes in the 
phosphorylation status of PML upon infection. 
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4.3.2 Phosphorylation at sites near the SIM alter ND10 morphology 
and influences Sp100 and Daxx recruitment to ND10s 
To examine the effect that phosphorylation at these sites has on PML, we 
created a series of retroviral constructs encoding FLAG- and CFP-tagged 
phosphorylation knockout and mimetic mutants, changing residues to alanine or 
glutamic acid, respectively.  During the course of this work, it was shown that 
PML-I is the most widely expressed of the PML isoforms [301] and, unlike PML-
III, has antiviral activity toward certain HSV-1 mutants [286].  Thus, these 
mutants were created in a PML-I background.  Because exogenous PML forms 
heterodimers with endogenous PML, which would complicate interpretation, we 
created cell lines that express shRNAs directed against PML and introduced the 
mutant forms of PML (which contained additional silent mutations to enable 
shRNA-resistance) into them.  Initially, we chose A549 cells, a human lung 
epithelial carcinoma cell line, because they are immortalized, have a functional 
interferon-based antiviral response to a number of viruses, and we found them 
to be amenable to depletion of PML using shRNAs. 
We first examined the ability of exogenous PML to form ND10s and to 
recruit the major ND10 constituents, Sp100 and Daxx.  As expected, cells 
transduced with the shRNA targeting PML were largely devoid of PML and 
Sp100 was largely diffuse in the nucleoplasm in contrast to the parental A549s 
(Figure 4.2A).  In cells transduced with the PML-I-expressing retrovirus, 
however, ND10s were clearly present along with, to a degree, colocalized Sp100 
and Daxx (Figure 4.2B).  An initial examination of the mutants failed to reveal 
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large differences in ND10 size or number for most of the PML phosphorylation 
mutants, with the exception being those bearing mutations near the SIM, 
S560/561/562/565A and –E, in which case the ND10s were larger; likewise, 
none of the mutants completely failed to recruit Sp100 or Daxx, though, again, 
those mutated near the SIM appeared to recruit both Sp100 and Daxx much 
more efficiently.  These results were also true when PML expression was 
restored in a HepaRG-based PML-depleted cell line (Figure 4.4), though the 
PML-I(K65/160/490R) SUMOylation-deficient mutant failed to recruit Sp100 and 
Daxx in these cells. 
A closer examination revealed subtle differences among the PML-
phosphorylation mutants in their ability to recruit Sp100 and Daxx (Figure 4.3).  
Notably, the S117E and S518E mutants were much more likely to recruit Sp100 
and somewhat better at recruiting Daxx, and specifically for S117E, Sp100 
colocalized with it in all cells that were examined.  Of the remaining mutants, we 
also found that S8/T28/S36/38/40A, S480/T482/S493A, S480/T482/S493E, and 
S504/505A mutants were marginally better at recruiting Sp100.  These data 
suggest that phosphorylation near the SIM, and potentially S117, has a large 
effect on Sp100 and Daxx recruitment and that phosphorylation at several other 
sites on PML may subtly influence ND10 member recruitment. 
4.3.3 Phosphorylation does not largely impact SUMOylation levels 
As previous reports suggested interplay between phosphorylation and 
SUMOylation and current evidence suggest that PML acts as an E3 SUMO 
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ligase, perhaps on itself, we decided to examine the SUMOylation state of the 
PML phosphorylation mutants.  HEp-2 cells depleted for PML (HEp-2-shPML) 
(Figure 4.5A) were used to allow us to examine the E3 ligase activity of PML 
without endogenous PML confounding our results.  The cells were transfected 
with the various phosphorylation mutants, one of two SUMOylation-deficient 
mutants, the NLS mutant, or the SIM mutant and the next day cell lysates were 
prepared and examined by western blot.  While FLAG-, CFP-tagged wild type 
PML-I exhibited the laddering typical of multiply SUMOylated proteins (Figure 
4.5B), both the K65/160/490R and K65/160/490/616R mutant forms of PML-I 
were largely devoid of SUMO modification, though a small amount of 
SUMOylation was detected.  These bands likely represent SUMOylation of 
minor, non-preferred or non-canonical sites [166,167].  Likewise, the NLS-
deletion mutant was essentially non-SUMOylated while the SIM-mutant was 
slightly less SUMOylated than wild type.  Of the phosphorylation mutants, while 
no gross differences in SUMOylation patterns were obvious, densitometric 
analysis showed that the S518A mutant was more highly SUMOylated while the 
S565A mutant was slightly less so, resembling the SIM-mutant.  These results 
indicate that the phosphorylation sites examined do not greatly affect 
SUMOylation levels of PML in resting cells. 
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4.3.4 Phosphorylation is not required for the colocalization of PML-I 
and ICP0 
The ability of ICP0 to interact with PML has been reported to be 
facilitated by PML SUMOylation.  Forms of ICP0 that do not colocalize with PML 
either fail to or are inefficient at inducing the degradation of PML.  As 
phosphorylation of PML can influence PML SUMOylation and potentially block 
or create a binding site for ICP0, we wished to determine whether PML 
phosphorylation affected PML:ICP0 colocalization.  While ICP0 induces the 
proteasomal-dependent degradation of PML, the use of proteasome inhibitors 
has been reported to change ND10 composition.  To determine a time point at 
which ICP0 levels were high enough for detection but had not yet induced 
substantial ND10 disassociation, PML-I-transduced HA-shPML cells were 
infected with HSV-1 and processed for immunofluorescence assays at 1, 2, 3, 4, 
5, and 6 hpi (data not shown).  We found that 2 hpi was an ideal time at which to 
examine PML:ICP0 colocalization.  HA-shPML cells were transduced with 
retroviral vectors encoding PML-I or one of the PML-I phosphorylation knockout 
mutants and two days later infected with HSV-1 at 2.5 PFU per cell to ensure all 
cells were infected.  At 2 hpi, the cells were fixed and processed for 
immunofluorescence staining for ICP0, with PML detected by autofluorescence.  
As expected, we found that in infected cells expressing PML-I, ICP0 was 
present at all ND10s (Figure 4.6).  When we examined infected cells transduced 
with the PML-I phosphorylation mutants, we again found that ICP0 was present 
at a majority of ND10s, with the sole exception being those formed by the 
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S8;T28;S36/38/40A mutant, in which a small number of ND10s appeared not to 
colocalize with ICP0 foci.  To confirm that ICP0 was at ND10s due to the 
presence of PML and not another ND10 constituent (such as SUMOylated 
Sp100), we also tested the ability of a PML NLS-deletion mutant to retain ICP0 
in the cytoplasm.  PML-I(ΔNLS) was, as expected, restricted to the cytoplasm, 
where it formed 2-3 puncta per cell.  In cells transduced with this construct, 
ICP0 was strongly retained in the cytoplasm.  We also examined colocalization 
between ICP0 and PML-I, the PML-I phosphorylation, SIM, NLS, and 
K65/160/490/616R mutants in the HA-shPML cells (Figure 4.7) and found that 
they recapitulated those in the A549-shPMLs.  These assays indicate that either 
none of the phosphorylation sites we examined greatly influence the ability of 
ICP0 to localize with PML-I or that there are multiple sites on or regions in PML 
to facilitate this process. 
4.3.5 PML phosphorylation has minor effects on ICP0-induced 
degradation 
Phosphorylation of PML has been shown to contribute to its the stability 
through a number of mechanisms.  To more directly assay whether any of the 
phosphorylation sites influence the stability of PML in the presence of ICP0, we 
cotransfected the retroviral constructs that express PML-I or its mutant forms 
along with either an empty control vector, a vector encoding ICP0, or a vector 
encoding the n212 truncation mutant of ICP0 (which is incapable of inducing 
PML degradation) into HEp-2 cells, which have previously been used in assays 
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examining ICP0-induced PML degradation [293].  Twenty-four h later, the levels 
of exogenous PML were examined by western blot.  As expected, expression of 
ICP0 lead to the near total loss of PML while expression of the n212 mutant did 
not (Figure 4.8).  Interestingly, while the NLS mutant and ICP0 colocalize (Figure 
4.6 and 4.7), ICP0 was unable to induce its degradation.  Examination of the 
phosphorylation mutants revealed that ICP0 was capable of reducing the levels 
all of these mutants; however, we noted that levels of the S480;T482;S493E, 
S504/505A, S504/505E, and S518E mutants, while lower in the presence of 
ICP0, were not diminished to the same degree as wild type PML-I.  These 
results indicate that phosphorylation may play a role in determining PML stability 
in the presence of ICP0. 
4.3.6 Mutation of the phosphoacceptor sites in the phosphoSIM of 
PML-I  prevents recruitment to incoming viral genomes 
As viral DNA is injected into the nucleus, it is recognized as either foreign 
or damaged DNA and as such, the cell mounts a response involving DNA 
damage factors, components of the SUMOylation machinery, and ND10 
members.  In the case of ND10s, preexisting ND10s breakdown and recoalesce 
around viral genomes, preventing these factors from accumulating around viral 
DNA correlates with a loss in their antiviral activity towards HSV-1.  In the case 
of PML, it has been shown that both SUMOylation of PML and the integrity of its 
SIM are required for relocalization at incoming genomes.  Consequently, we 
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wished to determine whether phosphorylation of PML played a role in this 
process. 
The recruitment of intrinsic antiviral effectors to incoming viral genomes 
can most easily be seen at the edge of spreading plaques on monolayers 
infected at low MOIs with ICP0-null mutant viruses.  Cells at the plaque edge 
experience a directional infection, with viral capsids primarily docking and 
injecting the viral DNA on one side of the cell.  This can be visualized by staining 
for the major viral transactivator, ICP4, which binds to the viral DNA.  Therefore, 
HA-shPML cells were transduced with the various PML-I retroviral constructs.  
Four days later, they were infected with an ICP0-null virus at a low multiplicity of 
infection, and overlaid with methylcellulose to restrict viral spread.  The next 
day, the cells were fixed and stained for ICP4, with PML detected by 
autofluorescence.  As expected, along the edges of plaques we observed cells 
in which ICP4 was found as a front along one side of the nuclear envelope 
(Figure 4.9A).  In cells transduced with PML-I, we found a strong recruitment to 
ICP4 foci whereas PML-I(V556/557/558A;I559S), in which the SIM is inactivated 
and cannot be recruited to incoming genomes, or PML-I(K65/160/490R), in 
which the major SUMOylation acceptor sites are mutated, failed to show any 
relocalization to ICP4 fronts (Figure 4.9A).  Of the various PML phosphorylation 
mutants, we found that only those that were mutated at sites in the 
phosphorylation region adjacent to in the SIM failed to relocalize to incoming 
genomes.  In all cases observed, both the S560/561/562/565A and 
S560/561/562/565E mutants failed to colocalize with ICP4, indicating that 
 113 
phosphorylation of the SIM may be required for PML’s antiviral activity.  Indeed, 
it has previously been shown that mutation of these serines to alanine decreases 
the ability of PML to interact with SUMOylated proteins in yeast two-hybrid 
assays [192] and in bioluminescence resonance energy transfer assays [191].  
As these sites are phosphorylated by the cellular kinase CK2, we then wished to 
determine whether the use of a CK2 inhibitor would prevent the recruitment of 
PML to incoming genomes.  PML-I- or PML-I SIM mutant- [PML-
I(V556/557/558A;I559S)] transduced HA-shPML cells were pretreated with 
DMSO (as vehicle control) or the CK2 inhibitor DMAT at 20 µM for 1 h, infected 
with the ICP0-null mutant at 0.1 PFU/cell in the presence of either DMSO or 
DMAT, overlaid with methylcellulose at 1 hpi, and processed for 
immunofluorescence assays at 24 hpi.  As expected, DMSO did not affect the 
ability of PML1 to respond to the presence of viral DNA nor did it change the 
inability of the PML-I-SIM mutant to do so (Figure 4.9B).  In the DMAT-treated 
cells, however, we unexpectedly found that PML-I could relocalize to incoming 
viral genomes.  Similar results were found when we used a second CK2 
inhibitor, TMCB.  While these findings were unexpected, we nonetheless have 
found that of the phosphorylation sites observed in PML, only mutation of those 
in the phosphoSIM appears to compromise the ability of PML to be recruited to 
incoming viral genomes. 
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4.3.7 Phosphorylation plays a minor role in the antiviral activity of 
PML toward HSV 
While ICP0-null mutant HSV-1 is at least 100-fold less likely than wild 
type HSV-1 to productively initiate an infection, it shows an increased likelihood 
to plaque on cells depleted of PML.  Reintroduction of PML isoforms I and II has 
been reported to partially restore the restriction of plaquing with an ICP0-null 
virus.  Thus, we wished to determine whether phosphorylation of PML was 
responsible for controlling its antiviral activity by examining whether expressing 
the PML-I phosphorylation mutants in PML depleted cells had an effect on the 
plating efficiency of HSV-1.  Initial testing showed that restoration using the 
retroviral constructs did not affect the plaquing efficiency of an ICP0-null virus 
(data not shown).  As overexpression of PML can result in a loss of its antiviral 
activity (Roger Everett, personal communication), we moved three of the 
mutants into a lentiviral expression system in which PML is under the control of 
the weak HSV-1 gD promoter, a construct that has been used in previous 
reports [286,290,292,295].  We chose to examine the S117A, S480;T482;S493A, 
and S560/561/562/565A mutants as S117 is phosphorylated by CHK2, the 
activity of which is stimulated by ICP0; S480;T482;S493 is predicted to be 
phosphorylated by PI3KKs, whose activities are modulated by HSV-1 infection; 
and S560/561/562/565A due to its inability to localize to incoming viral 
genomes.  HA-shNeg, HA-shPML, or HA-shPML cells expressing PML-I or one 
of these mutants were infected with one of two strains of serially diluted HSV-1, 
in1863 (ICP0+) or dl1403/CMVlacZ (ICP0-).  in1863 is an essentially wild type 
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virus that expresses the Escherichia coli β-galactosidase gene under the control 
of the HCMV major immediate-early promoter while dl1403/CMVlacZ is its ICP0-
null counterpart.  With these viruses, β-galactosidase activity serves as a marker 
for successful establishment of infection, independent of viral transactivator-
dependent gene expression.  While depletion of PML indeed resulted in a partial 
complementation of plaquing for dl1403/CMVlacZ, we were unable to achieve 
complementation to the same degree as in previous reports, with our results 
showing a roughly 3.5-fold increase in plating of dl1403/CMVlacZ (Figure 4.10); 
this result contrasts with a nearly 10-fold increase previously reported [292].  In 
our hands, restoration of PML-I alone resulted in little to no decrease in plating 
efficiency for dl1403/CMVlacZ as compared to that on PML-depleted cells.  Two 
of the mutants – the S117A and S480;T482;S493A – demonstrated a slight 
decrease in dl1403/CMVlacZ plating, indicating that these sites may play a 
minor role in PML’s antiviral activity.  In line with previous reports that mutant 
forms of PML that fail to relocalize to incoming viral genomes have no effect on 
viral plating, dl1403/CMVlacZ plated nearly equally efficiently on cells that were 
transduced with the S560/561/562/565A mutant as it did on cells depleted of 
PML expression.  While not expected, we also consistently observed a nearly 2-
fold decrease in plating efficacy for in1863 in PML-depleted cells. 
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4.4 Discussion 
PML is constitutively expressed and as such, can respond immediately to 
cellular insults; however, to do so, it must be regulated in a dynamic manner.  
One method of quickly controlling proteins includes altering their post-
translational modification state.  PML is known to be extensively modified and, 
in some instances, its post-translational state is changed in response to various 
stimuli when functioning in particular cellular pathways.  For instance, 
phosphorylation of PML has been tied to its role in cell cycle control [183], 
differentiation [195], and the DNA damage response [193].  In these cases, 
phosphorylation can alter the stability of PML, its ability to interact or recruit 
partner proteins, its localization within the cell, or influence other types of post-
translational modification.  While PML has been demonstrated to have antiviral 
activity towards a number of viruses, the role of phosphorylation in this 
response has received little attention. 
When this work was began, only a few studies had been performed that 
mapped phosphorylation on PML.  Those studies were limited to examining only 
a few sites that matched kinase consensus phosphorylation sites.  We and 
others have since made use of advances in mass spectrometry technology to 
perform precise mapping studies of PML phosphorylation [176,302].  While 
many of the phosphorylation sites we identified have also been noted in 
subsequent reports, we have identified a number of unique phosphorylation 
sites.  Furthermore, we are the first group to examine PML phosphorylation 
during viral infection.  Notably, we have mapped a cluster of sites that match the 
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S/T-Q phosphoinositide 3-kinase-related kinase (PI3KK) consensus motif [303].  
These sites are interesting, as PML has previously been demonstrated to be a 
substrate of ATR, a phosphorylation event that results in a translocation of PML 
from ND10s to nucleoli, transporting MDM2 with it, which results in the 
stabilization of p53.  In addition to these potential PI3KK acceptor sites, we 
found that serine 504 was phosphorylated only in uninfected cells and serine 
565 was so only in infected cells.  Phosphorylation of S565 by CK2 has 
previously been shown to promote PML polyubiquitination as well as increase 
the affinity of the SIM for SUMO [183,191]; however, as noted in Chapter 2, the 
use of pharmacological inhibitors of CK2 does not prevent the degradation of 
PML by ICP0 and we failed to observe that mutation of S565 increases the 
stability of the PML-I in the presence of ICP0.  The mechanism by which CK2 
induces degradation of PML, however, is unknown.  While phosphorylation at 
S504 has only been previously observed in a large scale phosphoproteome 
screen and thus its role has not been explored [304], it is located amongst a 
number of other residues that function in promoting the association of PML with 
Pin1, an interaction that destabilizes PML [181,189]; however, whether 
phosphorylation at S504 influences PML stability is unknown. 
A major function of PML is the nucleation and recruitment of other ND10 
member proteins.  Two proteins of note, particularly in terms of the antiviral 
effect mediated by ND10s, are Sp100 and Daxx, especially as these proteins 
cooperate to limit HSV-1 replication [295].  When we examined exogenous PML-
I expressed in PML depleted cells, we found that only a small proportion of the 
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reformed ND10s strongly recruited Sp100 and Daxx.  This is in agreement with 
previous results showing that expression of individual isoforms of PML failed to 
fully restore recruitment of Sp100 and Daxx.  The PML-I phosphorylation 
mutants generally behaved like wild type PML-I when it came to the recruitment 
of Sp100, although the ND10s formed by the S117E, S480;T482;S493E, and 
S504/505A mutants appeared to have higher levels of Sp100.  For the most 
part, Daxx recruitment followed a similar trend to that of Sp100, though overall it 
appeared to be much more likely to be nucleoplasmic.  The most notable 
exceptions were the S560/561/562/565A and S560/561/562/565E mutants, both 
of which were more likely to have intense Daxx staining at the reformed ND10s 
and Sp100 was more likely to localize with PML.  Little is understood about the 
mechanisms involved in targeting Sp100 to ND10s.  Some reports have 
suggested that they do not physically interact [164] and super-resolution 
microscopy shows them occupying separate portions of ND10s [136].  In some 
instances, particularly in stressed or senescence-inducing conditions, Sp100 is 
capable of forming foci independently of PML, and thus it may be that either 
PML and Sp100 nucleate around a common structure autonomously or that 
another protein serves as an adaptor between the two [305].  Phosphorylation of 
PML might influence its ability to either localize to the structure or interact with 
the adaptor protein and results in an indirect effect on PML:Sp100 
colocalization.  Notably, cytoplasmic localization of PML does not result in the 
cytoplasmic localization of Sp100 (Figure 4.2 and 4.3), unlike with Daxx (Figure 
4.2 and 4.3) or ICP0 (Figure 4.6 and 4.7).  Daxx, however, directly interacts with 
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PML in a manner that requires both SUMOylation of PML and a SIM present in 
Daxx [143,173].  In other studies involving depletion and restoration of PML 
expression, it was noted that either PML-VI, which lacks the SIM, or mutants of 
the other isoforms in which the PML SIM was mutated recruited Sp100 and 
Daxx more readily than wild type versions of PML-I though –V.  Unexpectedly, 
SUMOylation of Sp100 is not necessary for recruitment of Sp100 to ND10s 
[290].  It seems likely that the PML SIM is required for interaction with another 
protein that negatively regulates the interaction between Sp100 and Daxx with 
PML; however, the only proteins known to require the PML SIM for interacting 
with PML are subunits of the proteasome [306]. 
Early during infection, ICP0 colocalizes with PML and induces the 
proteasomal degradation of PML as well as the loss of certain forms of Sp100 
[291].  Though not strictly required for the ability of ICP0 to induce the loss of 
PML, forms that fail to localize to ND10s are inefficient at doing so [307].  We 
found that mutation of phosphorylation sites in PML-I did not noticeably affect 
the colocalization between PML and ICP0.  Recent work has shown 
SUMOylation of PML-II, -III, -IV, -V, and –VI is necessary for their interaction with 
ICP0, while a region in the C-terminus unique to PML-I has the ability to interact 
with ICP0 in a SUMOylation-independent manner [292].  Little is known about 
this region other than it is predicted to have an exonuclease-III domain and that 
it is necessary for nucleolar-localization of PML-I in senescent cells or those that 
have been induced to have double stranded DNA breaks [144].  As we used 
PML-I in these studies, it is likely that we were unable to distinguish between 
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phosphorylation-dependent effects from those of the motif with which ICP0 
interacts in the PML-I C-terminus.  Indeed, while inactivation of the PML RING 
or B-boxes typically results in nuclear diffuse PML, they form puncta when in the 
presence of ICP0 [292].  It would be interesting in the future to examine how the 
phosphorylation sites influence interactions between ICP0 and the other PML 
isoforms and to determine whether the C-terminus of PML-I harbors unique 
phosphorylation sites of its own. 
As noted above, colocalization between ICP0 and PML is not absolutely 
necessary for ICP0 to be able to induce the degradation of PML.  
Phosphorylation of PML can result it its destabilization [176,183] and certain 
cellular factors that control the stability of PML have been shown to interact with 
PML in a phosphorylation-dependent manner.  When we examined the ability of 
ICP0 to induce the degradation of PML-I or the PML-I phosphorylation mutants, 
we found a number that appear to be somewhat more stable in the presence of 
ICP0, though none were completely resistant.  Of interest, mutation of S505 and 
S518, the latter site implicated in mediating interaction with Pin1 upon its 
phosphorylation by CDK1, CDK2, or ERK2 which results in the 
polyubiquitination of PML by the Cullin3-KLHL20 E3 ligase [181], appeared to 
result in increased stability.  In contrast, mutation of S565, which is implicated in 
the control of PML protein levels by PIAS1/CK2/RNF4 [141], had no effect.  As 
noted in Chapter 2, the use of CK2 inhibitors does not prevent the degradation 
of PML by ICP0 during the course of infection.  For Pin1, mutation of 
S403/505/518/527A has been found to be necessary to abrogate interaction 
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between PML and Pin1 [176]; nonetheless, as the region to which ICP0 binds is 
both C-terminal to these sites and specific to PML-I, it is intriguing to 
hypothesize that ICP0 may act in concert with Pin1, though it is known that 
CDK1 and CDK2 are not necessary for ICP0-induced PML degradation [308] nor 
do any of the immediate early HSV-1 proteins induce ERK2 activation [309,310].  
Additionally, it will be of interest to determine what, if any, effects these 
phosphorylation sites have on the stability of other isoforms of PML. 
Entry of viral DNA into the nucleus triggers the deposition of DNA 
damage response factors, SUMOylation machinery, and ND10 components at 
or near the viral DNA [19,26,284].  While the specific host cell activator of these 
factors in response to viral infection has not been identified, it is notable that 
many of the same factors assemble around sites of DNA damage [311].  
Recruitment of PML to incoming viral genomes, which is essential for its antiviral 
function, requires the RING-finger, B-box 1, coiled-coil, SIM, and SUMOylation 
on either K160, K490, or both [290].  In the case of DNA damage, ND10s 
undergo an ATM-, CHK2-, and ATR-dependent fragmentation where portions of 
preexisting ND10s bud off and move to sites of damage, indicating that 
phosphorylation of PML may play a role in this process [312].  It is unknown 
whether this phosphorylation-dependent breakdown of ND10s is also required 
for recruitment to viral DNA, though the deposition of ND10 components near 
viral DNA does first require the exchange between ND10s and the nucleoplasm 
[26]. 
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Of the phosphorylation mutants examined, we found that only sites near 
the SIM detectably influence recruitment of PML to incoming viral genomes.  
Phosphorylation of the phosphoSIM motifs of Daxx and PIAS1 have been shown 
to affect the ability of the SIM-domain containing protein to interact with SUMO, 
and in the case of Daxx, determining SUMO paralog preference [313], although 
this was not the case for PML [191].  It was also reported that the SUMO 
conjugation pathway components Ubc9, PIAS2β, and SUMO2/3 are found 
juxtaposed to viral genomes and depletion of Ubc9 compromises the ability of 
PML, Sp100, and Daxx to respond to the entry of viral DNA [19].  As 
SUMOylation of PML is also required for this response, it is unclear whether 
Ubc9 is needed to SUMOylate a PML-interacting partner with which PML binds 
in a SIM-dependent manner or if it is needed to SUMOylate PML and allow for 
PML’s exit from ND10s [172].  Curiously, mutation of the serines of the 
phosphoSIM motif to either alanine, which would block phosphorylation, or 
glutamic acid, which should mimic phosphorylation, both lead to the same 
phenotype.  In this instance, it might be that the reversible phosphorylation of 
the phosphoSIM is necessary for recruitment, as the introduction of glutamic 
acid may disrupt the proper folding near the SIM and results in its inactivation, 
or that glutamic acid fails to fully mimic the steric and electrostatic properties of 
phosphorylation at these sites.  Previous work using a PML-III 
S560/561/562/565D mutant in bioluminescence resonance energy transfer 
assays, however, showed that mutation of these sites to aspartic acid does not 
compromise the ability of the SIM to interact with unconjugated SUMO1, unlike 
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their mutation to alanine [191]; this result suggests that it is dynamic 
phosphorylation of the phosphoSIM which is required for recruitment to viral 
genomes.  These sites have previously been demonstrated to act as a substrate 
for CK2-mediated phosphorylation [183] and the phosphoSIM motifs of both 
PIAS1 and Daxx have been found to be phosphorylated by CK2 [192,313].  In 
both cases, the use of CK2 inhibitors resulted in a reduction in the ability of the 
proteins to bind to SUMO.  We observed that treating cells with CK2 inhibitors 
did not compromise the ability of PML-I to relocalize to incoming viral genomes.  
While it is possible that the levels of the CK2 inhibitors used were insufficient to 
block CK2 activity, these inhibitors were used at the same concentration as in 
Chapter 2 and previous reports [314,315] and we did note that the number of 
plaques was decreased and their sizes were smaller suggesting an effect on 
CK2 activity.  It is also possible that the inhibitors failed to prevent recruitment of 
PML due to PML being phosphorylated before treatment with the inhibitors; this 
seems unlikely, however, as phosphorylation at these sites also promotes 
degradation of PML [183].  While none of the other phosphorylation mutants 
demonstrated a defect in their recruitment, this does not rule out a role for 
overall PML phosphorylation or these sites in this activity.  Multiple sites may 
serve redundant roles, as has been seen for the interaction between PML and 
Pin1 [176].  Additionally, our assays might not be sensitive enough to detect 
differences imposed by the mutations.  Another possibility is that mutation of 
one site leads to a shift in phosphorylation to secondary sites, as HIPK2 
phosphorylates S36 when its preferred residue at S38 on PML is mutated to 
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alanine [178].  Finally, our mass spectrometry failed to map a large portion of the 
N-terminus of PML, and this region might contain novel sites that contribute to 
the recruitment of PML to viral genomes. 
PML has previously been established to have antiviral activity toward 
HSV-1, particularly for ICP0-null mutants [30,33,148,286,287,295].  While 
depletion of PML indeed resulted in a partial complementation of plaquing for 
dl1403/CMVlacZ, we were unable to achieve complementation to the same 
degree as in previous reports, with our results showing a roughly 3.5-fold 
increase in plating for dl1403/CMVlacZ, unlike a previous report of a ~10-fold 
increase [292].  This degree of complementation makes determining the antiviral 
activity of knocked in PML mutants limited, especially as the expression of a 
single PML isoform fails to completely restore the restriction of the ICP0-null 
virus.  We are unable to explain the differences between our data and that of the 
Everett group, though it should be noted that our results were reproducible.  
Likewise, we have had difficulty establishing that the expression of PML-I or its 
mutant forms in PML-depleted cell lines restores restriction of an ICP0-null 
virus, or other assays that measure viral replication or gene expression (data not 
shown).  Given these limitations, of the three mutants examined here, the 
S560/561/562/565A mutant, as expected due to its inability to be recruited to 
incoming genomes, had little to no antiviral activity while the S480;T482;S493A 
mutant appeared to have the strongest antiviral effect.  It is unclear how 
preventing phosphorylation at S480, T482, and S493 might contribute to PML’s 
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antiviral activity, as mutations of these sites did not lead to an obvious 
phenotype in our functional assays for PML activities. 
In sum, we have mapped a number of phosphorylation sites on PML.  An 
examination of these, as well as a number of other sites already reported in the 
literature, revealed that only those in the phosphoSIM motif appear to play a 
significant role in either the ability of PML to form ND10s or in its response to 
viral infection; however, we failed to observe these forms of PML have a 
substantial effect on viral replication.  It is possible that our lack of a replication 
phenotype is due to PML isoform specific mechanisms, and as such further 
investigation should focus on other isoforms or in cells in which multiple 
isoforms have been restored.  It is also possible that the difference in plating 
efficiency between control- and PML-depleted cell lines is too small to observe 
an effect and that such differences might be more obvious in other contexts.  
For instance, the simultaneous depletion of PML, Sp100, and Daxx results in a 
50-fold increase in the plating efficiency for an ICP0-null virus and restoration 
into these cells may make differences among the phosphorylation mutants more 
obvious [295].  Additionally, as the requirement for ICP0 is much greater in 
primary or primary-like cells, these cell types may be more appropriate for 
examining restrictions on viral replication.  Also, differences in the ability to 
restrict HSV-1 replication might also be more apparent in combination with other 
viral mutations, such as in the viral transactivator, VP16, as the lack of functional 
VP16 leads to a greater requirement for ICP0 in viral replication.  Lastly it is 
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plausible that one or more phosphorylation sites of PML contribute to novel and 
combinatory antiviral mechanisms that have not yet been identified. 
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4.5 Tables 
Table 4.1: Sites of Phosphorylation on PML-III 
Uninfected  HSV-1 infected 
 Coverage 
gaps 
  Coverage 
gaps 
S399 1-44  S403 1-7 
S403 57-86  T409 18-44 
T409 147-149  S505 57-97 
S480 212-216  S518 132-153 
T482   S527 206-216 
S493   S565 336-337 
S504   T594 395-399 
S505   S598 478-486 
S518   S603  
S527   S613  
T594   S637  
S598     
S603     
S608     
S613     
S616     
S619     
T620     
S637     
HEL-299 cells were transduced with a retrovirus encoding FLAG-, CFP-
tagged PML-III.  Protein was then isolated from uninfected cells or those 
infected with HSV-1 for 5 h in the presence of the proteasome inhibitor MG132.  
Sites of phosphorylation were identified by tandem mass spectrometry. 
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Table 4.2: Properties of PML-I and PML-I mutants 
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PML-I and the PML-I mutants were scored for their relative ability to 
recruit Sp100 or Daxx, their levels of SUMOylation, their ability to colocalize with 
ICP0, their resistance to ICP0-mediated degradation, their recruitment to 
incoming viral genomes, and ability to suppress viral plaque formation as 
detailed in Figures 4.1-4.9.  ND, not determined; -, unable; +, weak; ++, 
moderate; -+++, strong 
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4.6 Figures 
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Figure 4.1.  Map of known and novel sites of PML-III phosphorylation and 
the kinases that target these residues. 
Sites of phosphorylation from published studies and Table 4.1.  Table 
below lists kinases that phosphorylate or are predicted by either NetPhos 2.0 
[316] or PROSITE [317,318] (in italics) to phosphorylate the indicated residues. 
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Figure 4.2.  Recruitment of Sp100 and Daxx to PML-I and PML-I 
phosphorylation mutants in PML-depleted A594 cells. 
(A) A549 or A549 cells that express an shRNA that targets PML (A549-
shPML) and antibody stained to detect PML and Sp100 by 
immunofluorescence. 
(B) A549-shPMLs were transduced with FLAG-, CFP-tagged PML-I, or a 
SUMOylation-deficient, NLS-inactivated, SIM-inactivated, or phosphorylation 
mutant form of PML-I.  Sp100 and Daxx were detected by immunofluorescence, 
and exogenous PML was detected by autofluorescence. 
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Figure 4.3.  Quantification of Sp100 and Daxx recruitment to PML in PML-
depleted A549 cells that express wild type and mutant forms of PML-I. 
A549-shPML cells transduced with CFP-tagged PML-I or each PML-I 
mutant were scored on a four-point scale based on how well they recruited 
Sp100 (A) or Daxx (B), with either none (none), less than 50% (weak), between 
50-90% (moderate), or >90% (all/most) of the protein being localized at ND10s, 
as judged using fluorescence microscopy. 
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Figure 4.4.  Recruitment of Sp100 and Daxx to PML-I and PML-I mutants in 
PML-depleted HepaRG cells. 
(A) HepaRG cells that either express a control shRNA (HA-shNeg) or an 
shRNA that targets PML (HA-shPML) and stained with antibodies to detect PML 
and Sp100 or Daxx by immunofluorescence. 
(B) HA-shPMLs were transduced with FLAG-, CFP-tagged PML-I, or a 
SUMOylation-deficient, NLS-inactivated, SIM-inactivated, or phosphorylation 
mutant form of PML-I.  Sp100, Daxx, and PML were detected as in Figure 4.2. 
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Figure 4.5.  SUMOylation of PML-I or PML-I mutants in PML-depleted cells. 
(A) HEp-2 cells and HEp-2 cells depleted of PML and antibody stained to 
detect PML and Sp100 by immunofluorescence. 
(B) HEp-2-shPML cells were transfected with 900 ng of pGEM-3 (as 
carrier DNA) and 100 ng of a plasmid encoding FLAG-, CFP-tagged PML-I or a 
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mutant of PML-I.  The next day, the lysates of the cells were prepared, resolved 
by SDS-PAGE, and analyzed by western blot with an anti-FLAG antibody. 
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Figure 4.6.  Colocalization between PML-I or PML-I mutants and ICP0 in 
A549-shPML cells. 
A549-shPML cells transduced with FLAG-, CFP-tagged PML-I or each 
PML-I mutant were infected with HSV-1 at 2 PFU/cell.  At 2 hpi, the cells were 
fixed and stained with antibodies against ICP0.  PML is shown as red and ICP0 
as green in the merged image. 
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Figure 4.7.  Colocalization between PML-I or PML-I mutants and ICP0 in 
HA-shPML cells. 
HA-shPML cells transduced with FLAG-, CFP-tagged PML-I or each 
PML-I mutant were infected with HSV-1 at 2 PFU/cell.  At 2 hpi, the cells were 
fixed and stained with antibodies against ICP0 and ICP4.  PML is shown as red, 
ICP0 as green, and ICP4 as blue in the merged image. 
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Figure 4.8.  Degradation of PML-I or PML-I mutants by ICP0. 
HEp-2 were transfected with 900 ng of an empty vector (pGEM-3), a 
vector encoding ICP0, or a vector encoding the ICP0 mutant n212 and 100 ng of 
a plasmid encoding FLAG-, CFP-tagged PML-I or a PML-I mutant.  Twenty-four 
hs later, cells were lysed, resolved by SDS-PAGE, and analyzed by western blot 
with an anti-FLAG or anti-β-actin antibody. 
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Figure 4.9.  Recruitment of PML-I or PML-I mutants to incoming viral 
genomes. 
(A) HA-shPML cells transduced with FLAG-, CFP-tagged PML-I or a 
PML-I mutant were infected with an ICP0-null virus at 0.1 PFU/cell.  At 24 hpi, 
the cells were fixed and stained with antibody against ICP4 as a marker of viral 
DNA. 
(B) Same as in (A), except that 1 h prior to infection, the cells were 
pretreated with DMSO or one of two CK2 inhibitors, DMAT or TMCB, which 
were then used throughout infection. 
(C) HA-shNeg cells were treated, infected, and stained as described for 
HA-shPML cells.  
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Figure 4.10. Plating efficiency of HSV-1 on HepaRG-based cells 
HA-shNeg, HA-shPML, and HA-shPML cells expressing eYFP-tagged 
PML-I, PML-I(S117A), PML-I(S480;T482;S493A), or PML-I(S560/561/562/565A) 
cells were infected with 3-fold serial dilutions of in1863 (wild type) or 
dl1403/CMVlacZ (ICP0-null) and incubated with methylcellulose to restrict viral 
spread.  At 24 hpi, the cells were fixed and stained with X-gal to visualize 
plaques, and plaques consisting of greater than 4-6 cells were counted.  The 
data are shown as the number of plaques on an individual cell line normalized to 
that on HA-shNeg cells and represent the average of three separate 
experiments performed in duplicate. 
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Chapter 5: Conclusions and Future Directions 
HSV-1 is endemic in the human population.  Its success is partially due to 
its ability to establish a latent infection for the life of the host and because it can 
overcome cellular antiviral defenses.  This dissertation has examined the role of 
three cellular factors in the host’s antiviral response to HSV-1. 
Despite the known requirement for cellular kinases and the large number 
of either known or potential viral substrates, the role of cellular kinase CK2 in the 
life cycle of HSV-1 has received little attention.  In Chapter 2, I have shown that 
CK2 activity is largely unnecessary for HSV-1 replication.  The use of two CK2 
inhibitors did not affect the ability of the virus to initiate replication (Table 2.1), 
the ability to spread from cell to cell (Table 2.1), to or produce viral proteins 
(Figure 2.2) and there was no affect on the overall amount of virus produced in 
inhibitor-treated cells (Figure 2.1).  However, these same activities were 
impaired when cells with a pre-existing IFN response where infected in the 
presence of the CK2 inhibitors (Table 2.1 and Figure 2.1A and 2.1C).  I examined 
one potential viral CK2 substrates that is involved in countering the IFN 
response, ICP0, and found that in the absence of ICP0, the inhibitors no longer 
increase the IFN-sensitivity of HSV-1 (Figure 2.1B and 2.1D).  Surprisingly, I 
found that this was independent of ICP0’s E3 ligase function (Figures 2.3 and 
2.4).  There are a number of potential models to explain this outcome (Figure 
5.1).  ICP0 has been shown to transactivate a number of viral genes 
independently of its E3 ligase activity [319], which was not examined in this 
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thesis.  It is possible that phosphorylation of ICP0 by CK2 affects its ability to 
transactivate the expression of another viral gene, such as ICP34.5 or vhs, and 
that the product of this gene is responsible for overcoming the interferon 
response (Figure 5.1A).  Indeed, the use of the CDK inhibitor, roscovitine, affects 
ICP0’s transactivation activity but not the E3 function in a similar fashion [308].  
It would be of interest to examine whether this second function of ICP0 is linked 
to its anti-IFN counter activity.  While ICP0 is phosphorylated on several 
residues that are present within CK2 consensus sequences, whether CK2 
actually phosphorylates ICP0 has yet to be demonstrated.  Alternatively, it might 
be that the product of an ICP0 transactivated gene requires CK2-mediated 
phosphorylation to impair the IFN response (Figure 5.1B).  Another possibility is 
that ICP0 might interact with a partner protein whose activity it stimulates in a 
CK2 phosphorylation-dependent manner (Figure 5.1C).  Furthermore, it is 
plausible that ICP0 interacts with CK2 to stimulate its activity toward certain 
target proteins (Figure 5.1D).  Indeed, the EBV protein, EBNA1, interacts with 
CK2 and utilizes its activity to disrupt ND10s [77].  Finally, while I failed to 
observe such an effect for PML, it is possible that one or more interferon 
effector proteins that have activity towards HSV-1, but not Ad5 or VSV, are 
phosphorylated by CK2, and this phosphorylation is required for ICP0-mediated 
proteasomal degradation of the target (Figure 5.1E).  The above interpretations 
are not mutually exclusive and several may function during viral infection.  
Future work will need to be performed to identify the viral target of CK2 
responsible for overcoming restriction by IFNs.  Also, while CK2-inhibition did 
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not enhance restriction of IFN-β with adenovirus or vesicular stomatitis virus, it 
is unknown whether this effect would extend to other herpesvirus family 
members.  As noted above, EBV, a γ-herpesvirus, relocalizes CK2 to ND10s to 
induce PML degradation [77], suggesting that the use of CK2 to evade host 
immune responses may be a general feature of herpesviruses.  Lastly, while it is 
unlikely that the compounds used have a non-specific cellular target in 
common, a stronger argument for CK2 in facilitating HSV-1 replication in the 
face of an IFN response could be made if CK2’s activity was depleted or 
inhibited using siRNAs or cells that express one or more dominant negative 
forms of the CK2 enzyme. 
A number of previous reports have shown that human fibroblasts could 
be immortalized through the expression of hTERT.  Additionally, several reports 
demonstrated that HCMV replication was unaffected by hTERT-immortalization.  
On the other hand, some studies had shown that hTERT has non-telomerase 
related roles (e.g., anti-apoptotic) and that its expression can lead to changes in 
gene expression.  However, the ability of hTERT-immortalized cells to mount a 
cellular antiviral response to HSV-1 had not previously been examined.  Chapter 
2 demonstrates that exogenous hTERT expression does not impair the ability of 
cells to produce antiviral cytokines (most likely IFNs) (Figure 3.9) in response to 
viral infection nor does it cause ISG dysregulation (Figures 3.4 and 3.5).  This is 
in contrast to cells that are transformed with a viral oncogene, which leads to a 
greatly reduced ability to induce ISG expression and persistent ISG protein 
production.  Like HCMV [280,281], hTERT does not affect HSV-1 replication nor 
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does it change the ability of IFN to restrict the growth of an IFN-sensitive HSV-1 
mutant (Figures 3.6 and 3.7).  Additionally, unlike in traditionally immortalized 
cells, the requirement for the HSV-1 protein ICP0 is preserved.  Thus, the HEL-
TERT cells represent the creation of a reagent that should facilitate future work 
that examines intrinsic- and IFN-based antiviral responses and aid in the study 
of certain HSV-1 mutants.  Though the interferon response to HSV-1 and VSV 
were unaffected, it remains possible that the process of immortalization affects 
other cellular pathways that can impact viral replication.  Additionally, there may 
be other ISGs than the four tested in this thesis that are affected by either 
hTERT expression or long term culturing, which would be found in an expanded 
examination of ISG gene expression. 
PML is known to function in antiviral pathways, and many of its activities 
are controlled by post-translational modifications; however, no study to date has 
examined the role of PML phosphorylation in regulating its antiviral activity.  A 
number of studies have identified sites of PML phosphorylation during the 
course of this dissertation [176,178,185,187,304] and confirm the authenticity of 
my mass spectrometry data; nonetheless, my thesis research represents the 
first study to examine PML phosphorylation during viral infection, using HSV-1 
as the pathogen.  As I initially examined the phosphorylation status of PML-III, it 
would be interesting to examine the C-terminus of the remaining PML isoforms, 
particularly PML-I and –II due to their antiviral activities on HSV-1 and see 
whether they also have unique sites of phosphorylation.  Mutations of the 
phosphorylation sites resulted, for the most part, in minor effects on a number of 
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PML properties when these mutants were expressed in PML-depleted cells.  
Only mutation of sites near the SIM resulted in visible changes to ND10 
morphology and the ability to recruit the ND10 associated proteins Sp100 and 
Daxx.  Mutation of the SIM proximal sites also compromised the ability of PML 
to relocate to incoming viral genomes, though it is unclear at this time whether 
this is due to a change in phosphorylation at these sites.  While phosphorylation 
has been implicated in the degradation of PML by cellular factors, mutation of 
the sites examined in this thesis did not, for the most part, inhibit the ability of 
ICP0 to induce PML degradation.  This might be due to the ability of ICP0 to 
physically interact with a C-terminal portion of PML-I and future work should 
examine whether these phosphorylation sites differentially control the ability of 
ICP0 to induce the loss of other PML isoforms, much like polySUMOylation at 
K160 [293].  When PML-I and several of the PML-I phosphorylation knockout 
mutants were assayed for antiviral activity toward HSV-1 infection, they all failed 
to substantially restrict the establishment of infection.  It should be said, 
however, that not only did restoration of PML-I expression itself fail to restrict 
the plaquing of an HSV-1 ICP0-null mutant but that, in my hands, knock-down 
of endogenous PML did not result in the same increase in plaquing as in 
previous reports.  While HepaRG cells, the line used for these assays, have a 
high requirement for ICP0, they are transformed and thus the use of another cell 
line, such as the HEL-TERT cells created in Chapter 2, may prove more suitable 
in an examination of intrinsic defense.  Additionally, using a technology such as 
transcription activator-like effector nucleases or zinc finger nucleases to knock 
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out, instead of knocking down, PML may result in a larger degree of 
complementation for plaquing with an ICP0-null mutant.  I expect that switching 
from PML-I to PML-II or restoring the expression of multiple isoforms 
simultaneously would likely increase the antiviral activity of PML. 
To explain how mutations adjacent to the SUMO interaction motif 
influence the antiviral activity of PML, I would propose the following model 
(Figure 5.2).  In a resting cell, the localization of PML can be found in equilibrium 
between the ND10s and the nucleoplasm.  This equilibrium serves to allow PML 
to act as a nuclear sensor that detects SUMOylated proteins and can either 
recruit them into ND10s or nucleate new ND10s at the site of these SUMOylated 
proteins.  In the absence of a high number of positionally stable, non-ND10-
localized SUMOylated proteins, PML favors interacting with itself to form 
ND10s.  When the amount of non-ND10 SUMOylated proteins is high, the 
localization equilibrium shifts, and PML is gradually lost from ND10s.  In the 
absence of ICP0, foci of SUMOylated proteins as well as Ubc9 and certain 
SUMO E3 ligases can be found at viral DNA [19,290].  While the SUMOylated 
targets are unknown, several DDR members, including BRCA1, 53BP1, MDC1, 
and RNF168 [320–322] have been shown to be modified by the SUMO paralogs.  
The high concentration of SUMOylated proteins results in nucleoplasmic PML 
being recruited to areas containing incoming viral genomes and depletes ND10 
of PML.  PML localization next to viral DNA may play a similar role similar to the 
one it performs at stem cell telomeres, where PML cooperates with another 
ND10 member, ATRX, in the establishment of heterochromatin [323].  
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Additionally, it is possible that PML uses its E3 ligase function to amplify the 
SUMOylation signal at viral DNA to further recruit effector proteins like RNF168, 
which amplifies the ubiquitination signal on γH2AX at DNA damage foci and 
allows for the recruitment of 53BP1 and BRCA1 [324,325].  In support of this 
model, PML has been found to act as a stabilizing factor in the recruitment of 
certain DNA damage response proteins [326].  As mutation of the 
phosphoacceptor sites near the PML SIM compromises its ability to interact 
with SUMOylated proteins, the amount of time PML spends in the nucleoplasm 
is short and the localization equilibrium shifts in favor of ND10-resident PML.  
Additionally, SIM-inactivated forms of PML are unable to detect the signal 
present at incoming viral DNA, which compromises its ability to effect a 
repression of viral gene expression.  The increase in the residence of PML in 
ND10s also serves to more strongly recruit other ND10 members it interacts 
with such as Sp100 and Daxx.  While it was not examined in this thesis, it would 
be interesting to see whether Sp100 and Daxx are still recruited to incoming viral 
in cells expressing SIM-inactivated PML or whether SIM-deficient forms of PML 
retain these two proteins at ND10s during infection. 
In conclusion, I have established in this thesis that host cells have several 
defenses (i.e,, IFN-β and PML) to limit or inhibit HSV-1 replication. The virus, in 
turn, has developed strategies to counteract these defenses, either through the 
activities of viral encoded proteins (i.e. ICP0) or cellular kinases (i.e. CK2).  
Ultimately, the interactions between these factors will dictate whether HSV-1 will 
establish a lytic or latent/quiescent infection in its host.  
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Figure 5.1 Role of CK2 in IFN response impairment during HSV-1 infection 
(A) CK2 phosphorylates ICP0, allowing ICP0 to activate the expression of 
a viral protein that counteracts the IFN response. 
(B) ICP0 transactivates the expression of a viral protein that requires CK2-
mediated phosphorylation for its anti-IFN effector activity. 
(C) ICP0 is phosphorylated by CK2, enabling it to interact with a partner 
protein.  The complex formed by this partner and ICP0 functions to disarm the 
IFN response. 
(D) ICP0 interacts with CK2 and directs the kinase activity of CK2 toward 
a viral or cellular target that results in the impairment of the IFN response. 
(E) CK2 phosphorylates a cellular IFN effector protein, with this 
phosphorylation being necessary to enable the ICP0-mediated 
polyubiquitination and proteasomal degradation of the effector protein.  
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Figure 5.2 Function of the phosphoSIM in the antiviral activity of PML 
(A) In cells expressing WT PML, injection of the viral genome into the 
nucleus results in the recruitment of DNA damage response and SUMOylation 
proteins to sites of viral DNA, leading to chromatinization of the viral genome.  A 
SUMOylation signal on one or more proteins associated with this viral chromatin 
then recruits nucleoplasmic PML, which promotes the formation of a repressive 
chromatin state and an impairment of viral gene expression. 
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(B) In cells expressing a form of PML in which the phosphoSIM cannot be 
phosphorylated, nucleoplasmic PML fails to interact with the viral chromatin-
associated SUMO signal, preventing the formation of a repressive chromatin 
state and allowing for increased viral gene expression.  Consequently, due to 
the inability of this mutant form of PML to interact with SUMOylated proteins, 
PML is present in ND10s to a larger degree and produces larger ND10s that 
more strongly recruit certain ND10 members that it interacts with in a SIM-
independent manner. 
 170 
Bibliography 
[1]  B.N. Fields, D.M. Knipe, P.M. Howley, D.E. Griffin, Fields Virology, 
Lippincott Williams & Wilkins, 2007. 
[2]  R.J. Whitley, D.W. Kimberlin, B. Roizman, Herpes Simplex Viruses, Clin. 
Infect. Dis. 26 (1998) 541–555. 
[3]  C.M. Roberts, J.R. Pfister, S.J. Spear, Increasing proportion of herpes 
simplex virus type 1 as a cause of genital herpes infection in college 
students, Sex. Transm. Dis. 30 (2003) 797–800. 
[4]  S.J. Macdonald, H.H. Mostafa, L.A. Morrison, D.J. Davido, Genome 
Sequence of Herpes Simplex Virus 1 Strain KOS, J. Virol. 86 (2012) 6371–
6372. 
[5]  S. Loret, G. Guay, R. Lippe, Comprehensive Characterization of 
Extracellular Herpes Simplex Virus Type 1 Virions, J. Virol. 82 (2008) 8605–
8618. 
[6]  I. Liashkovich, W. Hafezi, J.M. Kühn, H. Oberleithner, V. Shahin, Nuclear 
delivery mechanism of herpes simplex virus type 1 genome, J. Mol. 
Recognit. 24 (2011) 414–421. 
[7]  R.W. Honess, B. Roizman, Regulation of Herpesvirus Macromolecular 
Synthesis I. Cascade Regulation of the Synthesis of Three Groups of Viral 
Proteins, J. Virol. 14 (1974) 8–19. 
[8]  P. Lomonte, K.F. Sullivan, R.D. Everett, Degradation of Nucleosome-
associated Centromeric Histone H3-like Protein CENP-A Induced by 
Herpes Simplex Virus Type 1 Protein ICP0, J. Biol. Chem. 276 (2001) 
5829–5835. 
[9]  P. Lomonte, E. Morency, Centromeric protein CENP-B proteasomal 
degradation induced by the viral protein ICP0, Febs Lett. 581 (2007) 658–
662. 
[10]  R.D. Everett, W.C. Earnshaw, J. Findlay, P. Lomonte, Specific destruction 
of kinetochore protein CENP-C and disruption of cell division by herpes 
simplex virus immediate-early protein Vmw110, Embo J. 18 (1999) 1526–
1538. 
[11]  S. Gross, F. Catez, H. Masumoto, P. Lomonte, Centromere Architecture 
Breakdown Induced by the Viral E3 Ubiquitin Ligase ICP0 Protein of 
Herpes Simplex Virus Type 1, Plos One. 7 (2012) e44227. 
[12]  C.E. Lilley, M.S. Chaurushiya, C. Boutell, S. Landry, J. Suh, S. Panier, et 
al., A viral E3 ligase targets RNF8 and RNF168 to control histone 
ubiquitination and DNA damage responses, Embo J. 29 (2010) 943–955. 
[13]  J. Parkinson, S.P. Lees-Miller, R.D. Everett, Herpes Simplex Virus Type 1 
Immediate-Early Protein Vmw110 Induces the Proteasome-Dependent 
Degradation of the Catalytic Subunit of DNA-Dependent Protein Kinase, J. 
Virol. 73 (1999) 650–657. 
 171 
[14]  M. Kummer, N.M. Turza, P. Muhl-Zurbes, M. Lechmann, C. Boutell, R.S. 
Coffin, et al., Herpes Simplex Virus Type 1 Induces CD83 Degradation in 
Mature Dendritic Cells with Immediate-Early Kinetics via the Cellular 
Proteasome, J Virol. 81 (2007) 6326–6338. 
[15]  C. Boutell, M. Canning, A. Orr, R.D. Everett, Reciprocal Activities between 
Herpes Simplex Virus Type 1 Regulatory Protein ICP0, a Ubiquitin E3 
Ligase, and Ubiquitin-Specific Protease USP7, J Virol. 79 (2005) 12342–
12354. 
[16]  L. Diao, B. Zhang, J. Fan, X. Gao, S. Sun, K. Yang, et al., Herpes virus 
proteins ICP0 and BICP0 can activate NF-[kappa]B by catalyzing 
I[kappa]B[alpha] ubiquitination, Cell. Signal. 17 (2005) 217–229. 
[17]  M.H. Orzalli, N.A. DeLuca, D.M. Knipe, Nuclear IFI16 induction of IRF-3 
signaling during herpesviral infection and degradation of IFI16 by the viral 
ICP0 protein, Proc. Natl. Acad. Sci. 109 (2012) E3008–E3017. 
[18]  Y. Fukuyo, N. Horikoshi, A.M. Ishov, S.J. Silverstein, T. Nakajima, The 
Herpes Simplex Virus Immediate-Early Ubiquitin Ligase ICP0 Induces 
Degradation of the ICP0 Repressor Protein E2FBP1, J Virol. 85 (2011) 
3356–3366. 
[19]  C. Boutell, D. Cuchet-Lourenço, E. Vanni, A. Orr, M. Glass, S. McFarlane, 
et al., A Viral Ubiquitin Ligase Has Substrate Preferential SUMO Targeted 
Ubiquitin Ligase Activity that Counteracts Intrinsic Antiviral Defence, Plos 
Pathog. 7 (2011) e1002245. 
[20]  R.D. Everett, M.K. Chelbi-Alix, PML and PML nuclear bodies: Implications 
in antiviral defence, Biochimie. 89 (2007) 819–830. 
[21]  R. Hagglund, B. Roizman, Role of ICP0 in the Strategy of Conquest of the 
Host Cell by Herpes Simplex Virus 1, J. Virol. 78 (2004) 2169–2178. 
[22]  K.L. Mossman, A.A. Ashkar, Herpesviruses and the innate immune 
response, Viral Immunol. 18 (2005) 267–281. 
[23]  M.D. Weitzman, C.E. Lilley, M.S. Chaurushiya, Genomes in conflict: 
maintaining genome integrity during virus infection, Annu. Rev. Microbiol. 
64 (2010) 61–81. 
[24]  G.G. Maul, D. Negorev, P. Bell, A.M. Ishov, Review: Properties and 
Assembly Mechanisms of ND10, PML Bodies, or PODs, J. Struct. Biol. 
129 (2000) 278–287. 
[25]  G.G. Maul, A.M. Ishov, R.D. Everett, Nuclear Domain 10 as Preexisting 
Potential Replication Start Sites of Herpes Simplex Virus Type-1, Virology. 
217 (1996) 67–75. 
[26]  R.D. Everett, J. Murray, ND10 Components Relocate to Sites Associated 
with Herpes Simplex Virus Type 1 Nucleoprotein Complexes during Virus 
Infection, J Virol. 79 (2005) 5078–5089. 
[27]  R.D. Everett, P. Freemont, H. Saitoh, M. Dasso, A. Orr, M. Kathoria, et al., 
The Disruption of ND10 during Herpes Simplex Virus Infection Correlates 
with the Vmw110- and Proteasome-Dependent Loss of Several PML 
Isoforms, J Virol. 72 (1998) 6581–6591. 
 172 
[28]  J. Parkinson, R.D. Everett, Alphaherpesvirus Proteins Related to Herpes 
Simplex Virus Type 1 ICP0 Affect Cellular Structures and Proteins, J Virol. 
74 (2000) 10006–10017. 
[29]  V. Lukashchuk, R.D. Everett, Regulation of ICP0-Null Mutant Herpes 
Simplex Virus Type 1 Infection by ND10 Components ATRX and hDaxx, J 
Virol. 84 (2010) 4026–4040. 
[30]  R.D. Everett, S. Rechter, P. Papior, N. Tavalai, T. Stamminger, A. Orr, PML 
Contributes to a Cellular Mechanism of Repression of Herpes Simplex 
Virus Type 1 Infection That Is Inactivated by ICP0, J. Virol. 80 (2006) 7995–
8005. 
[31]  P. Härle, B. Sainz, D.J.J. Carr, W.P. Halford, The Immediate-Early Protein, 
ICP0, Is Essential for the Resistance of Herpes Simplex Virus to Interferon-
α/β, Virology. 293 (2002) 295–304. 
[32]  R.D. Everett, A. Orr, Herpes Simplex Virus Type 1 Regulatory Protein ICP0 
Aids Infection in Cells with a Preinduced Interferon Response but Does 
Not Impede Interferon-Induced Gene Induction, J Virol. 83 (2009) 4978–
4983. 
[33]  A.V. Chee, P. Lopez, P.P. Pandolfi, B. Roizman, Promyelocytic Leukemia 
Protein Mediates Interferon-Based Anti-Herpes Simplex Virus 1 Effects, J 
Virol. 77 (2003) 7101–7105. 
[34]  R.D. Everett, D.F. Young, R.E. Randall, A. Orr, STAT-1- and IRF-3-
Dependent Pathways Are Not Essential for Repression of ICP0-Null 
Mutant Herpes Simplex Virus Type 1 in Human Fibroblasts, J Virol. 82 
(2008) 8871–8881. 
[35]  W. Halford, C. Weisend, J. Grace, M. Soboleski, D. Carr, J. Balliet, et al., 
ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: 
implications for the regulation of viral latency, Virol. J. 3 (2006) 44. 
[36]  G. Uzé, D. Monneron, IL-28 and IL-29: Newcomers to the interferon family, 
Biochimie. 89 (2007) 729–734. 
[37]  M.G. Katze, Y. He, M. Gale, Viruses and interferon: a fight for supremacy, 
Nat Rev Immunol. 2 (2002) 675–687. 
[38]  M. Paulson, C. Press, E. Smith, N. Tanese, D.E. Levy, IFN-Stimulated 
transcription through a TBP-free acetyltransferase complex escapes viral 
shutoff, Nat. Cell Biol. 4 (2002) 140–147. 
[39]  H. Kristiansen, H.H. Gad, S. Eskildsen-Larsen, P. Despres, R. Hartmann, 
The Oligoadenylate Synthetase Family: An Ancient Protein Family with 
Multiple Antiviral Activities, J. Interferon Cytokine Res. 31 (2011) 41–47. 
[40]  O. Haller, G. Kochs, Interferon-Induced Mx Proteins: Dynamin-Like 
GTPases with Antiviral Activity, Traffic. 3 (2002) 710–717. 
[41]  A. Pindel, A. Sadler, The Role of Protein Kinase R in the Interferon 
Response, J. Interferon Cytokine Res. 31 (2011) 59–70. 
[42]  V. Fensterl, G.C. Sen, The ISG56/IFIT1 Gene Family, J. Interferon Cytokine 
Res. 31 (2011) 71–78. 
[43]  F. Meggio, L.A. Pinna, One-thousand-and-one substrates of protein kinase 
CK2?, Faseb J. 17 (2003) 349–368. 
 173 
[44]  L.A. Pinna, Casein kinase 2: an “eminence grise” in cellular regulation?, 
Biochim. Biophys. Acta. 1054 (1990) 267–284. 
[45]  G. Vilk, J.E. Weber, J.P. Turowec, J.S. Duncan, C. Wu, D.R. Derksen, et al., 
Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells, 
Cell. Signal. 20 (2008) 1942–1951. 
[46]  T. Buchou, M. Vernet, O. Blond, H.H. Jensen, H. Pointu, B.B. Olsen, et al., 
Disruption of the Regulatory β Subunit of Protein Kinase CK2 in Mice 
Leads to a Cell-Autonomous Defect and Early Embryonic Lethality, Mol. 
Cell. Biol. 23 (2003) 908–915. 
[47]  E. Schneider, S. Kartarius, N. Schuster, M. Montenarh, The cyclin 
H/cdk7/Mat1 kinase activity is regulated by CK2 phosphorylation of cyclin 
H, Oncogene. 21 (2002) 5031–5037. 
[48]  N. Allende-Vega, S. Dias, D. Milne, D. Meek, Phosphorylation of the acidic 
domain of Mdm2 by protein kinase CK2, Mol. Cell. Biochem. 274 (2005) 
85–90. 
[49]  D.M. Keller, X. Zeng, Y. Wang, Q.H. Zhang, M. Kapoor, H. Shu, et al., A 
DNA Damage–Induced p53 Serine 392 Kinase Complex Contains CK2, 
hSpt16, and SSRP1, Mol. Cell. 7 (2001) 283–292. 
[50]  N. Watanabe, H. Arai, J. Iwasaki, M. Shiina, K. Ogata, T. Hunter, et al., 
Cyclin-dependent kinase (CDK) phosphorylation destabilizes somatic 
Wee1 via multiple pathways, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 
11663–11668. 
[51]  N. St-Denis, D. Litchfield, From birth to death: The role of protein kinase 
CK2 in the regulation of cell proliferation and survival, Cell. Mol. Life Sci. 
66 (2009) 1817–1829. 
[52]  T.B. Panova, K.I. Panov, J. Russell, J.C.B.M. Zomerdijk, Casein Kinase 2 
Associates with Initiation-Competent RNA Polymerase I and Has Multiple 
Roles in Ribosomal DNA Transcription, Mol. Cell. Biol. 26 (2006) 5957–
5968. 
[53]  D.J. Hockman, M.C. Schultz, Casein kinase II is required for efficient 
transcription by RNA polymerase III., Mol. Cell. Biol. 16 (1996) 892–898. 
[54]  P. Hu, S. Wu, N. Hernandez, A Minimal RNA Polymerase III Transcription 
System from Human Cells Reveals Positive and Negative Regulatory Roles 
for CK2, Mol. Cell. 12 (2003) 699–709. 
[55]  P. Hu, K. Samudre, S. Wu, Y. Sun, N. Hernandez, CK2 Phosphorylation of 
Bdp1 Executes Cell Cycle-Specific RNA Polymerase III Transcription 
Repression, Mol. Cell. 16 (2004) 81–92. 
[56]  K.L. Abbott, M.B. Renfrow, M.J. Chalmers, B.D. Nguyen, A.G. Marshall, P. 
Legault, et al., Enhanced Binding of RNAP II CTD Phosphatase FCP1 to 
RAP74 Following CK2 Phosphorylation, Biochemistry (Mosc.). 44 (2005) 
2732–2745. 
[57]  L.R. Martins, P. Lúcio, M.C. Silva, K.L. Anderes, P. Gameiro, M.G. Silva, et 
al., Targeting CK2 overexpression and hyperactivation as a novel 
therapeutic tool in chronic lymphocytic leukemia, Blood. 116 (2010) 2724–
2731. 
 174 
[58]  H. Lawnicka, M. Kowalewicz-Kulbat, P. Sicinska, Z. Kazimierczuk, P. 
Grieb, H. Stepien, Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-
dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and 
hormonal activity of human adrenocortical carcinoma cell line (H295R) in 
vitro, Cell Tissue Res. 340 (2010) 371–379. 
[59]  S. Shin, Y. Lee, W. Kim, H. Ko, H. Choi, K. Kim, Caspase-2 primes cancer 
cells for TRAIL-mediated apoptosis by processing procaspase-8, Embo J. 
24 (2005) 3532–3542. 
[60]  J.P. Turowec, J.S. Duncan, G.B. Gloor, D.W. Litchfield, Regulation of 
caspase pathways by protein kinase CK2: identification of proteins with 
overlapping CK2 and caspase consensus motifs, Mol. Cell. Biochem. 356 
(2011) 159–167. 
[61]  J.C. Tapia, V.A. Torres, D.A. Rodriguez, L. Leyton, A.F.G. Quest, Casein 
kinase 2 (CK2) increases survivin expression via enhanced β-catenin–T cell 
factor/lymphoid enhancer binding factor-dependent transcription, Proc. 
Natl. Acad. Sci. 103 (2006) 15079–15084. 
[62]  Y. Zheng, H. Qin, S.J. Frank, L. Deng, D.W. Litchfield, A. Tefferi, et al., A 
CK2-dependent mechanism for activation of the JAK-STAT signaling 
pathway, Blood. 118 (2011) 156–166. 
[63]  Z. Sun, H. Ren, Y. Liu, J.L. Teeling, J. Gu, Phosphorylation of RIG-I by 
Casein Kinase II Inhibits Its Antiviral Response, J. Virol. 85 (2011) 1036–
1047. 
[64]  A. Schmidt, T. Schwerd, W. Hamm, J.C. Hellmuth, S. Cui, M. Wenzel, et 
al., 5′-triphosphate RNA requires base-paired structures to activate 
antiviral signaling via RIG-I, Proc. Natl. Acad. Sci. 106 (2009) 12067–
12072. 
[65]  S. Veeranki, D. Choubey, Interferon-inducible p200-family protein IFI16, an 
innate immune sensor for cytosolic and nuclear double-stranded DNA: 
Regulation of subcellular localization, Mol. Immunol. 49 (2012) 567–571. 
[66]  L.J. Briggs, R.W. Johnstone, R.M. Elliot, C.-Y. Xiao, M. Dawson, J.A. 
Trapani, et al., Novel properties of the protein kinase CK2-site-regulated 
nuclear- localization sequence of the interferon-induced nuclear factor IFI 
16, Biochem. J. 353 (2001) 69–77. 
[67]  J. Friborg, A. Ladha, H. Göttlinger, W.A. Haseltine, E.A. Cohen, Functional 
analysis of the phosphorylation sites on the human immunodeficiency 
virus type 1 Vpu protein, J. Acquir. Immune Defic. Syndr. Hum. 
Retrovirology Off. Publ. Int. Retrovirology Assoc. 8 (1995) 10–22. 
[68]  E. Haneda, T. Furuya, S. Asai, Y. Morikawa, K. Ohtsuki, Biochemical 
Characterization of Casein Kinase II as a Protein Kinase Responsible for 
Stimulation of HIV-1 Protease in Vitro, Biochem. Biophys. Res. Commun. 
275 (2000) 434–439. 
[69]  S. Harada, E. Haneda, T. Maekawa, Y. Morikawa, S. Funayama, N. Nagata, 
et al., Casein kinase II (CK-II)-mediated stimulation of HIV-1 reverse 
transcriptase activity and characterization of selective inhibitors in vitro, 
Biol. Pharm. Bull. 22 (1999) 1122–1126. 
 175 
[70]  K. Ohtsuki, T. Maekawa, S. Harada, A. Karino, Y. Morikawa, M. Ito, 
Biochemical characterization of HIV-1 Rev as a potent activator of casein 
kinase II in vitro, Febs Lett. 428 (1998) 235–240. 
[71]  M. Schindler, D. Rajan, C. Banning, P. Wimmer, H. Koppensteiner, A. 
Iwanski, et al., Vpu serine 52 dependent counteraction of tetherin is 
required for HIV-1 replication in macrophages, but not in ex vivo human 
lymphoid tissue, Retrovirology. 7 (2010) 1. 
[72]  M.I. Barrasa, N.Y. Harel, J.C. Alwine, The Phosphorylation Status of the 
Serine-Rich Region of the Human Cytomegalovirus 86-Kilodalton Major 
Immediate-Early Protein IE2/IEP86 Affects Temporal Viral Gene 
Expression, J. Virol. 79 (2005) 1428–1437. 
[73]  Y. Gao, K. Colletti, G.S. Pari, Identification of Human Cytomegalovirus 
UL84 Virus- and Cell-Encoded Binding Partners by Using Proteomics 
Analysis, J. Virol. 82 (2008) 96–104. 
[74]  M.T. Nogalski, J.P. Podduturi, I.B. DeMeritt, L.E. Milford, A.D. Yurochko, 
The Human Cytomegalovirus Virion Possesses an Activated Casein Kinase 
II That Allows for the Rapid Phosphorylation of the Inhibitor of NF-κB, 
IκBα, J. Virol. 81 (2007) 5305–5314. 
[75]  A.S. El-Guindy, G. Miller, Phosphorylation of Epstein-Barr Virus ZEBRA 
Protein at Its Casein Kinase 2 Sites Mediates Its Ability To Repress 
Activation of a Viral Lytic Cycle Late Gene by Rta, J. Virol. 78 (2004) 7634–
7644. 
[76]  C. Medina-Palazon, H. Gruffat, F. Mure, O. Filhol, V. Vingtdeux-Didier, H. 
Drobecq, et al., Protein Kinase CK2 Phosphorylation of EB2 Regulates Its 
Function in the Production of Epstein-Barr Virus Infectious Viral Particles, 
J. Virol. 81 (2007) 11850–11860. 
[77]  N. Sivachandran, J.Y. Cao, L. Frappier, Epstein-Barr Virus Nuclear Antigen 
1 Hijacks the Host Kinase CK2 To Disrupt PML Nuclear Bodies, J Virol. 84 
(2010) 11113–11123. 
[78]  N. Franck, J.L. Seyec, C. Guguen-Guillouzo, L. Erdtmann, Hepatitis C Virus 
NS2 Protein Is Phosphorylated by the Protein Kinase CK2 and Targeted 
for Degradation to the Proteasome, J. Virol. 79 (2005) 2700–2708. 
[79]  A.V. Ivanov, O.A. Smirnova, O.N. Ivanova, O.V. Masalova, S.N. Kochetkov, 
M.G. Isaguliants, Hepatitis C Virus Proteins Activate NRF2/ARE Pathway 
by Distinct ROS-Dependent and Independent Mechanisms in HUH7 Cells, 
Plos One. 6 (2011) e24957. 
[80]  T.L. Tellinghuisen, K.L. Foss, J. Treadaway, Regulation of Hepatitis C Virion 
Production via Phosphorylation of the NS5A Protein, Plos Pathog. 4 (2008) 
e1000032. 
[81]  M. Yi, Y. Ma, J. Yates, S.M. Lemon, trans-Complementation of an NS2 
Defect in a Late Step in Hepatitis C Virus (HCV) Particle Assembly and 
Maturation, Plos Pathog. 5 (2009) e1000403. 
[82]  W.-M. Chien, J.N. Parker, D.-C. Schmidt-Grimminger, T.R. Broker, L.T. 
Chow, Casein Kinase II Phosphorylation of the Human Papillomavirus-18 
 176 
E7 Protein Is Critical for Promoting S-Phase Entry, Cell Growth Differ. 11 
(2000) 425–435. 
[83]  N.J. Genovese, N.S. Banerjee, T.R. Broker, L.T. Chow, Casein Kinase II 
Motif-Dependent Phosphorylation of Human Papillomavirus E7 Protein 
Promotes p130 Degradation and S-Phase Induction in Differentiated 
Human Keratinocytes, J. Virol. 82 (2008) 4862–4873. 
[84]  J. Yue, R. Shukla, R. Accardi, I. Zanella-Cleon, M. Siouda, M.-P. Cros, et 
al., Cutaneous Human Papillomavirus Type 38 E7 Regulates Actin 
Cytoskeleton Structure for Increasing Cell Proliferation through CK2 and 
the Eukaryotic Elongation Factor 1A, J. Virol. 85 (2011) 8477–8494. 
[85]  W. Ching, T. Dobner, E. Koyuncu, The Human Adenovirus Type 5 E1B 55-
Kilodalton Protein Is Phosphorylated by Protein Kinase CK2, J. Virol. 86 
(2012) 2400–2415. 
[86]  P. Massimi, D. Pim, A. Storey, L. Banks, HPV-16 E7 and adenovirus E1a 
complex formation with TATA box binding protein is enhanced by casein 
kinase II phosphorylation, Oncogene. 12 (1996) 2325–2330. 
[87]  S. Barik, A.K. Banerjee, Phosphorylation by cellular casein kinase II is 
essential for transcriptional activity of vesicular stomatitis virus 
phosphoprotein P, Proc. Natl. Acad. Sci. 89 (1992) 6570–6574. 
[88]  T. Das, A.K. Gupta, P.W. Sims, C.A. Gelfand, J.E. Jentoft, A.K. Banerjee, 
Role of Cellular Casein Kinase II in the Function of the Phosphoprotein (P) 
Subunit of RNA Polymerase of Vesicular Stomatitis Virus, J. Biol. Chem. 
270 (1995) 24100 –24107. 
[89]  A.K. Gupta, T. Das, A.K. Banerjee, Casein kinase II is the P protein 
phosphorylating cellular kinase associated with the ribonucleoprotein 
complex of purified vesicular stomatitis virus, J. Gen. Virol. 76 (1995) 365–
372. 
[90]  K. Xia, D.M. Knipe, N.A. DeLuca, Role of protein kinase A and the serine-
rich region of herpes simplex virus type 1 ICP4 in viral replication, J. Virol. 
70 (1996) 1050–1060. 
[91]  D.J. Davido, W.F. Zagorski, W.S. Lane, P.A. Schaffer, Phosphorylation Site 
Mutations Affect Herpes Simplex Virus Type 1 ICP0 Function, J. Virol. 79 
(2005) 1232–1243. 
[92]  C. Potel, G. Elliott, Phosphorylation of the Herpes Simplex Virus Tegument 
Protein VP22 Has No Effect on Incorporation of VP22 into the Virus but Is 
Involved in Optimal Expression and Virion Packaging of ICP0, J. Virol. 79 
(2005) 14057–14068. 
[93]  S. Rojas, K.A. Corbin-Lickfett, L. Escudero-Paunetto, R.M. Sandri-Goldin, 
ICP27 Phosphorylation Site Mutants Are Defective in Herpes Simplex Virus 
1 Replication and Gene Expression, J. Virol. 84 (2010) 2200–2211. 
[94]  H.H. Mostafa, T.W. Thompson, D.J. Davido, N-Terminal Phosphorylation 
Sites of Herpes Simplex Virus 1 ICP0 Differentially Regulate Its Activities 
and Enhance Viral Replication, J. Virol. 87 (2013) 2109–2119. 
 177 
[95]  P.A. Bates, N.A. DeLuca, The Polyserine Tract of Herpes Simplex Virus 
ICP4 Is Required for Normal Viral Gene Expression and Growth in Murine 
Trigeminal Ganglia, J. Virol. 72 (1998) 7115–7124. 
[96]  R.M. Sandri-Goldin, The many roles of the regulatory protein ICP27 during 
herpes simplex virus infection, Front. Biosci. J. Virtual Libr. 13 (2008) 
5241–56. 
[97]  M.D. Koffa, J. Kean, G. Zachos, S.A. Rice, J.B. Clements, CK2 Protein 
Kinase Is Stimulated and Redistributed by Functional Herpes Simplex 
Virus ICP27 Protein, J. Virol. 77 (2003) 4315–4325. 
[98]  K.A. Corbin-Lickfett, S. Rojas, L. Li, M.J. Cocco, R.M. Sandri-Goldin, 
ICP27 Phosphorylation Site Mutants Display Altered Functional 
Interactions with Cellular Export Factors Aly/REF and TAP/NXF1 but Are 
Able To Bind Herpes Simplex Virus 1 RNA, J. Virol. 84 (2010) 2212–2222. 
[99]  A.L. Fridman, L. Tang, O.I. Kulaeva, B. Ye, Q. Li, F. Nahhas, et al., 
Expression profiling identifies three pathways altered in cellular 
immortalization: interferon, cell cycle, and cytoskeleton, J. Gerontol. A. 
Biol. Sci. Med. Sci. 61 (2006) 879–889. 
[100]  O.I. Kulaeva, S. Draghici, L. Tang, J.M. Kraniak, S.J. Land, M.A. Tainsky, 
Epigenetic silencing of multiple interferon pathway genes after cellular 
immortalization, Oncogene. 22 (2003) 4118–4127. 
[101]  J. Shou, R. Soriano, S.W. Hayward, G.R. Cunha, P.M. Williams, W.-Q. 
Gao, Expression Profiling of a Human Cell Line Model of Prostatic Cancer 
Reveals a Direct Involvement of Interferon Signaling in Prostate Tumor 
Progression, Proc. Natl. Acad. Sci. 99 (2002) 2830–2835. 
[102]  G. Untergasser, H.B. Koch, A. Menssen, H. Hermeking, Characterization 
of Epithelial Senescence by Serial Analysis of Gene Expression 
Identification of Genes Potentially Involved in Prostate Cancer, Cancer 
Res. 62 (2002) 6255–6262. 
[103]  L. Hayflick, The limited in vitro lifetime of human diploid cell strains, Exp. 
Cell Res. 37 (1965) 614–636. 
[104]  E. Gilson, V. Geli, How telomeres are replicated, Nat Rev Mol Cell Biol. 8 
(2007) 825–838. 
[105]  T. de Lange, How Telomeres Solve the End-Protection Problem, Science. 
326 (2009) 948–952. 
[106]  Y. Zhao, H. Hoshiyama, J.W. Shay, W.E. Wright, Quantitative Telomeric 
Overhang Determination Using a Double-Strand Specific Nuclease, 
Nucleic Acids Res. 36 (2008) e14. 
[107]  C.B. Harley, A.B. Futcher, C.W. Greider, Telomeres shorten during ageing 
of human fibroblasts, Publ. Online 31 May 1990 Doi101038345458a0. 345 
(1990) 458–460. 
[108]  E.H. Blackburn, C.W. Greider, E. Henderson, M.S. Lee, J. Shampay, D. 
Shippen-Lentz, Recognition and elongation of telomeres by telomerase, 
Genome Natl. Res. Counc. Can. Génome Cons. Natl. Rech. Can. 31 (1989) 
553–560. 
 178 
[109]  J. Feng, W.D. Funk, S.-S. Wang, S.L. Weinrich, A.A. Avilion, C.-P. Chiu, et 
al., The RNA Component of Human Telomerase, Science. 269 (1995) 
1236–1241. 
[110]  P. Neumeister, C. Albanese, B. Balent, J. Greally, R.G. Pestell, 
Senescence and epigenetic dysregulation in cancer, Int. J. Biochem. Cell 
Biol. 34 (2002) 1475–1490. 
[111]  J. Campisi, F. d’ Adda di Fagagna, Cellular senescence: when bad things 
happen to good cells, Nat Rev Mol Cell Biol. 8 (2007) 729–740. 
[112]  J. Campisi, Cellular senescence as a tumor-suppressor mechanism, 
Trends Cell Biol. 11 (2001) S27–S31. 
[113]  M. Braig, C.A. Schmitt, Oncogene-Induced Senescence: Putting the 
Brakes on Tumor Development, Cancer Res. 66 (2006) 2881–2884. 
[114]  J.R. Smith, O.M. Pereira-Smith, Replicative Senescence: Implications for 
in Vivo Aging and Tumor Suppression, Science. 273 (1996) 63–67. 
[115]  C.M. Beausejour, A. Krtolica, F. Galimi, M. Narita, S.W. Lowe, P. Yaswen, 
et al., Reversal of human cellular senescence: roles of the p53 and p16 
pathways, Embo J. 22 (2003) 4212–4222. 
[116]  P. Hawley-Nelson, K.H. Vousden, N.L. Hubbert, D.R. Lowy, J.T. Schiller, 
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin 
keratinocytes., Embo J. 8 (1989) 3905. 
[117]  J.B. Hudson, M.A. Bedell, D.J. McCance, L.A. Laiminis, Immortalization 
and Altered Differentiation of Human Keratinocytes in Vitro by the E6 and 
E7 Open Reading Frames of Human Papillomavirus Type 18., J. Virol. 64 
(1990) 519–526. 
[118]  J.W. Shay, W.E. Wright, Quantitation of the frequency of immortalization 
of normal human diploid fibroblasts by SV40 large T-antigen, Exp. Cell 
Res. 184 (1989) 109–118. 
[119]  J.W. Shay, B.A. Van Der Haegen, Y. Ying, W.E. Wright, The frequency of 
immortalization of human fibroblasts and mammary epithelial cells 
transfected with SV40 large T-antigen, Exp. Cell Res. 209 (1993) 45–52. 
[120]  M. Meyerson, C.M. Counter, E.N. Eaton, L.W. Ellisen, P. Steiner, S.D. 
Caddle, et al., hEST2, the Putative Human Telomerase Catalytic Subunit 
Gene, Is Up-Regulated in Tumor Cells and during Immortalization, Cell. 90 
(1997) 785–795. 
[121]  A.G. Bodnar, M. Ouellette, M. Frolkis, S.E. Holt, C.-P. Chiu, G.B. Morin, et 
al., Extension of Life-Span by Introduction of Telomerase into Normal 
Human Cells, Science. 279 (1998) 349–352. 
[122]  S. Franco, K.L. MacKenzie, S. Dias, S. Alvarez, S. Rafii, M.A.S. Moore, 
Clonal Variation in Phenotype and Life Span of Human Embryonic 
Fibroblasts (MRC-5) Transduced with the Catalytic Component of 
Telomerase (hTERT), Exp. Cell Res. 268 (2001) 14–25. 
[123]  R.J. O’Sullivan, J. Karlseder, Telomeres: protecting chromosomes against 
genome instability, Nat Rev Mol Cell Biol. 11 (2010) 171–181. 
 179 
[124]  C.P. Morales, S.E. Holt, M. Ouellette, K.J. Kaur, Y. Yan, K.S. Wilson, et al., 
Absence of cancer-associated changes in human fibroblasts immortalized 
with telomerase, Nat Genet. 21 (1999) 115–118. 
[125]  E. Lapi, S.D. Agostino, S. Donzelli, H. Gal, E. Domany, G. Rechavi, et al., 
PML, YAP, and p73 Are Components of a Proapoptotic Autoregulatory 
Feedback Loop, Mol. Cell. 32 (2008) 803–814. 
[126]  S. Buonamici, D. Li, F.M. Mikhail, A. Sassano, L.C. Platanias, O. 
Colamonici, et al., EVI1 Abrogates Interferon-{alpha} Response by 
Selectively Blocking PML Induction, J Biol Chem. 280 (2005) 428–436. 
[127]  K. Jensen, C. Shiels, P.S. Freemont, PML protein isoforms and the 
RBCC/TRIM motif, Oncogene. 20 (2001) 7223–4233. 
[128]  B.B. Quimby, V. Yong-Gonzalez, T. Anan, A.V. Strunnikov, M. Dasso, The 
promyelocytic leukemia protein stimulates SUMO conjugation in yeast, 
Oncogene. 25 (2006) 2999–3005. 
[129]  Y. Chu, X. Yang, SUMO E3 ligase activity of TRIM proteins, Oncogene. 
(2010). 
[130]  R. Bernardi, P.P. Pandolfi, Structure, dynamics and functions of 
promyelocytic leukaemia nuclear bodies, Nat Rev Mol Cell Biol. 8 (2007) 
1006–1016. 
[131]  V. Lallemand-Breitenbach, H. de Thé, PML Nuclear Bodies, Cold Spring 
Harb. Perspect. Biol. 2 (2010). 
[132]  E. Van Damme, K. Laukens, T.H. Dang, X. Van Ostade, A manually 
curated network of the PML nuclear body interactome reveals an 
important role for PML-NBs in SUMOylation dynamics, Int. J. Biol. Sci. 6 
(2010) 51–67. 
[133]  A. Janer, E. Martin, M.-P. Muriel, M. Latouche, H. Fujigasaki, M. Ruberg, 
et al., PML clastosomes prevent nuclear accumulation of mutant ataxin-7 
and other polyglutamine proteins, J. Cell Biol. 174 (2006) 65–76. 
[134]  L. Fu, Y. Gao, A. Tousson, A. Shah, T.-L.L. Chen, B.M. Vertel, et al., 
Nuclear Aggresomes Form by Fusion of PML-associated Aggregates, Mol 
Biol Cell. 16 (2005) 4905–4917. 
[135]  T.G. Hofmann, H. Will, Body language: the function of PML nuclear 
bodies in apoptosis regulation, Cell Death Differ. 10 (2003) 1290–1299. 
[136]  M. Lang, T. Jegou, I. Chung, K. Richter, S. Munch, A. Udvarhelyi, et al., 
Three-dimensional organization of promyelocytic leukemia nuclear bodies, 
J Cell Sci. 123 (2010) 392–400. 
[137]  C.H. Eskiw, G. Dellaire, D.P. Bazett-Jones, Chromatin Contributes to 
Structural Integrity of Promyelocytic Leukemia Bodies through a SUMO-1-
independent Mechanism, J. Biol. Chem. 279 (2004) 9577–9585. 
[138]  G. Meroni, Graciana Diez-Roux, TRIM/RBCC, a novel class of “single 
protein RING finger” E3 ubiquitin ligases, BioEssays. 27 (2005) 1147–1157. 
[139]  K. Ozato, D.-M. Shin, T.-H. Chang, H.C. Morse, TRIM family proteins and 
their emerging roles in innate immunity, Nat Rev Immunol. 8 (2008) 849–
860. 
 180 
[140]  H. Tao, B.N. Simmons, S. Singireddy, M. Jakkidi, K.M. Short, T.C. Cox, et 
al., Structure of the MID1 Tandem B-Boxes Reveals an Interaction 
Reminiscent of Intermolecular Ring Heterodimers†,‡, Biochemistry 
(Mosc.). 47 (2008) 2450–2457. 
[141]  A. Rabellino, B. Carter, G. Konstantinidou, S.-Y. Wu, A. Rimessi, L.A. 
Byers, et al., The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor 
PML and Its Oncogenic Counterpart PML-RARA, Cancer Res. 72 (2012) 
2275–2284. 
[142]  X. Wei, Z.K. Yu, A. Ramalingam, S.R. Grossman, J.H. Yu, D.B. Bloch, et 
al., Physical and Functional Interactions between PML and MDM2, J Biol 
Chem. 278 (2003) 29288–29297. 
[143]  T.H. Shen, H.-K. Lin, P.P. Scaglioni, T.M. Yung, P.P. Pandolfi, The 
Mechanisms of PML-Nuclear Body Formation, Mol. Cell. 24 (2006) 331–
339. 
[144]  W. Condemine, Y. Takahashi, M. Le Bras, H. de Thé, A nucleolar targeting 
signal in PML-I addresses PML to nucleolar caps in stressed or senescent 
cells, J Cell Sci. 120 (2007) 3219–3227. 
[145]  Y. Geng, S. Monajembashi, A. Shao, D. Cui, W. He, Z. Chen, et al., 
Contribution of the C-terminal Regions of Promyelocytic Leukemia Protein 
(PML) Isoforms II and V to PML Nuclear Body Formation, J. Biol. Chem. 
287 (2012) 30729–30742. 
[146]  M. Pampin, Y. Simonin, B. Blondel, Y. Percherancier, M.K. Chelbi-Alix, 
Cross Talk between PML and p53 during Poliovirus Infection: Implications 
for Antiviral Defense, J Virol. 80 (2006) 8582–8592. 
[147]  M.A. Maroui, M. Pampin, M.K. Chelbi-Alix, Promyelocytic Leukemia 
Isoform IV Confers Resistance to Encephalomyocarditis Virus via the 
Sequestration of 3D Polymerase in Nuclear Bodies ▿, J. Virol. 85 (2011) 
13164–13173. 
[148]  R.D. Everett, J. Murray, A. Orr, C.M. Preston, Herpes Simplex Virus Type 
1 Genomes Are Associated with ND10 Nuclear Substructures in 
Quiescently Infected Human Fibroblasts, J Virol. 81 (2007) 10991–11004. 
[149]  F. Catez, C. Picard, K. Held, S. Gross, A. Rousseau, D. Theil, et al., HSV-1 
Genome Subnuclear Positioning and Associations with Host-Cell PML-
NBs and Centromeres Regulate LAT Locus Transcription during Latency in 
Neurons, Plos Pathog. 8 (2012) e1002852. 
[150]  C.D. Meiering, M.L. Linial, The Promyelocytic Leukemia Protein Does Not 
Mediate Foamy Virus Latency In Vitro, J. Virol. 77 (2003) 2207–2213. 
[151]  M. Reichelt, L. Wang, M. Sommer, J. Perrino, A.M. Nour, N. Sen, et al., 
Entrapment of Viral Capsids in Nuclear PML Cages Is an Intrinsic Antiviral 
Host Defense against Varicella-Zoster Virus, Plos Pathog. 7 (2011) 
e1001266. 
[152]  T. Regad, A. Saib, V. Lallemand-Breitenbach, P.P. Pandolfi, H. de Thé, 
M.K. Chelbi-Alix, PML mediates the interferon-induced antiviral state 
against a complex retrovirus via its association with the viral 
transactivator, Embo J. 20 (2001) 3495–3505. 
 181 
[153]  B.E. Mchichi, T. Regad, M.-A. Maroui, M.S. Rodriguez, A. Aminev, S. 
Gerbaud, et al., SUMOylation Promotes PML Degradation during 
Encephalomyocarditis Virus Infection, J. Virol. 84 (2010) 11634–11645. 
[154]  G.G. Maul, H.H. Guldner, J.G. Spivack, Modification of discrete nuclear 
domains induced by herpes simplex virus type 1 immediate early gene 1 
product (ICP0), J. Gen. Virol. 74 (1993) 2679–2690. 
[155]  C.-H. Nagel, N. Albrecht, K. Milovic-Holm, L. Mariyanna, B. Keyser, B. 
Abel, et al., Herpes Simplex Virus Immediate Early Protein ICP0 is 
Targeted by SIAH-1 for Proteasomal Degradation, J Virol. (2011) 
JVI.02207–10. 
[156]  E. Guccione, K.J. Lethbridge, N. Killick, K.N. Leppard, L. Banks, HPV E6 
proteins interact with specific PML isoforms and allow distinctions to be 
made between different POD structures, Oncogene. 23 (2004) 4662–4672. 
[157]  J. Ahn, G. Hayward, The major immediate-early proteins IE1 and IE2 of 
human cytomegalovirus colocalize with and disrupt PML-associated 
nuclear bodies at very early times in infected permissive cells, J Virol. 71 
(1997) 4599–4613. 
[158]  H.-R. Lee, D.-J. Kim, J.-M. Lee, C.Y. Choi, B.-Y. Ahn, G.S. Hayward, et 
al., Ability of the Human Cytomegalovirus IE1 Protein To Modulate 
Sumoylation of PML Correlates with Its Functional Activities in 
Transcriptional Regulation and Infectivity in Cultured Fibroblast Cells, J. 
Virol. 78 (2004) 6527–6542. 
[159]  A.L. Adamson, S. Kenney, Epstein-Barr Virus Immediate-Early Protein 
BZLF1 Is SUMO-1 Modified and Disrupts Promyelocytic Leukemia Bodies, 
J Virol. 75 (2001) 2388–2399. 
[160]  L. Marcos-Villar, F. Lopitz-Otsoa, P. Gallego, C. Munoz-Fontela, J. 
Gonzalez-Santamaria, M. Campagna, et al., Kaposi’s Sarcoma-Associated 
Herpesvirus Protein LANA2 Disrupts PML Oncogenic Domains and Inhibits 
PML-Mediated Transcriptional Repression of the Survivin Gene, J Virol. 83 
(2009) 8849–8858. 
[161]  K.L.B. Borden, RING fingers and B-boxes: Zinc-binding protein-protein 
interaction domains, Biochem. Cell Biol. 76 (1998) 351. 
[162]  F. Puvion-Dutilleul, M.K. Chelbi-Alix, M. Koken, F. Quignon, E. Puvion, H. 
De Thé, Adenovirus Infection Induces Rearrangements in the Intranuclear 
Distribution of the Nuclear Body-Associated PML Protein, Exp. Cell Res. 
218 (1995) 9–16. 
[163]  X. Cheng, H.-Y. Kao, Post-translational modifications of PML: 
consequences and implications, Front. Oncol. 2 (2013). 
[164]  T. Sternsdorf, K. Jensen, H. Will, Evidence for Covalent Modification of 
the Nuclear Dot-associated Proteins PML and Sp100 by PIC1/SUMO-1, J 
Cell Biol. 139 (1997) 1621–1634. 
[165]  T. Kamitani, K. Kito, H.P. Nguyen, H. Wada, T. Fukuda-Kamitani, E.T.H. 
Yeh, Identification of Three Major Sentrinization Sites in PML, J. Biol. 
Chem. 273 (1998) 26675–26682. 
 182 
[166]  F. Galisson, L. Mahrouche, M. Courcelles, E. Bonneil, S. Meloche, M.K. 
Chelbi-Alix, et al., A novel proteomics approach to identify SUMOylated 
proteins and their modification sites in human cells, Mol. Cell. Proteomics. 
10 (2011). 
[167]  A.C.O. Vertegaal, J.S. Andersen, S.C. Ogg, R.T. Hay, M. Mann, A.I. 
Lamond, Distinct and Overlapping Sets of SUMO-1 and SUMO-2 Target 
Proteins Revealed by Quantitative Proteomics, Mol. Cell. Proteomics. 5 
(2006) 2298–2310. 
[168]  N. Saitoh, Y. Uchimura, T. Tachibana, S. Sugahara, H. Saitoh, M. Nakao, 
In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the 
nuclear rim and PML bodies, Exp. Cell Res. 312 (2006) 1418–1430. 
[169]  M.H. Tatham, M.-C. Geoffroy, L. Shen, A. Plechanovova, N. Hattersley, 
E.G. Jaffray, et al., RNF4 is a poly-SUMO-specific E3 ubiquitin ligase 
required for arsenic-induced PML degradation, Nat Cell Biol. 10 (2008) 
538–546. 
[170]  C. Gao, C.-C. Ho, E. Reineke, M. Lam, X. Cheng, K.J. Stanya, et al., 
Histone Deacetylase 7 Promotes PML Sumoylation and Is Essential for 
PML Nuclear Body Formation, Mol Cell Biol. 28 (2008) 5658–5667. 
[171]  M. Campagna, D. Herranz, M.A. Garcia, L. Marcos-Villar, J. Gonzalez-
Santamaria, P. Gallego, et al., SIRT1 stabilizes PML promoting its 
sumoylation, Cell Death Differ. (2010). 
[172]  S. Weidtkamp-Peters, T. Lenser, D. Negorev, N. Gerstner, T.G. Hofmann, 
G. Schwanitz, et al., Dynamics of component exchange at PML nuclear 
bodies, J Cell Sci. 121 (2008) 2731–2743. 
[173]  D.-Y. Lin, Y.-S. Huang, J.-C. Jeng, H.-Y. Kuo, C.-C. Chang, T.-T. Chao, et 
al., Role of SUMO-Interacting Motif in Daxx SUMO Modification, 
Subnuclear Localization, and Repression of Sumoylated Transcription 
Factors, Mol. Cell. 24 (2006) 341–354. 
[174]  V. Lallemand-Breitenbach, M. Jeanne, S. Benhenda, R. Nasr, M. Lei, L. 
Peres, et al., Arsenic degrades PML or PML-RAR[alpha] through a SUMO-
triggered RNF4/ubiquitin-mediated pathway, Nat Cell Biol. 10 (2008) 547–
555. 
[175]  Y. Erker, H. Neyret-Kahn, J.-S. Seeler, A. Dejean, A. Atfi, L. Levy, Arkadia, 
a novel SUMO-targeted ubiquitin ligase involved in PML degradation, Mol. 
Cell. Biol. (2013). 
[176]  E.L. Reineke, M. Lam, Q. Liu, Y. Liu, K.J. Stanya, K.-S. Chang, et al., 
Degradation of the Tumor Suppressor PML by Pin1 Contributes to the 
Cancer Phenotype of Breast Cancer MDA-MB-231 Cells, Mol Cell Biol. 28 
(2008) 997–1006. 
[177]  X.-W. Zhang, X.-J. Yan, Z.-R. Zhou, F.-F. Yang, Z.-Y. Wu, H.-B. Sun, et 
al., Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by 
Directly Binding PML, Science. 328 (2010) 240–243. 
[178]  E. Gresko, S. Ritterhoff, J. Sevilla-Perez, A. Roscic, K. Frobius, I. Kotevic, 
et al., PML tumor suppressor is regulated by HIPK2-mediated 
 183 
phosphorylation in response to DNA damage, Oncogene. 28 (2008) 698–
708. 
[179]  I. Nefkens, D.G. Negorev, A.M. Ishov, J.S. Michaelson, E.T.H. Yeh, R.M. 
Tanguay, et al., Heat shock and Cd2+ exposure regulate PML and Daxx 
release from ND10 by independent mechanisms that modify the induction 
of heat-shock proteins 70 and 25 differently, J Cell Sci. 116 (2003) 513–
524. 
[180]  M. Fanelli, A. Fantozzi, P. De Luca, S. Caprodossi, S. Matsuzawa, M.A. 
Lazar, et al., The Coiled-coil Domain Is the Structural Determinant for 
Mammalian Homologues of Drosophila Sina-mediated Degradation of 
Promyelocytic Leukemia Protein and Other Tripartite Motif Proteins by the 
Proteasome, J Biol Chem. 279 (2004) 5374–5379. 
[181]  W.-C. Yuan, Y.-R. Lee, S.-F. Huang, Y.-M. Lin, T.-Y. Chen, H.-C. Chung, 
et al., A Cullin3-KLHL20 Ubiquitin Ligase-Dependent Pathway Targets 
PML to Potentiate HIF-1 Signaling and Prostate Cancer Progression, 
Cancer Cell. 20 (2011) 214–228. 
[182]  D. Guan, D. Factor, Y. Liu, Z. Wang, H.-Y. Kao, The epigenetic regulator 
UHRF1 promotes ubiquitination-mediated degradation of the tumor-
suppressor protein promyelocytic leukemia protein, Oncogene. (2012). 
[183]  P.P. Scaglioni, T.M. Yung, L.F. Cai, H. Erdjument-Bromage, A.J. Kaufman, 
B. Singh, et al., A CK2-Dependent Mechanism for Degradation of the PML 
Tumor Suppressor, Cell. 126 (2006) 269–283. 
[184]  K.-S. Chang, Y.-H. Fan, M. Andreeff, J. Liu, Z.-M. Mu, The PML gene 
encodes a phosphoprotein associated with the nuclear matrix, Blood. 85 
(1995) 3646–3653. 
[185]  T. Shiromizu, J. Adachi, S. Watanabe, T. Murakami, T. Kuga, S. Muraoka, 
et al., Identification of Missing Proteins in the neXtProt Database and 
Unregistered Phosphopeptides in the PhosphoSitePlus Database As Part 
of the Chromosome-Centric Human Proteome Project, J. Proteome Res. 
(2013). 
[186]  F. Hayakawa, M.L. Privalsky, Phosphorylation of PML by mitogen-
activated protein kinases plays a key role in arsenic trioxide-mediated 
apoptosis, Cancer Cell. 5 (2004) 389–401. 
[187]  Q. Yang, X. Deng, B. Lu, M. Cameron, C. Fearns, M.P. Patricelli, et al., 
Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through 
Promyelocytic Leukemia Protein, Cancer Cell. 18 (2010) 258–267. 
[188]  J.H. Lim, Y. Liu, E. Reineke, H.-Y. Kao, Mitogen-activated Protein Kinase 
Extracellular Signal-regulated Kinase 2 Phosphorylates and Promotes Pin1 
Protein-dependent Promyelocytic Leukemia Protein Turnover, J. Biol. 
Chem. 286 (2011) 44403–44411. 
[189]  E.L. Reineke, Y. Liu, H.-Y. Kao, Promyelocytic Leukemia Protein Controls 
Cell Migration in Response to Hydrogen Peroxide and Insulin-like Growth 
Factor-1, J. Biol. Chem. 285 (2010) 9485–9492. 
 184 
[190]  Q. Yang, L. Liao, X. Deng, R. Chen, N.S. Gray, J.R. Yates, et al., BMK1 is 
involved in the regulation of p53 through disrupting the PML–MDM2 
interaction, Oncogene. (2012). 
[191]  Y. Percherancier, D. Germain-Desprez, F. Galisson, X.H. Mascle, L. 
Dianoux, P. Estephan, et al., Role of SUMO in RNF4-mediated PML 
degradation: PML sumoylation and phospho-switch control of its SUMO 
binding domain dissected in living cells, J Biol Chem. 284 (2009) 16595–
16608. 
[192]  P. Stehmeier, S. Muller, Phospho-Regulated SUMO Interaction Modules 
Connect the SUMO System to CK2 Signaling, Mol. Cell. 33 (2009) 400–
409. 
[193]  S. Yang, C. Kuo, J.E. Bisi, M.K. Kim, PML-dependent apoptosis after 
DNA damage is regulated by the checkpoint kinase hCds1/Chk2, Nat Cell 
Biol. 4 (2002) 865–870. 
[194]  R. Bernardi, P.P. Scaglioni, S. Bergmann, H.F. Horn, K.H. Vousden, P.P. 
Pandolfi, PML regulates p53 stability by sequestering Mdm2 to the 
nucleolus, Nat Cell Biol. 6 (2004) 665–672. 
[195]  Y. Tagata, H. Yoshida, L.A. Nguyen, H. Kato, H. Ichikawa, F. Tashiro, et 
al., Phosphorylation of PML is essential for activation of C/EBPε and PU.1 
to accelerate granulocytic differentiation, Leukemia. 22 (2008) 273–280. 
[196]  R.D. Everett, P. Lomonte, T. Sternsdorf, R. van Driel, A. Orr, Cell cycle 
regulation of PML modification and ND10 composition, J. Cell Sci. 112 
(1999) 4581–4588. 
[197]  L.M. Schang, J. Phillips, P.A. Schaffer, Requirement for Cellular Cyclin-
Dependent Kinases in Herpes Simplex Virus Replication and Transcription, 
J. Virol. 72 (1998) 5626–5637. 
[198]  G. Karaca, D. Hargett, T.I. McLean, J.S. Aguilar, P. Ghazal, E.K. Wagner, 
et al., Inhibition of the stress-activated kinase, p38, does not affect the 
virus transcriptional program of herpes simplex virus type 1, Virology. 329 
(2004) 142–156. 
[199]  S. Wang, P.M. Fischer, Cyclin-dependent kinase 9: a key transcriptional 
regulator and potential drug target in oncology, virology and cardiology, 
Trends Pharmacol. Sci. 29 (2008) 302–313. 
[200]  L.A. Samaniego, N. Wu, N.A. DeLuca, The herpes simplex virus 
immediate-early protein ICP0 affects transcription from the viral genome 
and infected-cell survival in the absence of ICP4 and ICP27, J. Virol. 71 
(1997) 4614–4625. 
[201]  K.O. Smith, Relationship Between the Envelope and the Infectivity of 
Herpes Simplex Virus, Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol. Med. 
New York N. 115 (1964) 814–816. 
[202]  W.Z. Cai, P.A. Schaffer, Herpes simplex virus type 1 ICP0 plays a critical 
role in the de novo synthesis of infectious virus following transfection of 
viral DNA., J. Virol. 63 (1989) 4579–4589. 
 185 
[203]  P.A. Schaffer, G.M. Aron, N. Biswal, M. Benyesh-Melnick, Temperature-
sensitive mutants of herpes simplex virus type 1: isolation, 
complementation and partial characterization, Virology. 52 (1973) 57–71. 
[204]  W.P. Halford, C.D. Kemp, J.A. Isler, D.J. Davido, P.A. Schaffer, ICP0, 
ICP4, or VP16 Expressed from Adenovirus Vectors Induces Reactivation of 
Latent Herpes Simplex Virus Type 1 in Primary Cultures of Latently 
Infected Trigeminal Ganglion Cells, J Virol. 75 (2001) 6143–6153. 
[205]  S.C. Das, D. Nayak, Y. Zhou, A.K. Pattnaik, Visualization of Intracellular 
Transport of Vesicular Stomatitis Virus Nucleocapsids in Living Cells, J. 
Virol. 80 (2006) 6368–6377. 
[206]  U.K. Laemmli, Cleavage of Structural Proteins during the Assembly of the 
Head of Bacteriophage T4, Nature. 227 (1970) 680–685. 
[207]  M.A. Pagano, J. Bain, Z. Kazimierczuk, S. Sarno, M. Ruzzene, G. Di 
Maira, et al., The selectivity of inhibitors of protein kinase CK2: an update, 
Biochem. J. 415 (2008) 353. 
[208]  K.L. Mossman, H.A. Saffran, J.R. Smiley, Herpes Simplex Virus ICP0 
Mutants Are Hypersensitive to Interferon, J. Virol. 74 (2000) 2052–2056. 
[209]  K.M. Eidson, W.E. Hobbs, B.J. Manning, P. Carlson, N.A. DeLuca, 
Expression of Herpes Simplex Virus ICP0 Inhibits the Induction of 
Interferon-Stimulated Genes by Viral Infection, J. Virol. 76 (2002) 2180–
2191. 
[210]  K.P. Anderson, E.H. Fennie, Adenovirus early region 1A modulation of 
interferon antiviral activity., J. Virol. 61 (1987) 787–795. 
[211]  Y. Zhi, R.M. Sandri-Goldin, Analysis of the Phosphorylation Sites of 
Herpes Simplex Virus Type 1 Regulatory Protein ICP27, J. Virol. 73 (1999) 
3246–3257. 
[212]  W.R. Sacks, C.C. Greene, D.P. Aschman, P.A. Schaffer, Herpes simplex 
virus type 1 ICP27 is an essential regulatory protein., J. Virol. 55 (1985) 
796–805. 
[213]  K. Xia, N.A. DeLuca, D.M. Knipe, Analysis of phosphorylation sites of 
herpes simplex virus type 1 ICP4, J. Virol. 70 (1996) 1061–1071. 
[214]  T. Wisner, C. Brunetti, K. Dingwell, D.C. Johnson, The Extracellular 
Domain of Herpes Simplex Virus gE Is Sufficient for Accumulation at Cell 
Junctions but Not for Cell-to-Cell Spread, J. Virol. 74 (2000) 2278–2287. 
[215]  C. Boutell, R.D. Everett, J. Hilliard, P.A. Schaffer, A. Orr, D.J. Davido, 
Herpes Simplex Virus Type 1 ICP0 Phosphorylation Mutants Impair the E3 
Ubiquitin Ligase Activity of ICP0 in a Cell Type-Dependent Manner, J. 
Virol. 82 (2008) 10647–56. 
[216]  S.G. Whalen, R.C. Marcellus, D. Barbeau, P.E. Branton, Importance of the 
Ser-132 phosphorylation site in cell transformation and apoptosis induced 
by the adenovirus type 5 E1A protein, J. Virol. 70 (1996) 5373–5383. 
[217]  J.W. Critchfield, J.E. Coligan, T.M. Folks, S.T. Butera, Casein kinase II is a 
selective target of HIV-1 transcriptional inhibitors, Proc. Natl. Acad. Sci. U. 
S. A. 94 (1997) 6110–6115. 
 186 
[218]  J. Rowe, R.J. Greenblatt, D. Liu, J.F. Moffat, Compounds that target host 
cell proteins prevent varicella-zoster virus replication in culture, ex vivo, 
and in SCID-Hu mice, Antiviral Res. 86 (2010) 276–285. 
[219]  A.V. Ljubimov, S. Caballero, A.M. Aoki, L.A. Pinna, M.B. Grant, R. 
Castellon, Involvement of Protein Kinase CK2 in Angiogenesis and Retinal 
Neovascularization, Invest. Ophthalmol. Vis. Sci. 45 (2004) 4583 –4591. 
[220]  R.E. Randall, S. Goodbourn, Interferons and viruses: an interplay between 
induction, signalling, antiviral responses and virus countermeasures, J Gen 
Virol. 89 (2008) 1–47. 
[221]  G.R. Stark, I.M. Kerr, B.R.G. Williams, R.H. Silverman, R.D. Schreiber, 
How Cells Respond to Interferons, Annu. Rev. Biochem. 67 (1998) 227–
264. 
[222]  C.D. Conrady, W.P. Halford, D.J.J. Carr, Loss of the Type I Interferon 
Pathway Increases Vulnerability of Mice to Genital Herpes Simplex Virus 2 
Infection, J. Virol. 85 (2011) 1625–1633. 
[223]  M.F. Van den Broek, U. Müller, S. Huang, M. Aguet, R.M. Zinkernagel, 
Antiviral defense in mice lacking both alpha/beta and gamma interferon 
receptors., J. Virol. 69 (1995) 4792–4796. 
[224]  S.Y. Hwang, P.J. Hertzog, K.A. Holland, S.H. Sumarsono, M.J. Tymms, 
J.A. Hamilton, et al., A null mutation in the gene encoding a type I 
interferon receptor component eliminates antiproliferative and antiviral 
responses to interferons alpha and beta and alters macrophage 
responses, Proc. Natl. Acad. Sci. 92 (1995) 11284. 
[225]  U. Muller, U. Steinhoff, L.F. Reis, S. Hemmi, J. Pavlovic, R.M. Zinkernagel, 
et al., Functional Role of Type I and Type II Interferons in Antiviral Defense, 
Science. 264 (1994) 1918–1921. 
[226]  S. Bereczky, G. Lindegren, H. Karlberg, S. Åkerström, J. Klingström, A. 
Mirazimi, Crimean–Congo Hemorrhagic Fever Virus Infection Is Lethal for 
Adult Type I Interferon Receptor-Knockout Mice, J. Gen. Virol. 91 (2010) 
1473–1477. 
[227]  C.N. Detje, T. Meyer, H. Schmidt, D. Kreuz, J.K. Rose, I. Bechmann, et al., 
Local Type I IFN Receptor Signaling Protects Against Virus Spread Within 
the Central Nervous System, J. Immunol. 182 (2009) 2297–2304. 
[228]  J.E. Durbin, R. Hackenmiller, M.C. Simon, D.E. Levy, Targeted Disruption 
of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral 
Disease, Cell. 84 (1996) 443–450. 
[229]  M.C. Smith, C. Boutell, D.J. Davido, HSV-1 ICP0: paving the way for viral 
replication, Future Virol. 6 (2011) 421–429. 
[230]  P. Paladino, K.L. Mossman, Mechanisms employed by herpes simplex 
virus 1 to inhibit the interferon response, J. Interf. Cytokine Res. Off. J. Int. 
Soc. Interf. Cytokine Res. 29 (2009) 599–607. 
[231]  P. Paladino, S.E. Collins, K.L. Mossman, Cellular Localization of the 
Herpes Simplex Virus ICP0 Protein Dictates Its Ability to Block IRF3-
Mediated Innate Immune Responses, Plos One. 5 (2010) e10428. 
 187 
[232]  K.L. Mossman, P.F. Macgregor, J.J. Rozmus, A.B. Goryachev, A.M. 
Edwards, J.R. Smiley, Herpes Simplex Virus Triggers and Then Disarms a 
Host Antiviral Response, J Virol. 75 (2001) 750–758. 
[233]  C.M. Counter, W.C. Hahn, W. Wei, S. Dickinson Caddle, R.L. 
Beijersbergen, P.M. Lansdorp, et al., Dissociation among in vitro 
telomerase activity, telomere maintenance, and cellular immortalization, 
Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14723–14728. 
[234]  K. Misawa, T. Nosaka, S. Morita, A. Kaneko, T. Nakahata, S. Asano, et al., 
A Method to Identify cDNAs Based on Localization of Green Fluorescent 
Protein Fusion Products, Proc. Natl. Acad. Sci. 97 (2000) 3062–3066. 
[235]  E.C. Dimmer, R.P. Huntley, Y. Alam-Faruque, T. Sawford, C. O’Donovan, 
M.J. Martin, et al., The UniProt-GO Annotation database in 2011, Nucleic 
Acids Res. 40 (2012) D565–D570. 
[236]  W.C. Hahn, S.K. Dessain, M.W. Brooks, J.E. King, B. Elenbaas, D.M. 
Sabatini, et al., Enumeration of the Simian Virus 40 Early Region Elements 
Necessary for Human Cell Transformation, Mol. Cell. Biol. 22 (2002) 2111–
2123. 
[237]  B. van der Loo, M.J. Fenton, J.D. Erusalimsky, Cytochemical Detection of 
a Senescence-Associated β-Galactosidase in Endothelial and Smooth 
Muscle Cells from Human and Rabbit Blood Vessels, Exp. Cell Res. 241 
(1998) 309–315. 
[238]  M. Hou, D. Xu, M. Björkholm, A. Gruber, Real-Time Quantitative Telomeric 
Repeat Amplification Protocol Assay for the Detection of Telomerase 
Activity, Clin. Chem. 47 (2001) 519–524. 
[239]  H. Zhu, C. Zheng, J. Xing, S. Wang, S. Li, R. Lin, et al., Varicella-Zoster 
Virus Immediate-Early Protein ORF61 Abrogates the IRF3-Mediated Innate 
Immune Response through Degradation of Activated IRF3, J. Virol. 85 
(2011) 11079 –11089. 
[240]  G.A.D. Hardy, S.F. Sieg, B. Rodriguez, W. Jiang, R. Asaad, M.M. 
Lederman, et al., Desensitization to type I interferon in HIV-1 infection 
correlates with markers of immune activation and disease progression, 
Blood. 113 (2009) 5497 –5505. 
[241]  R.-L. Kuo, C. Zhao, M. Malur, R.M. Krug, Influenza A virus strains that 
circulate in humans differ in the ability of their NS1 proteins to block the 
activation of IRF3 and interferon-β transcription, Virology. 408 (2010) 146–
158. 
[242] ATCC: Catalog Search, (n.d.). 
[243]  N.W. Kim, M.A. Piatyszek, K.R. Prowse, C.B. Harley, M.D. West, P.L.C. 
Ho, et al., Specific Association of Human Telomerase Activity with 
Immortal Cells and Cancer, Science. 266 (1994) 2011–2015. 
[244]  A.J. Klingelhutz, S.A. Foster, J.K. McDougall, Telomerase activation by 
the E6 gene product of human papillomavirus type 16, Nature. 380 (1996) 
79–82. 
[245]  K. Hiyama, Telomeres and Telomerase in Cancer, Springer, 2009. 
 188 
[246]  Q.M. Chen, V.C. Tu, J. Catania, M. Burton, O. Toussaint, T. Dilley, 
Involvement of Rb family proteins, focal adhesion proteins and protein 
synthesis in senescent morphogenesis induced by hydrogen peroxide, J. 
Cell Sci. 113 (2000) 4087–4097. 
[247]  G.P. Dimri, X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, et al., A 
biomarker that identifies senescent human cells in culture and in aging 
skin in vivo, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9363–9367. 
[248]  C.A. Brailovsky, L.D. Berman, C. Chany, Decreased interferon sensitivity 
and production in cells transformed by SV40 and other oncogenic agents, 
Int. J. Cancer J. Int. Cancer. 4 (1969) 194–203. 
[249]  A.V. Rathi, P.G. Cantalupo, S.N. Sarkar, J.M. Pipas, Induction of 
interferon-stimulated genes by Simian virus 40 T antigens, Virology. 406 
(2010) 202–211. 
[250]  Y. Ito, L. Montagnier, Heterogeneity of the sensitivity of vesicular 
stomatitis virus to interferons., Infect. Immun. 18 (1977) 23–27. 
[251]  W.E. Stewart, W.D. Scott, S.E. Sulkin, Relative Sensitivities of Viruses to 
Different Species of Interferon, J. Virol. 4 (1969) 147–153. 
[252]  R.T. Taylor, W.A. Bresnahan, Human Cytomegalovirus Immediate-Early 2 
Gene Expression Blocks Virus-Induced Beta Interferon Production, J. 
Virol. 79 (2005) 3873–3877. 
[253]  M.P. Langford, D.A. Weigent, G.J. Stanton, S. Baron, Virus plaque-
reduction assay for interferon: Microplaque and regular macroplaque 
reduction assays, in: Sidney Pestka (Ed.), Methods Enzymol., Academic 
Press, 1981: pp. 339–346. 
[254]  S.E. Collins, R.S. Noyce, K.L. Mossman, Innate Cellular Response to Virus 
Particle Entry Requires IRF3 but Not Virus Replication, J. Virol. 78 (2004) 
1706–1717. 
[255]  K.L. Mossman, J.R. Smiley, Herpes Simplex Virus ICP0 and ICP34.5 
Counteract Distinct Interferon-Induced Barriers to Virus Replication, J 
Virol. 76 (2002) 1995–1998. 
[256]  K.L. Norman, F. Farassati, P.W.K. Lee, Oncolytic viruses and cancer 
therapy, Cytokine Growth Factor Rev. 12 (2001) 271–282. 
[257]  G.N. Barber, VSV-tumor selective replication and protein translation, 
Oncogene. 24 (2005) 7710–7719. 
[258]  W.Z. Cai, P.A. Schaffer, A cellular function can enhance gene expression 
and plating efficiency of a mutant defective in the gene for ICP0, a 
transactivating protein of herpes simplex virus type 1., J Virol. 65 (1991) 
4078–4090. 
[259]  J.L. Douglas, M.P. Quinlan, Efficient nuclear localization and immortalizing 
ability, two functions dependent on the adenovirus type 5 (Ad5) E1A 
second exon, are necessary for cotransformation with Ad5 E1B but not 
with T24ras., J. Virol. 69 (1995) 8061–8065. 
[260]  J. Bartek, J. Bartkova, N. Kyprianou, E.N. Lalani, Z. Staskova, M. Shearer, 
et al., Efficient immortalization of luminal epithelial cells from human 
 189 
mammary gland by introduction of simian virus 40 large tumor antigen 
with a recombinant retrovirus, Proc. Natl. Acad. Sci. 88 (1991) 3520. 
[261]  D.E. Wazer, X.L. Liu, Q. Chu, Q. Gao, V. Band, Immortalization of Distinct 
Human Mammary Epithelial Cell Types by Human Papilloma Virus 16 E6 or 
E7, Proc. Natl. Acad. Sci. 92 (1995) 3687–3691. 
[262]  J.W. Shay, W.E. Wright, H. Werbin, Defining the molecular mechanisms of 
human cell immortalization, Biochim. Biophys. Acta Bba - Rev. Cancer. 
1072 (1991) 1–7. 
[263]  D. Ahuja, M.T. S|[aacute]|enz-Robles, J.M. Pipas, SV40 large T antigen 
targets multiple cellular pathways to elicit cellular transformation, 
Oncogene. 24 (2005) 7729–7745. 
[264]  A. Brehm, S.J. Nielsen, E.A. Miska, D.J. McCance, J.L. Reid, A.J. 
Bannister, et al., The E7 oncoprotein associates with Mi2 and histone 
deacetylase activity to promote cell growth, Embo J. 18 (1999) 2449–2458. 
[265]  D. Patel, S.-M. Huang, L.A. Baglia, D.J. McCance, The E6 protein of 
human papillomavirus type 16 binds to and inhibits co-activation by CBP 
and p300, Embo J. 18 (1999) 5061–5072. 
[266]  S.H. Ali, J.A. DeCaprio, Cellular transformation by SV40 large T antigen: 
interaction with host proteins, Semin. Cancer Biol. 11 (2001) 15–23. 
[267]  E. Valls, X. de la Cruz, M.A. Martínez-Balbás, The SV40 T antigen 
modulates CBP histone acetyltransferase activity, Nucleic Acids Res. 31 
(2003) 3114–3122. 
[268]  S.M. Frisch, J.S. Mymryk, Adenovirus-5 E1A: paradox and paradigm, Nat. 
Rev. Mol. Cell Biol. 3 (2002) 441–452. 
[269]  D. Brockmann, H. Esche, The multifunctional role of E1A in the 
transcriptional regulation of CREB/CBP-dependent target genes, Curr. 
Top. Microbiol. Immunol. 272 (2003) 97–129. 
[270]  P.L. Hyland, S.S. McDade, R. McCloskey, G.J. Dickson, K. Arthur, D.J. 
McCance, et al., Evidence for Alteration of EZH2, BMI1 and KDM6A and 
Epigenetic Reprogramming in Human Papillomavirus Type-16 E6/E7 
Expressing Keratinocytes, J. Virol. (2011). 
[271]  H.P. Li, Y.W. Leu, Y.S. Chang, Epigenetic changes in virus-associated 
human cancers, Cell Res. 15 (2005) 262–271. 
[272]  P.G. Cantalupo, M.T. Sáenz-Robles, A.V. Rathi, R.W. Beerman, W.H. 
Patterson, R.H. Whitehead, et al., Cell-type specific regulation of gene 
expression by simian virus 40 T antigens, Virology. 386 (2009) 183–191. 
[273]  J.J. Zhang, U. Vinkemeier, W. Gu, D. Chakravarti, C.M. Horvath, J.E. 
Darnell, Two Contact Regions Between Stat1 and CBP/P300 in Interferon 
Γ Signaling, Proc. Natl. Acad. Sci. 93 (1996) 15092–15096. 
[274]  L.V. Ronco, A.Y. Karpova, M. Vidal, P.M. Howley, Human papillomavirus 
16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its 
transcriptional activity, Genes Dev. 12 (1998) 2061–2072. 
[275]  R. Sundararajan, E. White, E1B 19K Blocks Bax Oligomerization and 
Tumor Necrosis Factor Alpha-Mediated Apoptosis, J. Virol. 75 (2001) 
7506–7516. 
 190 
[276]  J. Han, P. Sabbatini, D. Perez, L. Rao, D. Modha, E. White, The E1B 19K 
Protein Blocks Apoptosis by Interacting with and Inhibiting the P53-
Inducible and Death-Promoting Bax Protein., Genes Dev. 10 (1996) 461–
477. 
[277]  M. Debbas, E. White, Wild-Type P53 Mediates Apoptosis by E1A, Which 
Is Inhibited by E1B., Genes Dev. 7 (1993) 546–554. 
[278]  P. Rajan, S. Swaminathan, J. Zhu, C.N. Cole, G. Barber, M.J. Tevethia, et 
al., A novel translational regulation function for the simian virus 40 large-T 
antigen gene., J. Virol. 69 (1995) 785–795. 
[279]  C. Lindvall, M. Hou, T. Komurasaki, C. Zheng, M. Henriksson, J.M. 
Sedivy, et al., Molecular Characterization of Human Telomerase Reverse 
Transcriptase-immortalized Human Fibroblasts by Gene Expression 
Profiling: Activation of the Epiregulin Gene, Cancer Res. 63 (2003) 1743–
1747. 
[280]  W.A. Bresnahan, G.E. Hultman, T. Shenk, Replication of Wild-Type and 
Mutant Human Cytomegalovirus in Life-Extended Human Diploid 
Fibroblasts, J Virol. 74 (2000) 10816–10818. 
[281]  B.P. McSharry, C.J. Jones, J.W. Skinner, D. Kipling, G.W.G. Wilkinson, 
Human telomerase reverse transcriptase-immortalized MRC-5 and HCA2 
human fibroblasts are fully permissive for human cytomegalovirus, J Gen 
Virol. 82 (2001) 855–863. 
[282]  H. Xin, O.M. Pereira-Smith, D. Choubey, Role of IFI 16 in cellular 
senescence of human fibroblasts, Oncogene. 23 (2004) 6209–6217. 
[283]  M.L. Nguyen, R.M. Kraft, M. Aubert, E. Goodwin, D. DiMaio, J.A. Blaho, 
p53 and hTERT Determine Sensitivity to Viral Apoptosis, J Virol. 81 (2007) 
12985–12995. 
[284]  C.E. Lilley, M.S. Chaurushiya, C. Boutell, R.D. Everett, M.D. Weitzman, 
The Intrinsic Antiviral Defense to Incoming HSV-1 Genomes Includes 
Specific DNA Repair Proteins and Is Counteracted by the Viral Protein 
ICP0, Plos Pathog. 7 (2011) e1002084. 
[285]  M. Kalamvoki, B. Roizman, ICP0 enables and monitors the function of D 
cyclins in herpes simplex virus 1 infected cells, Proc. Natl. Acad. Sci. 106 
(2009) 14576–14580. 
[286]  D. Cuchet, A. Sykes, A. Nicolas, A. Orr, J. Murray, H. Sirma, et al., PML 
isoforms I and II participate in PML-dependent restriction of HSV-1 
replication, J Cell Sci. (2010) jcs.075390. 
[287]  R.D. Everett, C. Parada, P. Gripon, H. Sirma, A. Orr, Replication of ICP0-
Null Mutant Herpes Simplex Virus Type 1 Is Restricted by both PML and 
Sp100, J Virol. 82 (2008) 2661–2672. 
[288]  N.M. Sawtell, The role of PML in HSV pathogenesis and latency, (2008). 
[289]  R.D. Everett, G. Sourvinos, C. Leiper, J.B. Clements, A. Orr, Formation of 
Nuclear Foci of the Herpes Simplex Virus Type 1 Regulatory Protein ICP4 
at Early Times of Infection: Localization, Dynamics, Recruitment of ICP27, 
and Evidence for the De Novo Induction of ND10-Like Complexes, J Virol. 
78 (2004) 1903–1917. 
 191 
[290]  D. Cuchet-Lourenço, C. Boutell, V. Lukashchuk, K. Grant, A. Sykes, J. 
Murray, et al., SUMO Pathway Dependent Recruitment of Cellular 
Repressors to Herpes Simplex Virus Type 1 Genomes, Plos Pathog. 7 
(2011) e1002123. 
[291]  M.K. Chelbi-Alix, H. de Thé, Herpes virus induced proteasome-dependent 
degradation of the nuclear bodies-associated PML and Sp100 proteins, 
Oncogene. 18 (1999) 935–941. 
[292]  D. Cuchet-Lourenço, E. Vanni, M. Glass, A. Orr, R.D. Everett, Herpes 
Simplex Virus 1 Ubiquitin Ligase ICP0 Interacts with PML Isoform I and 
Induces Its SUMO-Independent Degradation, J. Virol. 86 (2012) 11209–
11222. 
[293]  C. Boutell, A. Orr, R.D. Everett, PML Residue Lysine 160 Is Required for 
the Degradation of PML Induced by Herpes Simplex Virus Type 1 
Regulatory Protein ICP0, J Virol. 77 (2003) 8686–8694. 
[294]  P. Gripon, S. Rumin, S. Urban, J. Le Seyec, D. Glaise, I. Cannie, et al., 
Infection of a human hepatoma cell line by hepatitis B virus, Proc. Natl. 
Acad. Sci. U. S. A. 99 (2002) 15655–15660. 
[295]  M. Glass, R.D. Everett, Components of Promyelocytic Leukemia Nuclear 
Bodies (ND10) Act Cooperatively To Repress Herpesvirus Infection, J. 
Virol. 87 (2013) 2174–2185. 
[296]  D.J. McGeoch, M.A. Dalrymple, A.J. Davison, A. Dolan, M.C. Frame, D. 
McNab, et al., The complete DNA sequence of the long unique region in 
the genome of herpes simplex virus type 1, J Gen Virol. 69 (1988) 1531–
1574. 
[297]  B.L. Strang, N.D. Stow, Blocks to herpes simplex virus type 1 replication 
in a cell line, tsBN2, encoding a temperature-sensitive RCC1 protein, J. 
Gen. Virol. 88 (2007) 376–383. 
[298]  L. Naldini, U. Blömer, P. Gallay, D. Ory, R. Mulligan, F.H. Gage, et al., In 
vivo gene delivery and stable transduction of nondividing cells by a 
lentiviral vector, Science. 272 (1996) 263–267. 
[299]  S. Kane, H. Sano, S.C.H. Liu, J.M. Asara, W.S. Lane, C.C. Garner, et al., A 
Method to Identify Serine Kinase Substrates. Akt PHOSPHORYLATES A 
NOVEL ADIPOCYTE PROTEIN WITH A Rab GTPASE-ACTIVATING 
PROTEIN (GAP) DOMAIN, J Biol Chem. 277 (2002) 22115–22118. 
[300]  A.G. Sotnikov, D. Negorev, A.M. Ishov, G.G. Maul, [Monoclonal antibodies 
against protein Daxx and its localization in nuclear domains 10], 
Tsitologiia. 43 (2001) 1123–1129. 
[301]  W. Condemine, Y. Takahashi, J. Zhu, F. Puvion-Dutilleul, S. Guegan, A. 
Janin, et al., Characterization of Endogenous Human Promyelocytic 
Leukemia Isoforms, Cancer Res. 66 (2006) 6192–6198. 
[302]  J.V. Olsen, B. Blagoev, F. Gnad, B. Macek, C. Kumar, P. Mortensen, et 
al., Global, In Vivo, and Site-Specific Phosphorylation Dynamics in 
Signaling Networks, Cell. 127 (2006) 635–648. 
 192 
[303]  S.-T. Kim, D.-S. Lim, C.E. Canman, M.B. Kastan, Substrate Specificities 
and Identification of Putative Substrates of ATM Kinase Family Members, 
J. Biol. Chem. 274 (1999) 37538–37543. 
[304]  G.L. Christensen, C.D. Kelstrup, C. Lyngsø, U. Sarwar, R. Bøgebo, S.P. 
Sheikh, et al., Quantitative Phosphoproteomics Dissection of Seven-
transmembrane Receptor Signaling Using Full and Biased Agonists, Mol. 
Cell. Proteomics. 9 (2010) 1540–1553. 
[305]  D.G. Negorev, O.V. Vladimirova, A.V. Kossenkov, E.V. Nikonova, R.M. 
Demarest, A.J. Capobianco, et al., Sp100 as a Potent Tumor Suppressor: 
Accelerated Senescence and Rapid Malignant Transformation of Human 
Fibroblasts through Modulation of an Embryonic Stem Cell Program, 
Cancer Res. 70 (2010) 9991 –10001. 
[306]  M.A. Maroui, S. Kheddache-Atmane, F. El Asmi, L. Dianoux, M. Aubry, 
M.K. Chelbi-Alix, Requirement of PML SUMO Interacting Motif for RNF4- 
or Arsenic Trioxide-Induced Degradation of Nuclear PML Isoforms, Plos 
One. 7 (2012) e44949. 
[307]  R.D. Everett, M.-L. Parsy, A. Orr, Analysis of the Functions of Herpes 
Simplex Virus Type 1 Regulatory Protein ICP0 That Are Critical for Lytic 
Infection and Derepression of Quiescent Viral Genomes, J Virol. 83 (2009) 
4963–4977. 
[308]  D.J. Davido, W.F. Zagorski, G.G. Maul, P.A. Schaffer, The Differential 
Requirement for Cyclin-Dependent Kinase Activities Distinguishes Two 
Functions of Herpes Simplex Virus Type 1 ICP0, J. Virol. 77 (2003) 12603–
12616. 
[309]  T.I. McLean, S.L. Bachenheimer, Activation of cJUN N-Terminal Kinase by 
Herpes Simplex Virus Type 1 Enhances Viral Replication, J Virol. 73 (1999) 
8415–8426. 
[310]  Z. Li, Y. Yamauchi, M. Kamakura, T. Murayama, F. Goshima, H. Kimura, 
et al., Herpes Simplex Virus Requires Poly(ADP-Ribose) Polymerase 
Activity for Efficient Replication and Induces Extracellular Signal-Related 
Kinase-Dependent Phosphorylation and ICP0-Dependent Nuclear 
Localization of Tankyrase 1, J. Virol. 86 (2012) 492–503. 
[311]  Y. Galanty, R. Belotserkovskaya, J. Coates, S. Polo, K.M. Miller, S.P. 
Jackson, Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote 
responses to DNA double-strand breaks, Nature. 462 (2009) 935–939. 
[312]  G. Dellaire, R.W. Ching, K. Ahmed, F. Jalali, K.C.K. Tse, R.G. Bristow, et 
al., Promyelocytic leukemia nuclear bodies behave as DNA damage 
sensors whose response to DNA double-strand breaks is regulated by 
NBS1 and the kinases ATM, Chk2, and ATR, J Cell Biol. 175 (2006) 55–66. 
[313]  C.-C. Chang, M.T. Naik, Y.-S. Huang, J.-C. Jeng, P.-H. Liao, H.-Y. Kuo, et 
al., Structural and Functional Roles of Daxx SIM Phosphorylation in SUMO 
Paralog-Selective Binding and Apoptosis Modulation, Mol. Cell. 42 (2011) 
62–74. 
 193 
[314]  L. Wu, K. Luo, Z. Lou, J. Chen, MDC1 regulates intra-S-phase checkpoint 
by targeting NBS1 to DNA double-strand breaks, Proc. Natl. Acad. Sci. 
105 (2008) 11200–11205. 
[315]  I. Torrecilla, E.J. Spragg, B. Poulin, P.J. McWilliams, S.C. Mistry, A. 
Blaukat, et al., Phosphorylation and regulation of a G protein–coupled 
receptor by protein kinase CK2, J. Cell Biol. 177 (2007) 127–137. 
[316]  N. Blom, S. Gammeltoft, S. Brunak, Sequence and structure-based 
prediction of eukaryotic protein phosphorylation sites, J. Mol. Biol. 294 
(1999) 1351–1362. 
[317]  C.J.A. Sigrist, E. de Castro, L. Cerutti, B.A. Cuche, N. Hulo, A. Bridge, et 
al., New and continuing developments at PROSITE, Nucleic Acids Res. 41 
(2012) D344–D347. 
[318]  C.J.A. Sigrist, L. Cerutti, N. Hulo, A. Gattiker, L. Falquet, M. Pagni, et al., 
PROSITE: A documented database using patterns and profiles as motif 
descriptors, Brief. Bioinform. 3 (2002) 265–274. 
[319]  R.D. Everett, Construction and Characterization of Herpes Simplex Virus 
Type 1 Mutants with Defined Lesions in Immediate Early Gene 1, J Gen 
Virol. 70 (1989) 1185–1202. 
[320]  J.R. Morris, C. Boutell, M. Keppler, R. Densham, D. Weekes, A. 
Alamshah, et al., The SUMO modification pathway is involved in the 
BRCA1 response to genotoxic stress, Nature. 462 (2009) 886–890. 
[321]  K. Luo, H. Zhang, L. Wang, J. Yuan, Z. Lou, Sumoylation of MDC1 is 
important for proper DNA damage response, Embo J. 31 (2012) 3008–
3019. 
[322]  J.R. Danielsen, L.K. Povlsen, B.H. Villumsen, W. Streicher, J. Nilsson, M. 
Wikström, et al., DNA damage–inducible SUMOylation of HERC2 
promotes RNF8 binding via a novel SUMO-binding Zinc finger, J. Cell Biol. 
197 (2012) 179–187. 
[323]  F.T.M. Chang, J.D. McGhie, F.L. Chan, M.C. Tang, M.A. Anderson, J.R. 
Mann, et al., PML bodies provide an important platform for the 
maintenance of telomeric chromatin integrity in embryonic stem cells, 
Nucleic Acids Res. 41 (2013) 4447–4458. 
[324]  C. Doil, N. Mailand, S. Bekker-Jensen, P. Menard, D.H. Larsen, R. 
Pepperkok, et al., RNF168 Binds and Amplifies Ubiquitin Conjugates on 
Damaged Chromosomes to Allow Accumulation of Repair Proteins, Cell. 
136 (2009) 435–446. 
[325]  G.S. Stewart, Solving the RIDDLE of 53BP1 recruitment to sites of 
damage, Cell Cycle. 8 (2009) 1532–1538. 
[326]  Z.-X. Xu, A. Timanova-Atanasova, R.-X. Zhao, K.-S. Chang, PML 
Colocalizes with and Stabilizes the DNA Damage Response Protein 
TopBP1, Mol Cell Biol. 23 (2003) 4247–4256. 
 
